U.S. Physical Therapy (USPH) 10-K 7 Jun 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Jun. 06, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	U S PHYSICAL THERAPY INC /NV
Entity Central Index Key	885,978
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 547,917,000
Entity Common Stock, Shares Outstanding		12,581,237
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016	[1]	Jun. 30, 2016	[1]	Mar. 31, 2016	[1]	Dec. 31, 2015	[1]	Sep. 30, 2015	[1]	Jun. 30, 2015	[1]	Mar. 31, 2015	[1]	Dec. 31, 2014	[1]	Dec. 31, 2013	[1]
Current assets:
Cash and cash equivalents	$ 20,047	$ 15,024		$ 20,453		$ 19,206		$ 15,778		$ 20,558		$ 12,972		$ 14,557		$ 14,271		$ 12,898
Patient accounts receivable, less allowance for doubtful accounts of $1,792 and $1,444, respectively	38,840	38,522		39,356		38,217		36,231		35,106		34,830		34,673
Accounts receivable - other, less allowance for doubtful accounts of $-0- and $198, respectively	2,649	2,272		2,335		2,345		2,388		1,939		1,338		1,378
Other current assets	4,428	11,616		8,794		8,781		5,803		6,058		6,509		5,291
Total current assets	65,964	67,434		70,938		68,549		60,200		63,661		55,649		55,899
Fixed assets:
Furniture and equipment	48,426	46,996		46,747		45,654		44,749		44,157		43,495		42,542
Leasehold improvements	26,765	26,206		25,733		25,547		25,160		25,006		24,107		23,565
Fixed assets, gross	75,191	73,202		72,480		71,201		69,909		69,163		67,602		66,107
Less accumulated depreciation and amortization	56,018	55,760		55,642		54,512		53,255		52,501		51,098		50,212
Fixed assets, net	19,173	17,442		16,838		16,689		16,654		16,662		16,504		15,895
Goodwill	226,806	215,057		215,094		214,877		195,373		194,675		194,740		183,002		171,740
Other identifiable intangible assets, net	38,060	33,389		33,909		34,428		30,296		23,798		24,167		24,537
Other assets	1,228	1,221		1,219		1,200		1,234		1,175		1,086		1,916
Total assets	351,231	334,543		337,998		335,743		303,757		299,971		292,146		281,249
Current liabilities:
Accounts payable - trade	1,634	2,181		1,668		2,244		1,636		1,662		1,451		2,292
Accrued expenses	21,756	23,216		26,273		20,684		16,596		18,287		19,446		18,178
Current portion of notes payable	1,227	986		1,044		1,253		775		1,412		800		932
Total current liabilities	24,617	26,383		28,985		24,181		19,007		21,361		21,697		21,402
Notes payable	4,596	4,546		4,547		4,621		4,335		1,679		1,059		483
Revolving line of credit	46,000	36,000		42,500		52,500		44,000		46,000		41,000		41,500
Mandatorily redeemable non-controlling interests	69,190	61,276		59,932		58,481		45,974	[2]	45,323		49,166		45,578		40,365
Deferred taxes	15,736	18,736		18,153		17,362		15,508		13,276		12,027		12,009
Deferred rent	1,575	1,313		1,285		1,391		1,395		1,192		1,040		984
Other long-term liabilities	829	914		923		968		1,228		2,774		2,930		1,485
Total liabilities	162,543	149,168		156,325		159,504		131,447		131,605		128,919		123,441
Commitments and contingencies
U.S. Physical Therapy, Inc. ("USPH") shareholders' equity:
Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding	0	0		0		0		0		0		0		0
Common stock, $.01 par value, 20,000,000 shares authorized, 14,732,699 and 14,635,874 shares issued, respectively	147	147		147		147		146		146		146		145
Additional paid-in capital	68,687	68,493		67,223		65,550		64,238		62,918		61,051		60,302
Retained earnings	150,342	147,223		144,547		140,664		138,301		135,403		131,760		127,288
Treasury stock at cost, 2,214,737 shares	(31,628)	(31,628)		(31,628)		(31,628)		(31,628)		(31,628)		(31,628)		(31,628)
Total USPH shareholders' equity	187,548	184,235		180,289		174,733		171,057		166,839		161,329		156,107
Non-controlling interests	1,140	1,140		1,384		1,506		1,253		1,527		1,898		1,701
Total USPH shareholders' equity and non-controlling interests	188,688	185,375		181,673		176,239		172,310		168,366		163,227		157,808		$ 153,939		$ 136,234
Total liabilities, USPH shareholders' equity and non-controlling interests	$ 351,231	$ 334,543		$ 337,998		$ 335,743		$ 303,757		$ 299,971		$ 292,146		$ 281,249
[1]	as restated
[2]	Mandatorily redeemable non-controlling interests

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Allowance for doubtful accounts, patient accounts receivable	$ 1,792	$ 1,444
Allowance for doubtful accounts, accounts receivable - other	$ 0	$ 198
U. S. Physical Therapy, Inc. shareholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	500,000	500,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, shares issued (in shares)	14,732,699	14,635,874
Treasury stock, shares (in shares)	2,214,737	2,214,737

CONSOLIDATED STATEMENTS OF NET

CONSOLIDATED STATEMENTS OF NET INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended															6 Months Ended				9 Months Ended				12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	[1]	Jun. 30, 2016	[1]	Mar. 31, 2016	[1]	Dec. 31, 2015	[1]	Sep. 30, 2015	[1]	Jun. 30, 2015	[1]	Mar. 31, 2015	[1]	Jun. 30, 2016	[1]	Jun. 30, 2015	[1]	Sep. 30, 2016	[1]	Sep. 30, 2015	[1]	Dec. 31, 2016	Dec. 31, 2015	[1]	Dec. 31, 2014	[1]
CONSOLIDATED STATEMENTS OF NET INCOME [Abstract]
Net patient revenues	$ 88,946	$ 86,411		$ 88,433		$ 85,049		$ 84,881		$ 82,154		$ 81,451		$ 75,807		$ 173,482		$ 157,258		$ 259,893		$ 239,412		$ 348,839	$ 324,293		$ 299,009
Other revenues		1,933		1,997		1,859				1,895		1,837		1,434		3,856		3,271		5,789		5,166		7,707	7,009		6,065
Net revenues	90,864	88,344		90,430		86,908		86,724		84,049		83,288		77,241		177,338		160,529		265,682		244,578		356,546	331,302		305,074
Clinic operating costs:
Salaries and related costs		49,868		48,837		47,804				46,594		44,398		43,052		96,641		87,450		146,509		134,044		198,495	180,514		163,417
Rent, clinic supplies, contract labor and other		17,885		17,546		17,507				17,428		16,681		16,325		35,053		33,006		52,938		50,434		71,868	68,046		61,209
Provision for doubtful accounts		917		956		1,089				1,067		1,062		990		2,045		2,052		2,962		3,119		4,040	4,170		4,112
Closure costs		9		32		13				88		5		32		45		37		54		125		131	211		169
Total clinic operating costs		68,679		67,371		66,413				65,177		62,146		60,399		133,784		122,545		202,463		187,722		274,534	252,941		228,907
Gross margin		19,665		23,059		20,495				18,872		21,142		16,842		43,554		37,984		63,219		56,856		82,012	78,361		76,167
Corporate office costs		7,610		8,026		9,004				6,923		7,593		7,657		17,030		15,250		24,640		22,173		32,479	31,067		30,399
Operating income	$ 10,954	12,055		15,033		11,491		$ 12,611		11,949		13,549		9,185		26,524		22,734		38,579		34,683		49,533	47,294		45,768
Interest and other income, net		21		21		20				24		16		8		41		24		62		48		93	81		18
Interest expense
Mandatorily redeemable non-controlling interests - change in redemption value		(1,934)		(1,931)		(2,191)				(501)		48		(244)		(4,122)		(196)		(6,056)		(697)		(6,169)	(2,670)	[2]	(2,978)	[2]
Mandatorily redeemable non-controlling interests - earnings allocable		(929)		(1,330)		(887)				(778)		(1,190)		(706)		(2,217)		(1,896)		(3,146)		(2,674)		(4,057)	(3,538)	[2]	(3,388)	[2]
Debt and other		(326)		(320)		(308)				(255)		(245)		(265)		(628)		(510)		(954)		(765)		(1,252)	(1,031)		(1,088)
Total interest expense		(3,189)		(3,581)		(3,386)				(1,534)		(1,387)		(1,215)		(6,967)		(2,602)		(10,156)		(4,136)		(11,478)	(7,239)		(7,454)
Income before taxes		8,887		11,473		8,125				10,439		12,178		7,978		19,598		20,156		28,485		30,595		38,148	40,136		38,332
Provision for income taxes		2,753		3,802		2,172				3,465		4,221		2,685		5,974		6,906		8,727		10,371		11,880	13,647		13,018
Net income		6,134		7,671		5,953				6,974		7,957		5,293		13,624		13,250		19,758		20,224		26,268	26,489		25,314
Less: net income attributable to non-controlling interests		(1,330)		(1,659)		(1,465)				(1,468)		(1,623)		(1,279)		(3,124)		(2,902)		(4,454)		(4,370)		(5,717)	(5,874)		(6,183)
Net income attributable to USPH shareholders		$ 4,804		$ 6,012		$ 4,488				$ 5,506		$ 6,334		$ 4,014		$ 10,500		$ 10,348		$ 15,304		$ 15,854		$ 20,551	$ 20,615		$ 19,131
Basic and diluted earnings per share attributable to USPH shareholders (in dollars per share)	$ 0.42	$ 0.38		$ 0.48		$ 0.36		$ 0.38		$ 0.44		$ 0.51		$ 0.33		$ 0.84		$ 0.84		$ 1.22		$ 1.28		$ 1.64	$ 1.66		$ 1.57
Shares used in computation - basic (in shares)		12,520		12,511		12,448				12,421		12,409		12,313		12,480		12,362		12,494		12,382		12,500	12,392		12,217
Shares used in computation - diluted (in shares)		12,520		12,511		12,448				12,421		12,409		12,313		12,480		12,362		12,494		12,382		12,500	12,392		12,221
Dividends declared per common share (in dollars per share)		$ 0.17		$ 0.17		$ 0.17				$ 0.15		$ 0.15		$ 0.15		$ 0.34		$ 0.30		$ 0.51		$ 0.45		$ 0.68	$ 0.60		$ 0.48
[1]	as restated
[2]	Mandatorily redeemable non-controlling interests

CONSOLIDATED STATEMENTS OF EQUI

CONSOLIDATED STATEMENTS OF EQUITY - USD ($) shares in Thousands, $ in Thousands		Common Stock [Member]	Additional Paid-In Capital [Member]		Retained Earnings [Member]		Treasury Stock [Member]		Total Shareholders' Equity [Member]		Non-controlling Interests [Member]		Total
Beginning balance (As Reported [Member]) at Dec. 31, 2013		$ 143	$ 40,569		$ 119,206		$ (31,628)		$ 128,290		$ 22,727		$ 151,017
Beginning balance (Adjustment [Member])		0	13,970		(7,329)		0		6,641		(21,424)		(14,783)
Beginning balance at Dec. 31, 2013	[1]	$ 143	54,539		111,877		$ (31,628)		134,931		1,303		136,234
Beginning balance (in shares) (As Reported [Member]) at Dec. 31, 2013		14,316					(2,215)
Beginning balance (in shares) at Dec. 31, 2013	[1]	14,316					(2,215)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Proceeds from exercise of stock options		$ 1	43		0		$ 0		44		0		44
Proceeds from exercise of stock options (in shares)		21					0
Net tax benefit from exercise of stock options		$ 0	948		0		$ 0		948		0		948
Issuance of restricted stock		$ 1	0		0		$ 0		1		0		1
Issuance of restricted stock (in shares)		150					0
Compensation expense - restricted stock/equity-based awards		$ 0	3,363		0		$ 0		3,363		0		3,363
Acquisitions and sales of non-controlling interests	[1]		(94)		0		0		(94)		(35)		(129)
Distributions to non-controlling interest partners	[1]	0	0		0		0		0		(5,963)		(5,963)
Dividends payable to USPT shareholders		0	0		(5,873)		0		(5,873)		0		(5,873)
Net income	[1]	0	0		19,131		0		19,131		6,183		25,314
Ending balance at Dec. 31, 2014	[1]	$ 145	58,799		125,135		$ (31,628)		152,451		1,488		153,939
Ending balance (in shares) at Dec. 31, 2014	[1]	14,487					(2,215)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Proceeds from exercise of stock options		$ 1	4		0		$ 0		5		0		5
Proceeds from exercise of stock options (in shares)		1					0
Net tax benefit from exercise of stock options		$ 0	947		0		$ 0		947		0		947
Issuance of restricted stock		$ 0	0		0		$ 0		0		0		0
Issuance of restricted stock (in shares)		148					0
Compensation expense - restricted stock/equity-based awards		$ 0	4,491		0		$ 0		4,491		0		4,491
Transfer of compensation liability for certain stock issued pursuant to long-term incentive plans		0	446		0		0		446		0		446
Acquisitions and sales of non-controlling interests		0	(449)	[1]	0	[1]	0	[1]	(449)	[1]	(217)	[1]	(666)	[1]
Distributions to non-controlling interest partners		0	0		0		0		0	[1]	(5,892)	[1]	(5,892)	[1]
Dividends payable to USPT shareholders		0	0		(7,449)		0		(7,449)		0		(7,449)
Net income	[1]	0	0		20,615		0		20,615		5,874		26,489
Ending balance at Dec. 31, 2015	[1]	$ 146	64,238		138,301		$ (31,628)		171,057		1,253		172,310
Ending balance (in shares) at Dec. 31, 2015	[1]	14,636					(2,215)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of restricted stock		$ 1	0		0		$ 0		1		0		1
Issuance of restricted stock (in shares)		97
Cancellation of restricted stock		$ 0	0		0		0		0		0		0
Compensation expense - restricted stock/equity-based awards		0	4,962		0		0		4,962		0		4,962
Transfer of compensation liability for certain stock issued pursuant to long-term incentive plans		0	211		0		0		211		0		211
Acquisitions and sales of non-controlling interests		0	(533)		0		0		(533)		(112)		(645)
Adjustment for prior year acquisitions of non-controlling interest - tax true up		0	(191)		0		0		(191)		0		(191)
Distributions to non-controlling interest partners		0	0		0		0		0		(5,718)		(5,718)
Dividends payable to USPT shareholders		0	0		(8,510)		0		(8,510)		0		(8,510)
Net income		0	0		20,551		0		20,551		5,717		26,268
Ending balance at Dec. 31, 2016		$ 147	$ 68,687		$ 150,342		$ (31,628)		$ 187,548		$ 1,140		$ 188,688
Ending balance (in shares) at Dec. 31, 2016		14,733					(2,215)
[1]	as restated

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands		3 Months Ended				6 Months Ended				9 Months Ended				12 Months Ended
		Mar. 31, 2016		Mar. 31, 2015		Jun. 30, 2016		Jun. 30, 2015		Sep. 30, 2016		Sep. 30, 2015		Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
OPERATING ACTIVITIES
Net income		$ 5,953	[1]	$ 5,293	[1]	$ 13,624	[1]	$ 13,250	[1]	$ 19,758	[1]	$ 20,224	[1]	$ 26,268	$ 26,489	[1]	$ 25,314	[1]
Adjustments to reconcile net income including non-controlling interests to net cash provided by operating activities:
Depreciation and amortization		2,091	[1]	1,807	[1]	4,158	[1]	3,674	[1]	6,210	[1]	5,656	[1]	8,779	7,952	[1]	6,740	[1]
Provision for doubtful accounts		1,089	[1]	990	[1]	2,045	[1]	2,052	[1]	2,962	[1]	3,119	[1]	4,040	4,170	[1]	4,112	[1]
Equity-based awards compensation expense		1,221	[1]	991	[1]	2,484	[1]	2,206	[1]	3,748	[1]	3,368	[1]	4,962	4,491	[1]	3,363	[1]
Loss on sale of fixed assets		(19)	[1]	17	[1]	0	[1]	(13)	[1]	31	[1]	3	[1]	152	84	[1]	35	[1]
Excess tax benefit from equity-based awards		142	[1]	(271)	[1]	0	[1]	(430)	[1]	0	[1]	(816)	[1]	0	(947)	[1]	(948)	[1]
Deferred income tax		1,823	[1]	473	[1]	2,503	[1]	2,056	[1]	3,238	[1]	2,918	[1]	2,979	5,953	[1]	5,106	[1]
Other		0	[1]	34	[1]	0	[1]	111	[1]	0	[1]	180	[1]	0	180	[1]	135	[1]
Changes in operating assets and liabilities:
Increase in patient accounts receivable		(2,185)	[1]	(2,185)	[1]	(2,449)	[1]	(2,880)	[1]	(2,548)	[1]	(4,148)	[1]	(3,275)	(5,519)	[1]	(5,388)	[1]
(Increase) decrease in accounts receivable - other		43	[1]	125	[1]	53	[1]	165	[1]	116	[1]	(145)	[1]	(400)	(852)	[1]	341	[1]
(Increase) decrease in other assets		(2,282)	[1]	106	[1]	(2,443)	[1]	(13)	[1]	(4,979)	[1]	(1,485)	[1]	(1,399)	(1,375)	[1]	1,155	[1]
Increase (decrease) in accounts payable and accrued expenses		3,392	[1]	(5,976)	[1]	6,603	[1]	(3,958)	[1]	3,582	[1]	(3,766)	[1]	2,994	(7,011)	[1]	1,868	[1]
Increase in mandatorily redeemable non-controlling interests		2,578	[1]	406	[1]	4,028	[1]	90	[1]	5,372	[1]	683	[1]	5,598	2,509	[1]	2,936	[1]
Increase (decrease) in other liabilities		365	[1]	665	[1]	447	[1]	927	[1]	708	[1]	380	[1]	352	1,396	[1]	(3,378)	[1]
Net cash provided by operating activities		14,211	[1]	2,475	[1]	31,053	[1]	17,237	[1]	38,198	[1]	26,171	[1]	51,050	37,520	[1]	41,391	[1]
INVESTING ACTIVITIES
Purchase of fixed assets		(1,738)	[1]	(1,419)	[1]	(3,453)	[1]	(2,873)	[1]	(5,620)	[1]	(4,690)	[1]	(8,260)	(6,263)	[1]	(5,167)	[1]
Purchase of businesses, net of cash acquired		(12,899)	[1]	(6,445)	[1]	(12,958)	[1]	(14,467)	[1]	(12,958)	[1]	(14,434)	[1]	(23,623)	(18,965)	[1]	(12,270)	[1]
Acquisitions of non-controlling interests		(388)	[1]	(359)	[1]	(250)	[1]	(968)	[1]	(664)	[1]	(942)	[1]	(670)	(968)	[1]	(227)	[1]
Proceeds on sale of fixed assets, net		42	[1]	8	[1]	42	[1]	72	[1]	42	[1]	71	[1]	61	71	[1]	47	[1]
Net cash used in investing activities		(14,983)	[1]	(8,215)	[1]	(16,619)	[1]	(18,236)	[1]	(19,200)	[1]	(19,995)	[1]	(32,492)	(26,125)	[1]	(17,617)	[1]
FINANCING ACTIVITIES
Distributions to non-controlling interests		(1,113)	[1]	(1,045)	[1]	(2,893)	[1]	(2,904)	[1]	(4,441)	[1]	(4,148)	[1]	(5,718)	(5,892)	[1]	(5,963)	[1]
Cash dividends to shareholders - funded		(2,125)	[1]			(4,254)	[1]	(3,723)	[1]	(6,382)	[1]	(5,586)	[1]	(8,510)	(7,449)	[1]	(5,873)	[1]
Proceeds from revolving line of credit		49,000	[1]	34,000	[1]	93,000	[1]	51,000	[1]	128,000	[1]	75,000	[1]	168,000	103,000	[1]	134,300	[1]
Payments on revolving line of credit		(40,500)	[1]	(27,000)	[1]	(94,500)	[1]	(44,500)	[1]	(136,000)	[1]	(63,500)	[1]	(166,000)	(93,500)	[1]	(139,800)	[1]
Payments to settle mandatorily redeemable non-controlling interests		(1,136)	[1]			(1,136)	[1]			(1,136)	[1]	(1,860)	[1]	(1,262)	(6,115)	[1]	(5,233)	[1]
Principal payments on notes payable		(250)	[1]	(200)	[1]	(533)	[1]	(608)	[1]	(592)	[1]	(616)	[1]	(800)	(884)	[1]	(825)	[1]
Tax benefit from equity-based awards		323	[1]	271	[1]	556	[1]	430	[1]	798	[1]	816	[1]	0	947	[1]	948	[1]
Other		1	[1]			1	[1]	5	[1]	1	[1]	5	[1]	1	5	[1]	45	[1]
Net cash (used in) provided by financing activities		4,200	[1]	6,026	[1]	(9,759)	[1]	(300)	[1]	(19,752)	[1]	111	[1]	(14,289)	(9,888)	[1]	(22,401)	[1]
Net increase in cash and cash equivalents		3,428	[1]	286	[1]	4,675	[1]	(1,299)	[1]	(754)	[1]	6,287	[1]	4,269	1,507	[1]	1,373	[1]
Cash and cash equivalents - beginning of period	[1]	15,778		14,271		15,778		14,271		15,778		14,271		15,778	14,271		12,898
Cash and cash equivalents - end of period		19,206	[1]	14,557	[1]	20,453	[1]	12,972	[1]	15,024	[1]	20,558	[1]	20,047	15,778	[1]	14,271	[1]
Cash paid during the period for:
Income taxes		2,265	[1]	1,275	[1]	5,513	[1]	3,835	[1]	10,051	[1]	5,659	[1]	10,584	7,779	[1]	9,253	[1]
Interest		248	[1]	235	[1]	512	[1]	460	[1]	770	[1]	616	[1]	784	884	[1]	1,103	[1]
Non-cash investing and financing transactions during the period:
Purchase of business - seller financing portion		500	[1]	$ 500	[1]	500	[1]	$ 1,350	[1]	500	[1]	1,350	[1]	1,000	1,800	[1]	400	[1]
Acquisition of noncontrolling interest - seller financing portion		388	[1]			388	[1]			388	[1]	0	[1]	387	0	[1]	0	[1]
Payment to settle redeemable non-controlling interest - financing portion		$ 126	[1]			126	[1]			126	[1]	$ 1,240	[1]	127	3,077	[1]	67	[1]
Receivable from sale of non-controlling interests						$ (148)	[1]			$ (148)	[1]			$ (138)	$ 0	[1]	$ 0	[1]
[1]	as restated

Organization, Nature of Operati

Organization, Nature of Operations and Basis of Presentation	12 Months Ended
	Dec. 31, 2016
Organization, Nature of Operations and Basis of Presentation [Abstract]
Organization, Nature of Operations and Basis of Presentation	1. Organization, Nature of Operations and Basis of Presentation U.S. Physical Therapy, Inc. and its subsidiaries (together, the “Company”) operate outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers and neurological-related injuries. As of December 31, 2016 the Company owned and/or operated 540 clinics in 42 states. The clinics’ business primarily originates from physician referrals. The principal sources of payment for the clinics’ services are managed care programs, commercial health insurance, Medicare/Medicaid, workers’ compensation insurance and proceeds from personal injury cases. In addition to the Company’s ownership and operation of outpatient physical therapy clinics, it also manages physical therapy facilities for third parties, such as physicians and hospitals, with 20 such third-party facilities under management as of December 31, 2016. The consolidated financial statements include the accounts of U.S. Physical Therapy, Inc. and its subsidiaries. All significant intercompany transactions and balances have been eliminated. The Company primarily operates through subsidiary clinic partnerships, in which the Company generally owns a 1% general partnership interest and a 49% to 99% limited partnership interest. The managing therapist of each clinic owns the remaining limited partnership interest in the majority of the clinics (hereinafter referred to as “Clinic Partnership”). To a lesser extent, the Company operates some clinics through wholly-owned subsidiaries under profit sharing arrangements with therapists (hereinafter referred to as “Wholly-Owned Facilities”). During the last three years, the Company completed the following multi-clinic acquisitions: Date % Interest Acquired Number of Clinics 2016 February 2016 Acquisition February 29 55 % 8 November 2016 Acquisition November 30 60 % 12 2015 January 2015 Acquisition January 31 60 % 9 April 2015 Acquisition April 30 70 % 3 June 2015 Acquisition June 30 70 % 4 December 2015 Acquisition December 31 59 % 4 2014 April 2014 Acquisition April 30 70 % 13 August 2014 Acquisition August 1 100 % 3 In addition to the multi-clinic acquisitions, the Company acquired two single clinic practices in separate transactions during 2016. During 2015, the Company acquired a 60% interest in a single clinic practice and, during 2014, the Company acquired four individual clinics in separate transactions. Clinic Partnerships For non-acquired Clinic Partnerships, the earnings and liabilities attributable to the non-controlling interest, typically owned by the managing therapist, directly or indirectly, are recorded within the statements of net income and balance sheets as non-controlling interests. For acquired Clinic Partnerships, the earnings and liabilities attributable to the non-controlling interest are recorded within the statements of net income line item: Wholly-Owned Facilities For Wholly-Owned Facilities with profit sharing arrangements, an appropriate accrual is recorded for the amount of profit sharing due the clinic partners/directors. The amount is expensed as compensation and included in clinic operating costs—salaries and related costs. The respective liability is included in current liabilities—accrued expenses on the balance sheets. Restatement of Prior Financial Statements Prior to issuing the 2016 annual financial statements, the Company determined it had previously incorrectly accounted for the non-controlling interests which were mandatorily redeemable. See Footnote 2 – Significant Accounting Policies – Mandatorily Redeemable Non-Controlling Interests – for a description of the accounting for mandatorily redeemable non-controlling interests. Management determined this correction was material to previously issued annual and quarterly consolidated financial statements. The Company, in this Annual Report on Form 10-K for the year ended December 31, 2016, is correcting its consolidated financial statements for the balance sheet as of December 31, 2015 and the statements of net income, cash flows and equity for the years ended December 31, 2015 and 2014, which includes a cumulative adjustment to the beginning balances as of January 1, 2014 (reported balances as of December 31, 2013). In addition, any prior information within footnotes, including quarterly data affected by this correction, is restated within the financial statements in this report. The following schedules present the impact of this correction on the Company’s previously reported consolidated balance sheet for the year ended December 31, 2015 and the consolidated statements of net income for the years ended December 31, 2015 and 2014 (in thousands, except share and per share data): Consolidated Balance Sheet on December 31, 2015: Description As Reported Adjustment As Restated Goodwill $ 171,457 $ 23,916 $ 195,373 Total assets $ 279,913 $ 23,844 $ 303,757 MRNCI (1) - $ 45,974 $ 45,974 Deferred taxes (liability) $ 8,355 $ 7,153 $ 15,508 Total liabilities $ 77,960 $ 53,487 $ 131,447 RNCI (2) $ 8,843 $ (8,843 ) - Additional paid-in capital $ 45,251 $ 18,987 $ 64,238 Retained earnings $ 149,016 $ (10,715 ) $ 138,301 Total liabilities and equity $ 279,913 $ 23,844 $ 303,757 (1) Mandatorily redeemable non-controlling interests (2) Redeemable non-controlling interests Consolidated Statement of Net Income for the Year Ended December 31, 2015: Description As Reported Adjustment As Restated Interest expense MRNCI (1) – changes in redemption value - $ 2,670 $ 2,670 MRNCI (1) – earnings allocable - $ 3,538 $ 3,538 Total interest expense $ 1,031 $ 6,208 $ 7,239 Net income before taxes $ 46,344 $ (6,208 ) $ 40,136 Provision for income taxes $ 14,653 $ (1,006 ) $ 13,647 Net income $ 31,691 $ (5,202 ) $ 26,489 Less: net income attributable to non-controlling interests $ 9,412 $ (3,538 ) $ 5,874 Net income attributable to USPH shareholders $ 22,279 $ (1,664 ) $ 20,615 Earnings per share $ 1.77 $ (0.11 ) $ 1.66 (1) See above. Consolidated Statement of Net Income for the Year Ended December 31, 2014: Description As Reported Adjustment As Restated Interest expense MRNCI (1) – change in redemption value - $ 2,978 $ 2,978 MRNCI (1) – earnings allocable - $ 3,388 $ 3,388 Total interest expense $ 1,088 $ 6,366 $ 7,454 Net income before taxes $ 44,698 $ (6,366 ) $ 38,332 Provision for income taxes $ 14,274 $ (1,256 ) $ 13,018 Net income $ 30,424 $ (5,110 ) $ 25,314 Less: net income attributable to non-controlling interests $ 9,571 $ (3,388 ) $ 6,183 Net income attributable to USPH shareholders $ 20,853 $ (1,722 ) $ 19,131 Earnings per share $ 1.62 $ (0.05 ) $ 1.57 (1) See above. The following schedules present the impact of this correction on the Company’s previously reported consolidated statements of cash flows for the years ended December 31, 2015 and 2014: Consolidated Statement of Cash Flows for the Year Ended December 31, 2015: Description As Reported Adjustment As Restated Net income $ 31,691 $ (5,202 ) $ 26,489 Deferred taxes $ 7,001 $ (1,048 ) $ 5,953 (Increase) decrease in other assets $ (1,477 ) $ 102 $ (1,375 ) (Decrease) increase in accounts payable and accrued expenses $ (7,013 ) $ 2 $ (7,011 ) Increase in mandatorily redeemable non-controlling interest $ - $ 2,509 $ 2,509 (Decrease) increase in other liabilities $ 1,482 $ (86 ) $ 1,396 Net cash provided by operating activities $ 41,243 $ (3,723 ) $ 37,520 Acquisitions of non-controlling interests $ (7,083 ) $ 6,115 $ (968 ) Net cash used in investing activities $ (32,240 ) $ 6,115 $ (26,125 ) Distributions to non-controlling interests (including redeemable non-controlling interests) $ (9,632 ) $ 9,632 $ - Distributions to non-controlling interests $ - $ (5,892 ) $ (5,892 ) Payments to settle mandatorily redeemable non-controlling interests $ - $ (6,115 ) $ (6,115 ) Other $ 22 $ (17 ) $ 5 Net cash used in financing activities $ (7,496 ) $ (2,392 ) $ (9,888 ) Consolidated Statement of Cash Flows for the Year Ended December 31, 2014: Description As Reported Adjustment As Restated Net income $ 30,424 $ (5,110 ) $ 25,314 Deferred taxes $ 6,275 $ (1,169 ) $ 5,106 (Increase) decrease in other assets $ (2,493 ) $ 3,648 $ 1,155 Increase in mandatorily redeemable non-controlling interest $ - $ 2,936 $ 2,936 (Decrease) increase in other liabilities $ 730 $ (4,108 ) $ (3,378 ) Net cash provided by operating activities $ 45,194 $ (3,803 ) $ 41,391 Acquisitions of non-controlling interests $ (5,490 ) $ 5,263 $ (227 ) Net cash used in investing activities $ (22,880 ) $ 5,263 $ (17,617 ) Distributions to non-controlling interests (including redeemable non-controlling interests) $ (9,913 ) $ 9,913 $ - Distributions to non-controlling interests $ - $ (5,963 ) $ (5,963 ) Payments to settle mandatorily redeemable non-controlling interests $ - $ (5,233 ) $ (5,233 ) Other $ 222 $ (177 ) $ 45 Net cash used in financing activities $ (20,941 ) $ (1,460 ) $ (22,401 )

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Significant Accounting Policies [Abstract]
Significant Accounting Policies	2. Significant Accounting Policies Cash Equivalents The Company maintains its cash and cash equivalents at financial institutions. The combined account balances at several institutions typically exceed Federal Deposit Insurance Corporation (“FDIC”) insurance coverage and, as a result, there is a concentration of credit risk related to amounts on deposit in excess of FDIC insurance coverage. Management believes that this risk is not significant. Long-Lived Assets Fixed assets are stated at cost. Depreciation is computed on the straight-line method over the estimated useful lives of the related assets. Estimated useful lives for furniture and equipment range from three to eight years and for software purchased from three to seven years. Leasehold improvements are amortized over the shorter of the related lease term or estimated useful lives of the assets, which is generally three to five years. Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of The Company reviews property and equipment and intangible assets with finite lives for impairment upon the occurrence of certain events or circumstances that indicate the related amounts may be impaired. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. Goodwill Goodwill represents the excess of the amount paid and fair value of the non-controlling interests over the fair value of the acquired business assets, which include certain identifiable intangible assets. Historically, goodwill has been derived from acquisitions and, prior to 2009, from the purchase of some or all of a particular local management’s equity interest in an existing clinic. Effective January 1, 2009, if the purchase price of a non-controlling interest by the Company exceeds or is less than the book value at the time of purchase, any excess or shortfall is recognized as an adjustment to additional paid-in capital. The fair value of goodwill and other identifiable intangible assets with indefinite lives are tested for impairment annually and upon the occurrence of certain events, and are written down to fair value if considered impaired. The Company evaluates goodwill for impairment on at least an annual basis (in its third quarter) by comparing the fair value of its reporting units to the carrying value of each reporting unit including related goodwill. The Company operates a one segment business which is made up of various clinics within partnerships. The partnerships are components of regions and are aggregated to the operating segment level for the purpose of determining the Company’s reporting units when performing its annual goodwill impairment test. In 2016, 2015 and 2014, there were six regions. An impairment loss generally would be recognized when the carrying amount of the net assets of a reporting unit, inclusive of goodwill and other identifiable intangible assets, exceeds the estimated fair value of the reporting unit. The estimated fair value of a reporting unit is determined using two factors: (i) earnings prior to taxes, depreciation and amortization for the reporting unit multiplied by a price/earnings ratio used in the industry and (ii) a discounted cash flow analysis. A weight is assigned to each factor and the sum of each weight times the factor is considered the estimated fair value. For 2016, the factors (i.e., price/earnings ratio, discount rate and residual capitalization rate) were updated to reflect current market conditions. The evaluation of goodwill in 2016, 2015 and 2014 did not result in any goodwill amounts that were deemed impaired. The Company has not identified any triggering events occurring after the testing date that would impact the impairment testing results obtained. Factors which could result in future impairment charges include but are not limited to: • cost, risks and uncertainties associated with the Company’s recent restatement of its prior financial statements due to the correction of its accounting methodology for redeemable non-controlling partnership interests, and including any pending and future claims or proceedings relating to such matters; • changes as the result of government enacted national healthcare reform; • changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification or enrollment status; • revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction; • business and regulatory conditions including federal and state regulation; • governmental and other third party payor inspections, reviews, investigations and audits; • compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information and associated fines and penalties for failure to comply; • legal actions, which could subject us to increased operating costs and uninsured liabilities; • changes in reimbursement rates or payment methods from third party payors including government agencies and deductibles and co-pays owed by patients; • revenue and earnings expectations; • general economic conditions; • availability and cost of qualified physical and occupational therapists; • personnel productivity and retaining key personnel; • competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain operations and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets; • acquisitions, purchases of non-controlling interests (minority interests) and the successful integration of the operations of the acquired business; • maintaining necessary insurance coverage; • availability, terms, and use of capital; and • weather and other seasonal factors. The Company will continue to monitor for any triggering events or other indicators of impairment. Mandatorily Redeemable Non-Controlling Interests – The non-controlling interests that are reflected as mandatorily redeemable non-controlling interests in the consolidated financial statements consist of those owners who have certain redemption rights, whether currently exercisable or not, and which currently, or in the future, require that the Company purchase the non-controlling interest of those owners at a predetermined formula based on a multiple of trailing twelve months earnings performance as defined in the respective limited partnership agreements. The redemption rights are triggered at such time as both of the following events have occurred: 1) termination of the owner’s employment, regardless of the reason for such termination, and 2) the passage of specified number of years after the closing of the transaction, typically three to five years, as defined in the limited partnership agreement. On the date the Company acquires a controlling interest in a partnership and the limited partnership agreement contains mandatory redemption rights, the fair value of the non-controlling interest is recorded in the long-term liabilities section of the consolidated balance sheet under the caption – Mandatorily redeemable non-controlling interests Interest expense – mandatorily redeemable non-controlling interests – change in redemption value and Interest expense – mandatorily redeemable non-controlling interests – earnings allocable Non-Controlling Interests The Company recognizes non-controlling interests as equity in the consolidated financial statements separate from the parent entity’s equity. The amount of net income attributable to non-controlling interests is included in consolidated net income on the face of the statements of net income. Changes in a parent entity’s ownership interest in a subsidiary that do not result in deconsolidation are treated as equity transactions if the parent entity retains its controlling financial interest. The Company recognizes a gain or loss in net income when a subsidiary is deconsolidated. Such gain or loss is measured using the fair value of the non-controlling equity investment on the deconsolidation date. When the purchase price of a non-controlling interest by the Company exceeds the book value at the time of purchase, any excess or shortfall is recognized as an adjustment to additional paid-in capital. Additionally, operating losses are allocated to non-controlling interests even when such allocation creates a deficit balance for the non-controlling interest partner. Revenue Recognition Revenues are recognized in the period in which services are rendered. Net patient revenues (patient revenues less estimated contractual adjustments) are reported at the estimated net realizable amounts from third-party payors, patients and others for services rendered. The Company has agreements with third-party payors that provide for payments to the Company at amounts different from its established rates. The allowance for estimated contractual adjustments is based on terms of payor contracts and historical collection and write-off experience. The Company determines allowances for doubtful accounts based on the specific agings and payor classifications at each clinic. The provision for doubtful accounts is included in clinic operating costs in the statements of net income. Patient accounts receivable, which are stated at the historical carrying amount net of contractual allowances, write-offs and allowance for doubtful accounts, includes only those amounts the Company estimates to be collectible. Medicare Reimbursement The Medicare program reimburses outpatient rehabilitation providers based on the Medicare Physician Fee Schedule (‘‘MPFS’’). The MPFS rates have historically been subject to an automatic annual update based on a formula, called the sustainable growth rate (‘‘SGR’’) formula. The use of the SGR formula would have resulted in calculated automatic reductions in rates in every year since 2002; however, for each year through September 30, 2015, Centers for Medicare & Medicaid Services (‘‘CMS’’) or Congress has taken action to prevent the implementation of SGR formula reductions. On April 16, 2015, the Medicare Access and CHIP Reauthorization Act of 2015 (‘‘MACRA’’) was signed into law, eliminating the SGR formula and the associated annual automatic rate reductions. For services provided between January 1, 2015 and June 30, 2015 a 0% payment update was applied to the Medicare physician fee schedule payment rates; for services provided between July 1, 2015 and December 31, 2015 a 0.5% increase was applied to the fee schedule payment rates; for services provided in 2016 a 0.3% decrease is being applied to the fee schedule payment rates, and for 2017 through 2019, a 0.5% increase will be applied each year to the fee schedule payment rates, unless further adjusted by CMS. The payment adjustments proposed by CMS for 2017 is a .08% reduction. In addition, the MACRA promotes the development of new payment models that focus on quality and outcomes. The Budget Control Act of 2011 increased the federal debt ceiling in connection with deficit reductions over the next ten years, and requires automatic reductions in federal spending by approximately $1.2 trillion. Payments to Medicare providers are subject to these automatic spending reductions, subject to a 2% cap. On April 1, 2013, a 2% reduction to Medicare payments was implemented. The Bipartisan Budget Act of 2015, enacted on November 2, 2015, extends the 2% reductions to Medicare payments through fiscal year 2025. As a result of the Balanced Budget Act of 1997, the formula for determining the total amount paid by Medicare in any one year for outpatient physical therapy, occupational therapy, and/or speech-language pathology services provided to any Medicare beneficiary (i.e., the ‘‘Therapy Cap’’ or ‘‘Limit’’) was established. Based on the statutory definitions which constrained how the Therapy Cap would be applied, there is one Limit for Physical Therapy and Speech Language Pathology Services combined, and one Limit for Occupational Therapy. For 2016, the annual Limit on outpatient therapy services is $1,960 for Physical and Speech Language Pathology Services combined and $1,960 for Occupational Therapy Services. Historically, these Therapy Caps applied to outpatient therapy services provided in all settings, except for services provided in departments of hospitals. However, the Protecting Access to Medicare Act of 2014, and prior legislation, extended the Therapy Caps to services furnished in hospital outpatient department settings. The application of these annual limits to hospital outpatient department settings will sunset on December 31, 2017 unless Congress extends it. In the Deficit Reduction Act of 2005, Congress implemented an exceptions process to the annual Limit for therapy expenses for therapy services above the annual Limit. Therapy services above the annual Limit that are medically necessary satisfy an exception to the annual Limit and such claims are payable by the Medicare program. The MACRA extended the exceptions process for outpatient therapy caps through December 31, 2017. Unless Congress extends the exceptions process further, the therapy caps will apply to all outpatient therapy services beginning January 1, 2018, except those services furnished and billed by outpatient hospital departments. For any claim above the annual Limit, the claim must contain a modifier indicating that the services are medically necessary and justified by appropriate documentation in the medical record. Furthermore, under the Middle Class Tax Relief and Job Creation Act of 2012 (‘‘MCTRA’’), since October 1, 2012, patients who met or exceeded $3,700 in therapy expenditures during a calendar year have been subject to a manual medical review to determine whether applicable payment criteria are satisfied. The $3,700 threshold is applied to Physical Therapy and Speech Language Pathology Services; a separate $3,700 threshold is applied to the Occupational Therapy. The MACRA directed CMS to modify the manual medical review process such that those reviews will no longer apply to all claims exceeding the $3,700 threshold and instead will be determined on a targeted basis based on a variety of factors that CMS considers appropriate. The new factors apply to exception requests for which CMS did not conduct a medical review by July 15, 2015. CMS adopted a multiple procedure payment reduction (‘‘MPPR’’) for therapy services in the final update to the MPFS for calendar year 2011. The MPPR applied to all outpatient therapy services paid under Medicare Part B — occupational therapy, physical therapy and speech-language pathology. Under the policy, the Medicare program pays 100% of the practice expense component of the Relative Value Unit (‘‘RVU’’) for the therapy procedure with the highest practice expense RVU, then reduces the payment for the practice expense component for the second and subsequent therapy procedures or units of service furnished during the same day for the same patient, regardless of whether those therapy services are furnished in separate sessions. Since 2013, the practice expense component for the second and subsequent therapy service furnished during the same day for the same patient was reduced by 50%. In addition, the MCTRA directed CMS to implement a claims-based data collection program to gather additional data on patient function during the course of therapy in order to better understand patient conditions and outcomes. All practice settings that provide outpatient therapy services are required to include this data on the claim form. Since 2013, therapists have been required to report new codes and modifiers on the claim form that reflect a patient’s functional limitations and goals at initial evaluation, periodically throughout care, and at discharge, CMS has rejected claims if the required data is not included in the claim. The Physician Quality Reporting System, or ‘‘PQRS,’’ is a CMS reporting program that uses a combination of incentive payments and payment reductions to promote reporting of quality information by ‘‘eligible professionals.’’ Although physical therapists, occupational therapists and qualified speech-language therapists are generally able to participate in the PQRS program, therapy professionals for whose services we bill through our certified rehabilitation agencies cannot participate because the Medicare claims processing systems currently cannot accommodate institutional providers such as certified rehabilitation agencies. Eligible professionals, such as those of our therapy professionals for whose services we bill using their individual Medicare provider numbers, who do not satisfactorily report data on quality measures will be subject to a 2% reduction in their Medicare payment in 2016 and 2017. As required under the MACRA, the PQRS program will be replaced with the Merit-Based Incentive Payment System (MIPS) on January 1, 2017. Physical therapists and occupational therapists are not required to participate in the MIPS program until January 1, 2019 or later, as determined by CMS. Statutes, regulations, and payment rules governing the delivery of therapy services to Medicare beneficiaries are complex and subject to interpretation. The Company believes that it is in compliance in all material respects with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing that would have a material effect on the Company’s financial statements as of September 30, 2016. Compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from the Medicare program. For the year ended December 31, 2016, net revenue from Medicare accounts for approximately $81.8 million. Management Contract Revenues Management contract revenues are derived from contractual arrangements whereby the Company manages a clinic for third party owners. The Company does not have any ownership interest in these clinics. Typically, revenues are determined based on the number of visits conducted at the clinic and recognized when services are performed. Costs, typically salaries for the Company’s employees, are recorded when incurred. Management contract revenues are included in “other revenues” in the accompanying Consolidated Statements of Net Income. Contractual Allowances Contractual allowances result from the differences between the rates charged for services performed and expected reimbursements by both insurance companies and government sponsored healthcare programs for such services. Medicare regulations and the various third party payors and managed care contracts are often complex and may include multiple reimbursement mechanisms payable for the services provided in Company clinics. The Company estimates contractual allowances based on its interpretation of the applicable regulations, payor contracts and historical calculations. Each month the Company estimates its contractual allowance for each clinic based on payor contracts and the historical collection experience of the clinic and applies an appropriate contractual allowance reserve percentage to the gross accounts receivable balances for each payor of the clinic. Based on the Company’s historical experience, calculating the contractual allowance reserve percentage at the payor level is sufficient to allow the Company to provide the necessary detail and accuracy with its collectability estimates. However, the services authorized and provided and related reimbursement are subject to interpretation that could result in payments that differ from the Company’s estimates. Payor terms are periodically revised necessitating continual review and assessment of the estimates made by management. The Company’s billing system does not capture the exact change in its contractual allowance reserve estimate from period to period in order to assess the accuracy of its revenues and hence its contractual allowance reserves. Management regularly compares its cash collections to corresponding net revenues measured both in the aggregate and on a clinic-by-clinic basis. In the aggregate, historically the difference between net revenues and corresponding cash collections has generally reflected a difference within approximately 1% of net revenues. Additionally, analysis of subsequent period’s contractual write-offs on a payor basis reflects a difference within approximately 1% between the actual aggregate contractual reserve percentage as compared to the estimated contractual allowance reserve percentage associated with the same period end balance. As a result, the Company believes that a change in the contractual allowance reserve estimate would not likely be more than 1% at December 31, 2016. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount to be recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company did not have any accrued interest or penalties associated with any unrecognized tax benefits nor was any interest expense recognized during the twelve months ended December 31, 2016 and 2015. The Company will book any interest or penalties, if required, in interest and/or other income/expense as appropriate. On September 13, 2013, the U.S. Treasury Department and the I.R.S. issued final regulations that address costs incurred in acquiring, producing, or improving tangible property (the “Tangible Property Regulations”). The Tangible Property Regulations are generally effective for tax years beginning on or after January 1, 2014, and may be adopted in earlier years. The Company adopted the tax treatment of expenditures to improve tangible property and the capitalization of inherently facilitative costs to acquire tangible property as of January 1, 2014. Historically, the Company has treated the expenditures to improve tangible property and the capitalization of inherently facilitative costs to acquire tangible property similar for tax and book. The impact of these changes were not material to the Company's consolidated financial statements. Fair Values of Financial Instruments The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable and notes payable approximate their fair values due to the short-term maturity of these financial instruments. The carrying amount under the Amended Credit Agreement (as defined in Note 9) approximates its fair value. The interest rate on the Credit Agreement, which is tied to the Eurodollar Rate, is set at various short-term intervals, as detailed in the Credit Agreement. Segment Reporting Operating segments are components of an enterprise for which separate financial information is available that is evaluated regularly by chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company identifies operating segments based on management responsibility and believes it meets the criteria for aggregating its operating segments into a single reporting segment. Use of Estimates In preparing the Company’s consolidated financial statements, management makes certain estimates and assumptions, especially in relation to, but not limited to, goodwill impairment, allowance for receivables, tax provision and contractual allowances, that affect the amounts reported in the consolidated financial statements and related disclosures. Actual results may differ from these estimates. Self-Insurance Program The Company utilizes a self-insurance plan for its employee group health insurance coverage administered by a third party. Predetermined loss limits have been arranged with the insurance company to minimize the Company’s maximum liability and cash outlay. Accrued expenses include the estimated incurred but unreported costs to settle unpaid claims and estimated future claims. Management believes that the current accrued amounts are sufficient to pay claims arising from self-insurance claims incurred through December 31, 2016. Restricted Stock Restricted stock issued to employees and directors is subject to continued employment or continued service on the board, respectively. Generally, restrictions on the stock granted to employees lapse in equal annual installments on the following four anniversaries of the date of grant. For those shares granted to directors, the restrictions will lapse in equal quarterly installments during the first year after the date of grant. For those granted to executive officers, the restriction will lapse in equal quarterly installments during the four years following the date of grant. Compensation expense for grants of restricted stock is recognized based on the fair value per share on the date of grant amortized over the vesting period. The restricted stock issued is included in basic and diluted shares for the earnings per share computation. Recently Adopted Accounting Guidance In September 2015, the FASB issued changes to the accounting for measurement-period adjustments related to business combinations. Currently, an acquiring entity is required to retrospectively adjust the balance sheet amounts of the acquiree recognized at the acquisition date with a corresponding adjustment to goodwill during the measurement period, as well as revise comparative information for prior periods presented within financial statements as needed, including revising income effects, such as depreciation and amortization, as a result of changes made to the balance sheet amounts of the acquiree. Such adjustments are required when new information is obtained about facts and circumstances that existed as of the acquisition date that if known, would have affected the measurement of the amounts initially recognized or would have resulted in the recognition of additional assets or liabilities. The measurement period is the period after the acquisition date during which the acquirer may adjust the balance sheet amounts recognized for a business combination (generally up to one year from the date of acquisition). The changes eliminate the requirement to make such retrospective adjustments, and, instead require the acquiring entity to record these adjustments in the reporting period they are determined. Additionally, the changes require the acquiring entity to present separately on the face of the income statement or disclose in the notes to the financial statements the portion of the amount recorded in current-period income by line item that would have been recorded in previous reporting periods if the adjustment to the balance sheet amounts had been recognized as of the acquisition date. These changes became effective for the Company on January 1, 2016. This change did not have a material impact on its consolidated financial statements. In March 2016, the FASB issued guidance to simplify some provisions in stock compensation accounting. The guidance amends how excess tax benefits and a company’s payments to cover tax bills for the recipients’ shares should be classified. Prior to this guidance, excess tax benefits were recorded in additional paid-in capital, but will now become a component of the income tax provision/benefit in the period in which they occur. This guidance allows companies to estimate the number of stock awards expected to vest and revises the withholding requirements for classifying stock awards as equity. For public business entities, this guidance is effective for fiscal years starting after December 15, 2016, including interim periods within those fiscal years but early adoption is allowed. The Company adopted this accounting treatment in the fourth quarter of 2016. The adoption increased earnings, by decreasing the tax provision, by $1.0 million, or $0.09 per share, for the full fiscal year 2016. The election to record forfeitures in the period they occur is consistent with the Company’s past approach, due to the immateriality of past forfeitures, and the Company believes the effect to be immaterial on the consolidated financial statements. Recently Issued Accounting Guidance In February 2016, the FASB issued amended accounting guidance which replaced most existing lease accounting guidance under U. S. generally accepted accounting principles. Among other changes, the amended guidance requires that a right-to-use asset, which is an asset that represents the lessee’s right to use, and a lease liability, which is a lessee’s obligation to make lease payments arising for a lease measured on a discounted basis, be recognized on the balance sheet by lessees for those leases with a term of greater than 12 months. The amended guidance is effective for reporting periods beginning after December 15, 2018; however, early adoption is permitted. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Since the Company leases all but one of its clinic facilities, it has been evaluating various lease management systems to capture the necessary information and the impact that this amended accounting guidance will have on its consolidated financial statements. Subsequent Event The Company has evaluated events occurring after the balance sheet date for possible disclosure as a subsequent event through the date that these consolidated financial statements were issued. In January 2017, the Company acquired a 70% interest in a physical therapy practice that owns and operates 17 clinics and manages an additional 8 clinics. The purchase price for the 70% interest was $11.4 million. In March 2017, the Company acquired a 55% interest in a company which is a provider of workforce performance solutions. The purchase price for the 55% interest was $6.6 million. In May 2017, the Company acquired a 70% interest in a physical therapy practice that owns and operates 4 clinics. The purchase price for the 70% interest was $2.5 million. Although the restatement of prior financial statements caused the Company to be in violation of our Amended Credit Agreement dated December 5, 2013, the Company was able to obtain necessary waivers and amendments, as applicable. On March 30, 2017, the Company entered into a Third Amendment to Amended and Restated Credit Agreement and Limited Waiver with its lenders. As of the date of this report, the Company is in compliance with the covenants in the Amended and Restated Credit Agreement.

Acquisitions of Businesses

Acquisitions of Businesses	12 Months Ended
	Dec. 31, 2016
Acquisitions of Businesses [Abstract]
Acquisitions of Businesses	3. Acquisitions of Businesses During 2016, 2015 and 2014, the Company completed the following multi-clinic acquisitions of physical therapy practices: Date % Interest Acquired Number of Clinics 2016 February 2016 Acquisition February 29 55 % 8 November 2016 Acquisition November 30 60 % 12 2015 January 2015 Acquisition January 31 60 % 9 April 2015 Acquisition April 30 70 % 3 June 2015 Acquisition June 30 70 % 4 December 2015 Acquisition December 31 59 % 4 2014 April 2014 Acquisition April 30 70 % 13 August 2014 Acquisition August 1 100 % 3 In addition to the multi-clinic acquisitions, the Company acquired two single clinic practices in separate transactions during 2016. During 2015, the Company acquired a 60% interest in a single clinic practice and, during 2014, the Company acquired four individual clinics in separate transactions. On November 30, 2016, the Company acquired a 60% interest in a 12 clinic physical therapy practice. The purchase price for the 60% interest was $11.0 million in cash and $0.5 million in a seller note that is payable in two principal installments of $250,000 each, plus accrued interest, in November 2017 and 2018. On February 29, 2016, the Company acquired a 55% interest in an eight-clinic physical therapy practice. The purchase price for the 55% interest was $13.2 million in cash and $0.5 million in a seller note that is payable in two principal installments of $250,000 each, plus accrued interest, in February 2017 and 2018. During 2016, two subsidiaries of the Company each acquired a single clinic therapy practice for an aggregate purchase price of $75,000. The purchase price for the 2016 acquisitions has been preliminarily allocated as follows (in thousands): Cash paid, net of cash acquired $ 23,623 Seller notes 1,000 Total consideration $ 24,623 Estimated fair value of net tangible assets acquired: Total current assets $ 1,712 Total non-current assets 1,202 Total liabilities (398 ) Net tangible assets acquired $ 2,516 Referral relationships 4,919 Non-compete 847 Tradename 3,802 Goodwill 31,419 Fair value of non-controlling interest (18,880 ) $ 24,623 On December 31, 2015, the Company acquired a 59% interest in a four-clinic physical therapy practice. The purchase price was $4.6 million in cash and $400,000 in seller notes payable that were payable in two principal installments of an aggregate of $200,000 each, plus accrued interest. The first payment was paid in December 2016 and the second installment is due December 2017. On June 30, 2015, the Company acquired a 70% interest in a four-clinic physical therapy practice. The purchase price was $3.6 million in cash and $0.7 million in seller notes that are payable plus accrued interest, in June 2018. On April 30, 2015, the Company acquired a 70% interest in a three-clinic physical therapy practice. The purchase price was $4.7 million in cash and $150,000 in a seller note that was payable in two principal installments of $75,000 each, plus accrued interest. The first payment was paid in April 2016 and the second installment is due in April 2017. On January 31, 2015, the Company acquired a 60% interest in a nine-clinic physical therapy practice. The purchase price for the 60% interest was $6.7 million in cash and $0.5 million in a seller note that is payable in two principal installments of $250,000 each, plus accrued interest. This note was paid in full in January 2017. In addition to the multi-clinic acquisitions, on August 31, 2015, the Company acquired a 60% interest in a single physical therapy clinic for $150,000 in cash and $50,000 in a seller note payable that is payable plus accrued interest was paid in August 2016. The purchase prices for the 2015 acquisitions have been allocated as follows (in thousands): Cash paid, net of cash acquired $ 18,965 Seller notes 1,800 Total consideration $ 20,765 Estimated fair value of net tangible assets acquired: Total current assets $ 1,952 Total non-current assets 1,068 Total liabilities (1,067 ) Net tangible assets acquired $ 1,953 Referral relationships 3,655 Non-compete 594 Tradename 3,417 Goodwill 23,437 Fair value of non-controlling interest (12,291 ) $ 20,765 The purchase price for the 70% interest in the April 2014 Acquisition was $10.6 million in cash and a $400,000 seller note, that was paid in two principal installments totaling $200,000 each, plus accrued interest, in April 2015 and 2016. The purchase price for the August 2014 Acquisition was $1.0 million in cash. In addition, during 2014, the Company acquired three individual clinic practices for an aggregate of $595,000. The purchase prices for the 2014 acquisitions have been allocated as follows (in thousands): Cash paid, net of cash acquired $ 12,270 Seller notes 400 Total consideration $ 12,670 Estimated fair value of net tangible assets acquired: Total current assets $ 1,213 Total non-current assets 1,051 Total liabilities (406 ) Net tangible assets acquired $ 1,858 Referral relationships 280 Non-compete 330 Tradename 1,600 Goodwill 13,327 Fair value of non-controlling interest (4,725 ) $ 12,670 The purchase prices plus the fair value of the non-controlling interests for the acquisitions in 2015 and 2014 were allocated to the fair value of the assets acquired, inclusive of identifiable intangible assets, i.e. trade names, referral relationships and non-compete agreements, and liabilities assumed based on the fair values at the acquisition date, with the amount exceeding the fair values being recorded as goodwill. For the acquisitions in 2016, the Company is in the process of completing its formal valuation analysis to identify and determine the fair value of tangible and identifiable intangible assets acquired and the liabilities assumed. Thus, the final allocation of the purchase price may differ from the preliminary estimates used at December 31, 2016 based on additional information obtained and completion of the valuation of the identifiable intangible assets. Changes in the estimated valuation of the tangible assets acquired, the completion of the valuation of identifiable intangible assets and the completion by the Company of the identification of any unrecorded pre-acquisition contingencies, where the liability is probable and the amount can be reasonably estimated, will likely result in adjustments to goodwill. For the acquisitions in 2015 and 2014, the values assigned to the referral relationships and non-compete agreements are being amortized to expense equally over the respective estimated lives. For referral relationships, the range of the estimated lives was 4½ to 13 years, and for non-compete agreements the estimated lives was five to six years. Generally, the values assigned to tradenames are tested annually for impairment, however with regards to one acquisition in 2013, the tradename was being amortized over the term of the six year agreement in which the Company has acquired the rights to use the specific tradename. In 2016, the remaining value of the tradename was charged to earnings as the Company decided to combine two acquired operations in Georgia; therefore, the tradename under this six year agreement will no longer be used. The values assigned to goodwill are tested annually for impairment. For the 2016, 2015 and 2014 acquisitions, total current assets primarily represent patient accounts receivable. Total non-current assets are fixed assets, primarily equipment, used in the practices. The consideration paid for each of the acquisitions was derived through arm’s length negotiations. Funding for the cash portions was derived from proceeds from the Company’s revolving credit facility. The results of operations of the acquisitions have been included in the Company’s consolidated financial statements since their respective date of acquisition. Unaudited proforma consolidated financial information for the acquisitions in 2016, 2015 and 2014 acquisitions have not been included as the results, individually and in the aggregate, were not material to current operations.

Non-Controlling Interests

Non-Controlling Interests	12 Months Ended
	Dec. 31, 2016
Non-Controlling Interests [Abstract]
Non-Controlling Interests	4. Non-Controlling Interests During 2016, the Company acquired additional interests in six partnerships included in non-controlling interest.. The interests in the partnerships purchased ranged from 2% to 35%. The aggregate purchase price paid was $0.9 million in cash and $0.4 million in a seller note, that is payable in two principal installments of $194,000 each in February 2017 and 2018. The purchase price included $112,000 of undistributed earnings. The remaining $1.2 million, less future tax benefits of $0.5 million, was recognized as an adjustment to additional paid-in capital. During 2016, the Company sold a 4% interest in one partnership and 35% in another. The sales prices included aggregate cash of $138,000 plus notes receivable of $148,000 with payments due monthly based on percentages of distributions and bonuses earned by the purchasers. The total sales price of $286,000, less the tax effect of $110,000, was charged to additional paid-in capital. In 2015, the Company purchased additional interests in six partnerships. The interests in the partnerships purchased ranged from 5% to 35%. The aggregate purchase prices paid were $0.9 million in cash. The purchase prices included an aggregate of $217,000 of undistributed earnings. The remaining $0.7 million, less future tax benefits of $0.3 million, was recognized as an adjustment to additional paid-in capital.

Redeemable Non-Controlling Inte

Redeemable Non-Controlling Interest	12 Months Ended
	Dec. 31, 2016
Redeemable Non-Controlling Interest [Abstract]
Redeemable Non-Controlling Interest	5. Redeemable Non-Controlling Interest The Company acquires a majority interest (the “Acquisition”) in a physical therapy clinic business (referred to as “Therapy Practice”). These Acquisitions occur in a series of steps which are described below. 1. Prior to the Acquisition, the Therapy Practice exists as a separate legal entity (the “Seller Entity”). The Seller Entity is owned by one or more individuals (the “Selling Shareholders”) most of whom are physical therapists that work in the Therapy Practice and provide physical therapy services to patients. 2. In conjunction with the Acquisition, the Seller Entity contributes the Therapy Practice into a newly-formed limited partnership (“NewCo”), in exchange for one hundred percent (100%) of the limited and general partnership interests in NewCo. Therefore, in this step, NewCo becomes a wholly-owned subsidiary of the Seller Entity. 3. The Company enters into an agreement (the “Purchase Agreement”) to acquire from the Seller Entity a majority (ranges from 50% to 90%) of the limited partnership interest and in all 4. The Company and the Seller Entity also execute a partnership agreement (the “Partnership Agreement”) for NewCo that sets forth the rights and obligations of the limited and general partners of NewCo. After the Acquisition, the Company is the general partner of NewCo. 5. As noted above, the Company does not purchase 100% of the limited partnership interests in NewCo and the Seller Entity retains a portion of the limited partnership interest in NewCo (“Seller Entity Interest”). 6. In most cases, some or all of the Selling Shareholders enter into an employment agreement (the “Employment Agreement”) with NewCo with an initial term that ranges from three to five years (the “Employment Term”), with automatic one-year renewals, unless employment is terminated prior to the end of the Employment Term. As a result, a Selling Shareholder becomes an employee (“Employed Selling Shareholder”) of NewCo. The employment of an Employed Selling Shareholder can be terminated by the Employed Selling Shareholder or NewCo, with or without cause, at any time. In a few situations, a Selling Shareholder does not become employed by NewCo and is not involved with NewCo following the closing; in those situations, such Selling Shareholders sell their entire ownership interest in the Seller Entity as of the closing of the Acquisition. 7. The compensation of each Employed Selling Shareholder is specified in the Employment Agreement and is customary and commensurate with his or her responsibilities based on other employees in similar capacities within NewCo, the Company and the industry. 8. The Company and the Selling Shareholder (including both Employed Selling Shareholders and Selling Shareholders not employed by NewCo) execute a non-compete agreement (the “Non-Compete Agreement”) which restricts the Selling Shareholder from engaging in competing business activities for a specified period of time (the “Non-Compete Term”). A Non-Compete Agreement is executed with the Selling Shareholders in all cases. That is, even if the Selling Shareholder does not become an Employed Selling Shareholder, the Selling Shareholder is restricted from engaging in a competing business during the Non-Compete Term. 9. The Non-Compete Term commences as of the date of the Acquisition and expires on the later a. Two years after the date an Employed Selling Shareholders’ employment is terminated (if the Selling Shareholder becomes an Employed Selling Shareholder) or b. Five to six years from the date of the Acquisition, as defined in the Non-Compete Agreement, regardless of whether the Selling Shareholder is employed by NewCo. 10. The Non-Compete Agreement applies to a restricted region which is defined as a 15-mile radius from the Therapy Practice. That is, an Employed Selling Shareholder is permitted to engage in competing businesses or activities outside the 15-mile radius (after such Employed Selling Shareholder no longer is employed by NewCo) and a Selling Shareholder who is not employed by NewCo immediately is permitted to engage in the competing business or activities outside the 15-mile radius. 11. The Partnership Agreement contains provisions for the redemption of the Seller Entity Interest, either at the option of the Company (the “Call Option”) or on a required basis (the “Required Redemption”): a. Required Redemption i. Once the Required Redemption is triggered, the Company is obligated to purchase from the Seller Entity and the Seller Entity is obligated to sell to the Company, the allocable portion of the Seller Entity Interest based on the terminated Selling Shareholder’s pro rata ownership interest in the Seller Entity (the “Allocable Portion”). Required Redemption is triggered when both 1. Termination of an Employed Selling Shareholder’s employment with NewCo, regardless of the reason for such termination, and 2. The expiration of an agreed upon period of time, typically three to five years, as set forth in the relevant Partnership Agreement (the “Holding Period”). ii. In the event an Employed Selling Shareholder’s employment terminates prior to the expiration of the Holding Period, the Required Redemption would occur only b. Call Option i. In the event that an Employed Selling Shareholder’s employment terminates prior to expiration of the Holding Period, the Company has the contractual right, but not the obligation, to acquire the Employed Selling Shareholder’s Allocable Portion of the Seller Entity Interest from the Seller Entity through exercise of the Call Option. c. For the Required Redemption and the Call Option, the purchase price is derived from a formula based on a specified multiple of NewCo’s trailing twelve months of earnings before interest, taxes, depreciation, amortization, and the Company’s internal management fee, plus an Allocable Portion of any undistributed earnings of NewCo (the “Redemption Amount”). NewCo’s earnings are distributed monthly based on available cash within NewCo; therefore the undistributed earnings amount is small, if any. d. The Purchase Price for the initial equity interest purchased by the Company is also based on the same specified multiple of the trailing twelve-month earnings that is used in the Required Redemption noted above. e. Although, the Required Redemption and the Call Option do not have an expiration date, the Seller Entity Interest eventually will be purchased by the Company. f. The Required Redemption and the Call Option never apply to Selling Shareholders who do not become employed by NewCo, since the Company requires that such Selling Shareholders sell their entire ownership interest in the Seller Entity at the closing of the Acquisition. 12. An Employed Selling Shareholder’s ownership of his or her equity interest in the Seller Entity predates the Acquisition and the Company’s purchase of its partnership interest in NewCo. The Employment Agreement and the Non-Compete Agreement do not contain any provision to escrow or “claw back” the equity interest in the Seller Entity held by such Employed Selling Shareholder, nor the Seller Entity Interest in NewCo, in the event of a breach of the employment or non-compete terms. More specifically, even if the Employed Selling Shareholder is terminated for “cause” by NewCo, such Employed Selling Shareholder does not forfeit his or her right to his or her full equity interest in the Seller Entity and the Seller Entity does not forfeit its right to any portion of the Seller Entity Interest. The Company’s only recourse against the Employed Selling Shareholder for breach of either the Employment Agreement or the Non-Compete Agreement is to seek damages and other legal remedies under such agreements. There are no conditions in any of the arrangements with an Employed Selling Shareholder that would result in a forfeiture of the equity interest held in the Seller Entity or of the Seller Entity Interest. The following table details the changes in the carrying amount of the mandatorily redeemable non-controlling interests (in thousands): Year Ended Year Ended (as restated) Beginning balance, as restated $ 45,974 $ 40,365 Operating results allocated to mandatorily redeemable non-controlling interest partners 4,057 3,538 Distributions to mandatorily redeemable non-controlling interest partners (4,628 ) (3,740 ) Changes in the redemption value of mandatorily redeemable non-controlling interest 6,169 2,670 Payments for settlement of mandatorily redeemable non-controlling interest (1,262 ) (9,192 ) Purchases of businesses - initial liability related to mandatorily redeemable non-controlling interests 18,880 12,291 Other - 42 Ending balance $ 69,190 $ 45,974 In 2016, as part of the acquisition of a non-controlling interest (classified as mandatorily redeemable non-controlling interests), the Company entered into $0.1 million note payable that is due and payable, with any accrued interest, in January 2018. In 2015, as part of the acquisition of a non-controlling interest (classified as mandatorily redeemable non-controlling interests), the Company entered into several notes payable aggregating $3.1 million. The notes are each payable in two installments plus accrued interest (interest accrues at 3.25%). The first principal installment in an aggregate of $1.2 million is due on December 31, 2018 and the second principal installment in an aggregate of $1.9 million is due on January 31, 2019. The following table details the carrying amount of the mandatorily redeemable non-controlling interests (in thousands): Year Ended Year Ended (as restated) Contractual time period has lapsed but holder's employment has not been terminated $ 24,700 $ 19,969 Contractual time period has not lapsed and holder's employment has not been terminated 46,949 27,893 Holder's employment has terminated and contractual time period has expired - - Holder's employment has terminated and contractual time period has not expired - - Redemption value prior to excess distributed earnings $ 71,649 $ 47,862 Excess distributions over earnings and losses (2,459 ) (1,888 ) $ 69,190 $ 45,974

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2016
Goodwill [Abstract]
Goodwill	6. Goodwill The changes in the carrying amount of goodwill as of December 31, 2016 and 2015 consisted of the following (in thousands): Year Ended December 31, 2016 Year Ended December 31, 2015 (as restated) Beginning balance, as restated $ 195,373 $ 171,740 Goodwill acquired during the period 31,419 23,437 Goodwill adjustments for purchase price allocation of business acquired 14 376 Goodwill written-off - closed clinics - (180 ) Ending balance $ 226,806 $ 195,373

Intangible Assets, net

Intangible Assets, net	12 Months Ended
	Dec. 31, 2016
Intangible Assets, net [Abstract]
Intangible Assets, net	7. Intangible Assets, net Intangible assets, net as of December 31, 2016 and 2015 consisted of the following (in thousands): December 31, 2016 December 31, 2015 Tradenames, net of accumulated amortization of $0 and $170, respectively $ 21,234 $ 17,660 Referral relationships, net of accumulated amortization of $5,275 and $3,763, respectively 14,859 10,866 Non-compete agreements, net of accumulated amortization of $3,380 and $2,855, respectively 1,967 1,770 $ 38,060 $ 30,296 Tradenames, referral relationships and non-compete agreements are related to the businesses acquired. The value assigned to tradenames has an indefinite life and is tested at least annually for impairment using the relief from royalty method in conjunction with the Company’s annual goodwill impairment test. The value assigned to referral relationships is being amortized over their respective estimated useful lives which range from six to 16 years. Non-compete agreements are amortized over the respective term of the agreements which range from five to six years. The following table details the amount of amortization expense recorded for intangible assets for the years ended December 31, 2016, 2015 and 2014 (in thousands): Year Ended Year Ended Year Ended December 31, 2016 December 31, 2015 December 31, 2014 Tradenames $ 330 $ 84 $ 86 Referral relationships 1,512 1,153 1,028 Non-compete agreements 525 478 427 $ 2,367 $ 1,715 $ 1,541 For one acquisition, the value assigned to tradename was being amortized over the term of the six year agreement in which the Company had acquired the right to use the specific tradename. In 2016, the remaining value of this tradename was charged to earnings and included in amortization expense in the above table as the Company decided to combine two acquired operations in Georgia and the tradename under this six year agreement will no longer be used. The remaining balances of the referral relationships and non-compete agreements is expected to be amortized as follows (in thousands): Referral Relationships Non-Compete Agreements Years Annual Amount Years Annual Amount 2017 1,682 2017 581 2018 1,636 2018 525 2019 1,547 2019 452 2020 1,547 2020 239 2021 1,547 2021 162 2022 1,498 2022 8 2023 1,391 2024 1,272 2025 1,166 2026 704 2027 544 2028 281 2029 44

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2016
Accrued Expenses [Abstract]
Accrued Expenses	8. Accrued Expenses Accrued expenses as of December 31, 2016 and 2015 consisted of the following (in thousands): December 31, 2016 December 31, 2015 Salaries and related costs $ 10,569 $ 9,414 Credit balances due to patients and payors 3,880 1,472 Group health insurance claims 2,499 2,276 Other 4,808 3,434 Total $ 21,756 $ 16,596

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2016
Notes Payable [Abstract]
Notes Payable	9. Notes Payable Notes payable as of December 31, 2016 and 2015 consisted of the following (dollars in thousands): December 31, 2016 December 31, 2015 Credit Agreement average effective interest rate of 2.5% inclusive of unused fee $ 46,000 $ 44,000 Various notes payable with $1,227 plus accrued interest due in the next year interest accrues in the range of 3.25% through 3.5% per annum 5,823 5,110 51,823 49,110 Less current portion (1,227 ) (775 ) Long term portion $ 50,596 $ 48,335 Effective December 5, 2013, we entered into an Amended and Restated Credit Agreement with a commitment for a $125.0 million revolving credit facility with a maturity date of November 30, 2018. This agreement was amended in August 2015 and January 2016 (hereafter referred to as “Amended Credit Agreement”). The Amended Credit Agreement is unsecured and has loan covenants, including requirements that the Company comply with a consolidated fixed charge coverage ratio and consolidated leverage ratio. Proceeds from the Amended Credit Agreement may be used for working capital, acquisitions, purchases of the Company’s common stock, dividend payments to the Company’s common stockholders, capital expenditures and other corporate purposes. The pricing grid which is based on the Company’s consolidated leverage ratio with the applicable spread over LIBOR ranging from 1.5% to 2.5% or the applicable spread over the Base Rate ranging from 0.1% to 1%. Fees under the Amended Credit Agreement include an unused commitment fee ranging from 0.1% to 0.25% depending on the Company’s consolidated leverage ratio and the amount of funds outstanding under the Amended Credit Agreement. The January 2016 amendment to the Amended Credit Agreement increased the cash and noncash consideration that the Company could pay with respect to acquisitions permitted under the Amended Credit Agreement to $50,000,000 for any fiscal year, and increased the amount the Company may pay in cash dividends to its shareholders in an aggregate amount not to exceed $10,000,000 in any fiscal year. On December 31, 2016, $46.0 million was outstanding on the Credit Agreement resulting in $79.0 million of availability. As of the date of this report, the Company was in compliance with all of the covenants thereunder. The Company generally enters into various notes payable as a means of financing a portion of its acquisitions, purchasing of non-controlling interests and paying the settlement of mandatorily redeemable non-controlling interests. In conjunction with the the transactions related to these in 2016, the Company entered into notes payable in the aggregate amount of $1.5 million of which an aggregate principal payment of $694,000 is due in 2017 and $819,000 in 2018. Interest accrues in the range of 3.25% to 3.5% per annum and is payable with each principal installment. Aggregate annual payments of principal required pursuant to the Credit Agreement and the above notes payable subsequent to December 31, 2016 are as follows (in thousands): During the twelve months ended December 31, 2017 $ 1,227 During the twelve months ended December 31, 2018 48,750 During the twelve months ended December 31, 2019 1,846 $ 51,823

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Taxes [Abstract]
Income Taxes	10. Income Taxes Significant components of deferred tax assets included in the consolidated balance sheets at December 31, 2016 and 2015 were as follows (in thousands): December 31, 2016 December 31, 2015 (as restated) Deferred tax assets: Compensation $ 1,914 $ 1,830 Allowance for doubtful accounts 572 472 Lease obligations - closed clinics 57 50 Deferred tax assets $ 2,543 $ 2,352 Deferred tax liabilities: Depreciation and amortization $ (17,896 ) $ (16,142 ) Other (383 ) (1,718 ) Deferred tax liabilities (18,279 ) (17,860 ) Net deferred tax liability $ (15,736 ) $ (15,508 ) During 2016, the Company recorded deferred tax assets of $0.4 million related to acquisitions of non-controlling interests, $2.4 million related to the revaluation of mandatorily redeemable non-controlling interests and $7.4 million related to acquired interests. Also, during 2016, the Company recorded an adjustment to the deferred tax assets of $2.7 million related to acquisitions of non-controlling interests in 2015 based on a detailed reconciliation of its federal and state taxes payable and receivable accounts along with its federal and state deferred tax asset and liability accounts. The offset to this adjustment was a reduction in the previously reported tax receivable of approximately $2.9 million and a charge to additional-paid-in-capital of $0.2 million. At December 31, 2016 and 2015, the Company had a tax receivable of $2.3 million and $3.4 million (prior to adjustment of $2.9 million), respectively, included in other current assets on the accompanying consolidated balance sheets. The differences between the federal tax rate and the Company’s effective tax rate for results of continuing operations for the years ended December 31, 2016, 2015 and 2014 were as follows (in thousands): December 31, 2016 December 31, 2015 December 31, 2014 (as restated) (as restated) U. S. tax at statutory rate $ 11,351 35.0 % $ 11,991 35.0 % $ 11,252 35.0 % State income taxes, net of federal benefit 945 2.9 % 1,337 3.9 % 1,474 4.6 % Excess equity compensation deduction (911 ) -2.8 % - 0.0 % - 0.0 % Non-deductible expenses 495 1.5 % 319 0.9 % 292 0.9 % $ 11,880 36.6 % $ 13,647 39.8 % $ 13,018 40.5 % In March 2016, the FASB issued guidance to simplify some provisions in stock compensation accounting. The Company adopted this guidance in the fourth quarter of 2016. Prior to this guidance, excess tax benefits were recorded in additional paid-in capital, but became a component of the income tax provision/benefit in the period in which they occurred. For 2016, the adoption resulted in a reduction of the income tax provision by $1.0 million. The federal tax portion is shown above as excess equity compensation deduction. Significant components of the provision for income taxes for continuing operations for the years ended December 31, 2016, 2015 and 2014 were as follows (in thousands): December 31, 2016 December 31, 2015 December 31, 2014 (as restated) (as restated) Current: Federal $ 7,620 $ 6,502 $ 6,972 State 1,281 1,192 940 Total current 8,901 7,694 7,912 Deferred: Federal 2,548 5,302 4,224 State 431 651 882 Total deferred 2,979 5,953 5,106 Total income tax provision for continuing operations $ 11,880 $ 13,647 $ 13,018 For 2016, 2015 and 2014, the Company performed a detailed reconciliation of its federal and state taxes payable and receivable accounts along with its federal and state deferred tax asset and liability accounts. As a result of this detailed analysis, the Company recorded an increase in the income tax provision of $34,000, $147,000 and $223,000 for 2016, 2015, and 2014, respectively. The Company considers this reconciliation process to be an annual control. The Company is required to establish a valuation allowance for deferred tax assets if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the projected future taxable income and tax planning strategies in making this assessment. Based upon the level of historical taxable income and projections for future taxable income in the periods which the deferred tax assets are deductible, management believes that a valuation allowance is not required, as it is more likely than not that the results of future operations will generate sufficient taxable income to realize the deferred tax assets. The Company’s U.S. federal returns remain open to examination for 2013 through 2015 and U.S. state jurisdictions are open for periods ranging from 2012 through 2015. The Company does not believe that it has any significant uncertain tax positions at December 31, 2016, nor is this expected to change within the next twelve months due to the settlement and expiration of statutes of limitation. The Company did not have any accrued interest or penalties associated with any unrecognized tax benefits nor was any interest expense recognized during the years ended December 31, 2016, 2015 and 2014.

Equity Based Plans

Equity Based Plans	12 Months Ended
	Dec. 31, 2016
Equity Based Plans [Abstract]
Equity Based Plans	11. Equity Based Plans The Company has the following equity based plans with outstanding equity grants: The Amended and Restated 1999 Employee Stock Option Plan (the “Amended 1999 Plan”) permits the Company to grant to non-employee directors and employees of the Company up to 600,000 non-qualified options to purchase shares of common stock and restricted stock (subject to proportionate adjustments in the event of stock dividends, splits, and similar corporate transactions). The exercise prices of options granted under the Amended 1999 Plan are determined by the Compensation Committee. The period within which each option will be exercisable is determined by the Compensation Committee. The Amended 1999 Plan was approved by the shareholders of the Company at the 2008 Shareholders Meeting on May 20, 2008. The Amended and Restated 2003 Stock Option Plan (the “Amended 2003 Plan”) permits the Company to grant to key employees and outside directors of the Company incentive and non-qualified options and shares of restricted stock covering up to 2,100,000 shares of common stock (subject to proportionate adjustments in the event of stock dividends, splits, and similar corporate transactions). The material terms of the Amended 2003 Plan was reapproved by the shareholders of the Company at the 2015 Shareholders Meeting on May 19, 2015 and an increase in the number of shares authorized for issuance from 1,750,000 to 2,100,000 was approved at the 2016 Shareholders Meeting on March 17, 2016. A cumulative summary of equity plans as of December 31, 2016 follows: Authorized Restricted Outstanding Stock Options Stock Options Shares Available Equity Plans Amended 1999 Plan 600,000 416,402 - 139,791 - 7,775 Amended 2003 Plan 2,100,000 763,357 - 778,300 - 558,343 2,700,000 1,179,759 - 918,091 - 566,118 During 2016, 2015 and 2014, the Company granted the following shares of restricted stock to directors, officers and employees pursuant to its equity plans as follows: Year Granted Number of Shares Weighted Average Fair 2014 159,443 $ 33.29 2015 147,928 $ 41.66 2016 101,790 $ 51.59 During 2016, 2015 and 2014, the following shares were cancelled due to employee terminations prior to restrictions lapsing: Year Cancelled Number of Shares Weighted Average Fair 2014 8,120 $ 23.49 2015 - - 2016 4,965 $ 35.78 Generally, restrictions on the stock granted to employees lapse in equal annual installments on the following four anniversaries of the date of grant. For those shares granted to directors, the restrictions will lapse in equal quarterly installments during the first year after the date of grant. For those granted to executive officers, the restriction will lapse in equal quarterly installments during the four years following the date of grant. As of December 31, 2016, there were 232,997 shares outstanding for which restrictions had not lapsed. The restrictions will lapse in 2017 through 2020. Compensation expense for grants of restricted stock is recognized based on the fair value on the date of grant. Compensation expense for restricted stock grants was $4,962,000, $4,491,000 and $3,363,000, respectively, for 2016, 2015 and 2014. As of December 31, 2016, the remaining $6.7 million of compensation expense will be recognized from 2017 through 2020.

Preferred Stock

Preferred Stock	12 Months Ended
	Dec. 31, 2016
Preferred Stock [Abstract]
Preferred Stock	12. Preferred Stock The Board is empowered, without approval of the shareholders, to cause shares of preferred stock to be issued in one or more series and to establish the number of shares to be included in each such series and the rights, powers, preferences and limitations of each series. There are no provisions in the Company’s Articles of Incorporation specifying the vote required by the holders of preferred stock to take action. All such provisions would be set out in the designation of any series of preferred stock established by the Board. The bylaws of the Company specify that, when a quorum is present at any meeting, the vote of the holders of at least a majority of the outstanding shares entitled to vote who are present, in person or by proxy, shall decide any question brought before the meeting, unless a different vote is required by law or the Company’s Articles of Incorporation. Because the Board has the power to establish the preferences and rights of each series, it may afford the holders of any series of preferred stock, preferences, powers, and rights, voting or otherwise, senior to the right of holders of common stock. The issuance of the preferred stock could have the effect of delaying or preventing a change in control of the Company.

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2016
Common Stock [Abstract]
Common Stock	13. Common Stock From September 2001 through December 31, 2008, the Board authorized the Company to purchase, in the open market or in privately negotiated transactions, up to 2,250,000 shares of the Company’s common stock. In March 2009, the Board authorized the repurchase of up to 10% or approximately 1,200,000 shares of its common stock (“March 2009 Authorization”). The Amended Credit Agreement permits share repurchases of up to $15,000,000, subject to compliance with covenants. The Company is required to retire shares purchased under the March 2009 Authorization. Under the March 2009 Authorization, the Company has purchased a total of 859,499 shares. There is no expiration date for the share repurchase program. There are currently an additional estimated 213,675 shares (based on the closing price of $70.20 on December 30, 2016, the last business day in 2016) that may be purchased from time to time in the open market or private transactions depending on price, availability and the Company’s cash position. The Company did not purchase any shares of its common stock during 2016.

Defined Contribution Plan

Defined Contribution Plan	12 Months Ended
	Dec. 31, 2016
Defined Contribution Plan [Abstract]
Defined Contribution Plan	14. Defined Contribution Plan The Company has several 401(k) profit sharing plans covering all employees with three months of service. For certain plans, the Company makes matching contributions. The Company may also make discretionary contributions of up to 50% of employee contributions. The Company did not make any discretionary contributions for the years ended December 31, 2016, 2015 and 2014. The Company matching contributions totaled $1.1 million, $0.9 million and $0.7 million, respectively, for the years ended December 31, 2016, 2015 and 2014.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies [Abstract]
Commitments and Contingencies	15. Commitments and Contingencies Operating Leases The Company has entered into operating leases for its executive offices and clinic facilities. In connection with these agreements, the Company incurred rent expense of $30.3 million, $28.3 million and $25.6 million for the years ended December 31, 2016, 2015 and 2014, respectively. Several of the leases provide for an annual increase in the rental payment based upon the Consumer Price Index. The majority of the leases provide for renewal periods ranging from one to five years. The agreements to extend the leases typically specify that rental rates would be adjusted to market rates as of each renewal date. The future minimum operating lease commitments for each of the next five years and thereafter and in the aggregate as of December 31, 2016 are as follows (in thousands): December 31, 2016 2017 $ 30,376 2018 23,907 2019 17,041 2020 15,164 2021 6,850 Thereafter 3,095 Total $ 96,433 Employment Agreements At December 31, 2016, the Company had outstanding employment agreements with three of its executive officers. These agreements, which presently expire on December 31, 2017, provide for automatic two year renewals at the conclusion of each expiring term or renewal term. All of the agreements contain a provision for annual adjustment of salaries. In addition, the Company has outstanding employment agreements with most of the managing physical therapist partners of the Company’s physical therapy clinics and with certain other clinic employees which obligate subsidiaries of the Company to pay compensation of $23.2 million in 2017 and $14.8 million in the aggregate from 2018 through 2021. In addition, most of the employment agreements with the managing physical therapists provide for monthly bonus payments calculated as a percentage of each clinic’s net revenues (not in excess of operating profits) or operating profits.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Earnings Per Share	16. Earnings Per Share The computations of basic and diluted earnings per share for the years ended December 31, 2016, 2015 and 2014 are as follows (in thousands, except per share data): Year Ended Year Ended Year Ended December 31, 2016 December 31, 2015 December 31, 2014 (as restated) (as restated) Net income attributable to USPh shareholders $ 20,551 $ 20,615 $ 19,131 Basic and diluted net income per share attributable to USPH shareholders $ 1.64 $ 1.66 $ 1.57 Shares used in computation: Basic earnings per share - weighted-average shares 12,500 12,392 12,217 Effect of dilutive securities - stock options - - 4 Denominator for diluted earnings per share - adjusted weighted-average shares 12,500 12,392 12,221

Selected Quarterly Financial Da

Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2016
Selected Quarterly Financial Data (Unaudited) [Abstract]
Selected Quarterly Financial Data (Unaudited)	17. Selected Quarterly Financial Data (Unaudited) Q1 2016 Q2 2016 Q3 2016 Q4 2016 Net patient revenues $ 85,049 $ 88,433 $ 86,411 $ 88,946 Net revenues $ 86,908 $ 90,430 $ 88,344 $ 90,864 Operating income $ 11,491 $ 15,033 $ 12,055 $ 10,954 Net income $ 5,953 $ 7,671 $ 6,134 $ 6,510 Net income attributable to USPH shareholders $ 4,488 $ 6,012 $ 4,804 $ 5,247 Basic and diluted earnings per share attributable to common shareholders: $ 0.36 $ 0.48 $ 0.38 $ 0.42 Shares used in computation - basic and diluted 12,448 12,511 12,520 12,519 Q1 2015 Q2 2015 Q3 2015 Q4 2015 Net patient revenues $ 75,807 $ 81,451 $ 82,154 $ 84,881 Net revenues $ 77,241 $ 83,288 $ 84,049 $ 86,724 Operating income $ 9,185 $ 13,549 $ 11,949 $ 12,611 Net income $ 5,293 $ 7,957 $ 6,974 $ 6,265 Net income attributable to USPH shareholders $ 4,014 $ 6,334 $ 5,506 $ 4,761 Basic and diluted earnings per share attributable to common shareholders: $ 0.33 $ 0.51 $ 0.44 $ 0.38 Shares used in computation - basic and diluted 12,313 12,409 12,421 12,421 The following schedules present the impact of the correction related to mandatorily redeemable non-controlling interests on the Company’s previously reported quarterly balance sheets, income statements and cash flows included in its Quarterly Reports on Form 10-Q for the quarters ended March 31, June 30, September 30, 2016 and March 31, June 30 and September 30, 2015. In addition, the impact of the early adoption of the treatment of the excess tax benefits related to equity grants on the previously reported quarterly balance sheets and income statements included in its Quarterly Reports on Form 10-Q for the quarters ended March 31, June 30 and September 30, 2016 are included in the respective schedules. See Note 2. – Significant Accounting Policies – Recently Adopted Accounting Guidance. All schedules are in thousands, except share and per share data. Consolidated Balance Sheet as of September 30, 2016: As Reported September 30, 2016 Adjustments As Restated September 30, 2016 ASSETS Current assets: Cash and cash equivalents $ 15,024 $ - $ 15,024 Patient accounts receivable, less allowance for doubtful accounts of $1,770 38,522 - 38,522 Accounts receivable - other 2,272 - 2,272 Other current assets 10,800 816 11,616 Total current assets 66,618 816 67,434 Fixed assets: Furniture and equipment 46,996 - 46,996 Leasehold improvements 26,206 - 26,206 Fixed assets, gross 73,202 - 73,202 Less accumulated depreciation and amortization 55,760 - 55,760 Fixed assets, net 17,442 - 17,442 Goodwill 191,231 23,826 215,057 Other identifiable intangible assets, net 33,389 - 33,389 Other assets 1,221 - 1,221 Total assets $ 309,901 $ 24,642 $ 334,543 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable - trade $ 2,181 $ - $ 2,181 Accrued expenses 23,216 - 23,216 Current portion of notes payable 986 - 986 Total current liabilities 26,383 - 26,383 Notes payable 4,546 - 4,546 Revolving line of credit 36,000 - 36,000 Mandatorily redeemable non-controlling interests - 61,276 61,276 Deferred rent 1,313 - 1,313 Deferred taxes 13,727 5,009 18,736 Other long-term liabilities 860 54 914 Total liabilities 82,829 66,339 149,168 Commitments and contingencies Redeemable non-controlling interests 8,334 (8,334 ) - U.S. Physical Therapy, Inc. ("USPH") shareholders’ equity: Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding - - - Common stock, $.01 par value, 20,000,000 shares authorized, 14,734,963 shares issued 147 - 147 Additional paid-in capital 49,506 18,987 68,493 Retained earnings 160,746 (13,523 ) 147,223 Treasury stock at cost, 2,214,737 shares (31,628 ) - (31,628 ) Total USPH shareholders’ equity 178,771 5,464 184,235 Non-controlling interests 39,967 (38,827 ) 1,140 Total equity 218,738 (33,363 ) 185,375 Total liabilities and equity $ 309,901 $ 24,642 $ 334,543 Consolidated Balance Sheet as of June 30, 2016: As Reported June 30, 2016 Adjustments As Restated June 30, 2016 ASSETS Current assets: Cash and cash equivalents $ 20,453 $ - $ 20,453 Patient accounts receivable, less allowance for doubtful accounts of $1,672 39,356 - 39,356 Accounts receivable - other 2,335 - 2,335 Other current assets 8,220 574 8,794 Total current assets 70,364 574 70,938 Fixed assets: Furniture and equipment 46,747 - 46,747 Leasehold improvements 25,733 - 25,733 Fixed assets, gross 72,480 - 72,480 Less accumulated depreciation and amortization 55,642 - 55,642 Fixed assets, net 16,838 - 16,838 Goodwill 191,268 23,826 215,094 Other identifiable intangible assets, net 33,909 - 33,909 Other assets 1,219 - 1,219 Total assets $ 313,598 $ 24,400 $ 337,998 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable - trade $ 1,668 $ - $ 1,668 Accrued expenses 26,273 - 26,273 Current portion of notes payable 1,044 - 1,044 Total current liabilities 28,985 - 28,985 Notes payable 4,547 - 4,547 Revolving line of credit 42,500 - 42,500 Mandatorily redeemable non-controlling interests - 59,932 59,932 Deferred rent 1,285 - 1,285 Deferred taxes 12,361 5,792 18,153 Other long-term liabilities 869 54 923 Total liabilities 90,547 65,778 156,325 Commitments and contingencies Redeemable non-controlling interests 8,641 (8,641 ) - U.S. Physical Therapy, Inc. ("USPH") shareholders’ equity: Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding - - - Common stock, $.01 par value, 20,000,000 shares authorized, 14,734,963 shares issued 147 - 147 Additional paid-in capital 48,236 18,987 67,223 Retained earnings 157,161 (12,614 ) 144,547 Treasury stock at cost, 2,214,737 shares (31,628 ) - (31,628 ) Total USPH shareholders’ equity 173,916 6,373 180,289 Non-controlling interests 40,494 (39,110 ) 1,384 Total equity 214,410 (32,737 ) 181,673 Total liabilities and equity $ 313,598 $ 24,400 $ 337,998 Consolidated Balance Sheet as of March 31, 2016: As Reported March 31, 2016 Adjustments As Restated March 31, 2016 ASSETS Current assets: Cash and cash equivalents $ 19,206 $ - $ 19,206 Patient accounts receivable, less allowance for doubtful accounts of $1,568 38,217 - 38,217 Accounts receivable - other 2,345 - 2,345 Other current assets 8,298 483 8,781 Total current assets 68,066 483 68,549 Fixed assets: Furniture and equipment 45,654 - 45,654 Leasehold improvements 25,547 - 25,547 Fixed assets, gross 71,201 - 71,201 Less accumulated depreciation and amortization 54,512 - 54,512 Fixed assets, net 16,689 - 16,689 Goodwill 191,051 23,826 214,877 Other identifiable intangible assets, net 34,428 - 34,428 Other assets 1,200 - 1,200 Total assets $ 311,434 $ 24,309 $ 335,743 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable - trade $ 2,244 $ - $ 2,244 Accrued expenses 20,684 - 20,684 Current portion of notes payable 1,253 - 1,253 Total current liabilities 24,181 - 24,181 Notes payable 4,621 - 4,621 Revolving line of credit 52,500 - 52,500 Mandatorily redeemable non-controlling interests - 58,481 58,481 Deferred rent 1,391 - 1,391 Deferred taxes 10,789 6,573 17,362 Other long-term liabilities 914 54 968 Total liabilities 94,396 65,108 159,504 Commitments and contingencies Redeemable non-controlling interests 7,591 (7,591 ) - U.S. Physical Therapy, Inc. ("USPH") shareholders’ equity: Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding - - - Common stock, $.01 par value, 20,000,000 shares authorized, 14,717,463 shares issued 147 - 147 Additional paid-in capital 46,563 18,987 65,550 Retained earnings 152,219 (11,555 ) 140,664 Treasury stock at cost, 2,214,737 shares (31,628 ) - (31,628 ) Total USPH shareholders’ equity 167,301 7,432 174,733 Non-controlling interests 42,146 (40,640 ) 1,506 Total equity 209,447 (33,208 ) 176,239 Total liabilities and equity $ 311,434 $ 24,309 $ 335,743 Consolidated Balance Sheet as of September 30, 2015: As Reported September 30, 2015 Adjustments As Restated September 30, 2015 ASSETS Current assets: Cash and cash equivalents $ 20,558 $ - $ 20,558 Patient accounts receivable, less allowance for doubtful accounts of $1,556 35,106 - 35,106 Accounts receivable - other 1,939 - 1,939 Other current assets 6,058 - 6,058 Total current assets 63,661 - 63,661 Fixed assets: Furniture and equipment 44,157 - 44,157 Leasehold improvements 25,006 - 25,006 Fixed assets, gross 69,163 - 69,163 Less accumulated depreciation and amortization 52,501 - 52,501 Fixed assets, net 16,662 - 16,662 Goodwill 170,849 23,826 194,675 Other identifiable intangible assets, net 23,798 - 23,798 Other assets 1,175 - 1,175 Total assets $ 276,145 $ 23,826 $ 299,971 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable - trade $ 1,662 $ - $ 1,662 Accrued expenses 18,287 - 18,287 Current portion of notes payable 1,412 - 1,412 Total current liabilities 21,361 - 21,361 Notes payable 1,679 - 1,679 Revolving line of credit 46,000 - 46,000 Mandatorily redeemable non-controlling interests - 45,323 45,323 Deferred rent 1,192 - 1,192 Deferred taxes - 13,276 13,276 Other long-term liabilities 10,769 (7,995 ) 2,774 Total liabilities 81,001 50,604 131,605 Commitments and contingencies Redeemable non-controlling interests 9,024 (9,024 ) - U.S. Physical Therapy, Inc. ("USPH") shareholders’ equity: Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding - - - Common stock, $.01 par value, 20,000,000 shares authorized, 14,635,874 shares issued 146 - 146 Additional paid-in capital 45,536 17,382 62,918 Retained earnings 144,888 (9,485 ) 135,403 Treasury stock at cost, 2,214,737 shares (31,628 ) - (31,628 ) Total USPH shareholders’ equity 158,942 7,897 166,839 Non-controlling interests 27,178 (25,651 ) 1,527 Total equity 186,120 (17,754 ) 168,366 Total liabilities and equity $ 276,145 $ 23,826 $ 299,971 Consolidated Balance Sheet as of June 30, 2015: As Reported June 30, 2015 Adjustments As Restated June 30, 2015 ASSETS Current assets: Cash and cash equivalents $ 12,972 $ - $ 12,972 Patient accounts receivable, less allowance for doubtful accounts of $1,618 34,830 - 34,830 Accounts receivable - other 1,338 - 1,338 Other current assets 6,509 - 6,509 Total current assets 55,649 - 55,649 Fixed assets: Furniture and equipment 43,495 - 43,495 Leasehold improvements 24,107 - 24,107 Fixed assets, gross 67,602 - 67,602 Less accumulated depreciation and amortization 51,098 - 51,098 Fixed assets, net 16,504 - 16,504 Goodwill 170,914 23,826 194,740 Other identifiable intangible assets, net 24,167 - 24,167 Other assets 1,086 - 1,086 Total assets $ 268,320 $ 23,826 $ 292,146 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable - trade $ 1,451 $ - $ 1,451 Accrued expenses 19,446 - 19,446 Current portion of notes payable 800 - 800 Total current liabilities 21,697 - 21,697 Notes payable 1,059 - 1,059 Revolving line of credit 41,000 - 41,000 Mandatorily redeemable non-controlling interests - 49,166 49,166 Deferred rent 1,040 - 1,040 Deferred taxes - 12,027 12,027 Other long-term liabilities 10,925 (7,995 ) 2,930 Total liabilities 75,721 53,198 128,919 Commitments and contingencies Redeemable non-controlling interests 10,585 (10,585 ) - U.S. Physical Therapy, Inc. ("USPH") shareholders’ equity: Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding - - - Common stock, $.01 par value, 20,000,000 shares authorized, 14,635,674 shares issued 146 - 146 Additional paid-in capital 45,829 15,222 61,051 Retained earnings 140,933 (9,173 ) 131,760 Treasury stock at cost, 2,214,737 shares (31,628 ) - (31,628 ) Total USPH shareholders’ equity 155,280 6,049 161,329 Non-controlling interests 26,734 (24,836 ) 1,898 Total equity 182,014 (18,787 ) 163,227 Total liabilities and equity $ 268,320 $ 23,826 $ 292,146 Consolidated Balance Sheet as of March 31, 2015: As Reported March 31, 2015 Adjustments As Restated March 31, 2015 ASSETS Current assets: Cash and cash equivalents $ 14,557 $ - $ 14,557 Patient accounts receivable, less allowance for doubtful accounts of $1,633 34,673 - 34,673 Accounts receivable - other 1,378 - 1,378 Other current assets 5,291 - 5,291 Total current assets 55,899 - 55,899 Fixed assets: Furniture and equipment 42,542 - 42,542 Leasehold improvements 23,565 - 23,565 Fixed assets, gross 66,107 - 66,107 Less accumulated depreciation and amortization 50,212 - 50,212 Fixed assets, net 15,895 - 15,895 Goodwill 159,176 23,826 183,002 Other identifiable intangible assets, net 24,537 - 24,537 Other assets 1,916 - 1,916 Total assets $ 257,423 $ 23,826 $ 281,249 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable - trade $ 2,292 $ - $ 2,292 Accrued expenses 18,178 - 18,178 Current portion of notes payable 932 - 932 Total current liabilities 21,402 - 21,402 Notes payable 483 - 483 Revolving line of credit 41,500 - 41,500 Mandatorily redeemable non-controlling interests - 45,578 45,578 Deferred rent 984 - 984 Deferred taxes - 12,009 12,009 Other long-term liabilities 9,480 (7,995 ) 1,485 Total liabilities 73,849 49,592 123,441 Commitments and contingencies Redeemable non-controlling interests 7,373 (7,373 ) - U.S. Physical Therapy, Inc. ("USPH") shareholders’ equity: Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding - - - Common stock, $.01 par value, 20,000,000 shares authorized, 14,613,374 shares issued 145 - 145 Additional paid-in capital 45,080 15,222 60,302 Retained earnings 136,491 (9,203 ) 127,288 Treasury stock at cost, 2,214,737 shares (31,628 ) - (31,628 ) Total USPH shareholders’ equity 150,088 6,019 156,107 Non-controlling interests 26,113 (24,412 ) 1,701 Total equity 176,201 (18,393 ) 157,808 Total liabilities and equity $ 257,423 $ 23,826 $ 281,249 Consolidated Statement of Net Income as of September 30, 2016: For the Three Months Ended For the Nine Months Ended As Reported September 30, 2016 Adjustments As Restated September 30, 2016 As Reported September 30, 2016 Adjustments As Restated September 30, 2016 Net patient revenues $ 86,411 $ - $ 86,411 $ 259,893 $ - $ 259,893 Other revenues 1,933 - 1,933 5,789 - 5,789 Net revenues 88,344 - 88,344 265,682 - 265,682 Clinic operating costs: Salaries and related costs 49,868 - 49,868 146,509 - 146,509 Rent, clinic supplies, contract labor and other 17,885 - 17,885 52,938 - 52,938 Provision for doubtful accounts 917 - 917 2,962 - 2,962 Closure costs 9 - 9 54 - 54 Total clinic operating costs 68,679 - 68,679 202,463 - 202,463 Gross margin 19,665 - 19,665 63,219 - 63,219 Corporate office costs 7,610 - 7,610 24,640 - 24,640 Operating income 12,055 - 12,055 38,579 - 38,579 Interest and other income, net 21 - 21 62 - 62 Interest expense Mandatorily redeemable non-controlling interests - change in redemption value - (1,934 ) (1,934 ) - (6,056 ) (6,056 ) Mandatorily redeemable non-controlling interests - earnings allocable - (929 ) (929 ) - (3,146 ) (3,146 ) Debt and other (326 ) - (326 ) (954 ) - (954 ) Total interest expense (326 ) (2,863 ) (3,189 ) (954 ) (9,202 ) (10,156 ) Income before taxes 11,750 (2,863 ) 8,887 37,687 (9,202 ) 28,485 Provision for income taxes 3,778 (1,025 ) 2,753 11,975 (3,248 ) 8,727 Net income 7,972 (1,838 ) 6,134 25,712 (5,954 ) 19,758 Less: net income attributable to non-controlling interests (2,259 ) 929 (1,330 ) (7,600 ) 3,146 (4,454 ) Net income attributable to USPH shareholders $ 5,713 $ (909 ) $ 4,804 $ 18,112 $ (2,808 ) $ 15,304 Basic and diluted earnings per share attributable to USPH shareholders $ 0.46 $ (0.08 ) $ 0.38 $ 1.45 $ (0.23 ) $ 1.22 Shares used in computation - basic 12,520 12,520 12,494 12,494 Shares used in computation - diluted 12,520 12,520 12,494 12,494 Dividends declared per common share $ 0.17 $ 0.17 $ 0.51 $ 0.51 Consolidated Statement of Net Income as of June 30, 2016: For the Three Months Ended For the Six Months Ended As Reported June 30, 2016 Adjustments As Restated June 30, 2016 As Reported June 30, 2016 Adjustments As Restated June 30, 2016 Net patient revenues $ 88,433 $ - $ 88,433 $ 173,482 $ - $ 173,482 Other revenues 1,997 - 1,997 3,856 - 3,856 Net revenues 90,430 - 90,430 177,338 - 177,338 Clinic operating costs: Salaries and related costs 48,837 - 48,837 96,641 - 96,641 Rent, clinic supplies, contract labor and other 17,546 - 17,546 35,053 - 35,053 Provision for doubtful accounts 956 - 956 2,045 - 2,045 Closure costs 32 - 32 45 - 45 Total clinic operating costs 67,371 - 67,371 133,784 - 133,784 Gross margin 23,059 - 23,059 43,554 - 43,554 Corporate office costs 8,026 - 8,026 17,030 - 17,030 Operating income 15,033 - 15,033 26,524 - 26,524 Interest and other income, net 21 - 21 41 - 41 Interest expense Mandatorily redeemable non-controlling interests - change in redemption value - (1,931 ) (1,931 ) - (4,122 ) (4,122 ) Mandatorily redeemable non-controlling interests - earnings allocable - (1,330 ) (1,330 ) - (2,217 ) (2,217 ) Debt and other (320 ) - (320 ) (628 ) - (628 ) Total interest expense (320 ) (3,261 ) (3,581 ) (628 ) (6,339 ) (6,967 ) Income before taxes 14,734 (3,261 ) 11,473 25,937 (6,339 ) 19,598 Provision for income taxes 4,674 (872 ) 3,802 8,197 (2,223 ) 5,974 Net income 10,060 (2,389 ) 7,671 17,740 (4,116 ) 13,624 Less: net income attributable to non-controlling interests (2,989 ) 1,330 (1,659 ) (5,341 ) 2,217 (3,124 ) Net income attributable to USPH shareholders $ 7,071 $ (1,059 ) $ 6,012 $ 12,399 $ (1,899 ) $ 10,500 Basic and diluted earnings per share attributable to USPH shareholders $ 0.57 $ (0.09 ) $ 0.48 $ 0.99 $ (0.15 ) $ 0.84 Shares used in computation - basic 12,511 12,511 12,480 12,480 Shares used in computation - diluted 12,511 12,511 12,480 12,480 Dividends declared per common share $ 0.17 $ 0.17 $ 0.34 $ 0.34 Consolidated Statement of Net Income as of March 31, 2016: For the Three Months Ended As Reported March 31, 2016 Adjustments As Restated March 31, 2016 Net patient revenues $ 85,049 $ - $ 85,049 Other revenues 1,859 - 1,859 Net revenues 86,908 - 86,908 Clinic operating costs: Salaries and related costs 47,804 - 47,804 Rent, clinic supplies, contract labor and other 17,507 - 17,507 Provision for doubtful accounts 1,089 - 1,089 Closure costs 13 - 13 Total clinic operating costs 66,413 - 66,413 Gross margin 20,495 - 20,495 Corporate office costs 9,004 - 9,004 Operating income 11,491 - 11,491 Interest and other income, net 20 - 20 Interest expense Mandatorily redeemable non-controlling interests - change in redemption value - (2,191 ) (2,191 ) Mandatorily redeemable non-controlling interests - earnings allocable - (887 ) (887 ) Debt and other (308 ) - (308 ) Total interest expense (308 ) (3,078 ) (3,386 ) Income before taxes 11,203 (3,078 ) 8,125 Provision for income taxes 3,523 (1,351 ) 2,172 Net income 7,680 (1,727 ) 5,953 Less: net income attributable to non-controlling interests (2,352 ) 887 (1,465 ) Net income attributable to USPH shareholders $ 5,328 $ (840 ) $ 4,488 Basic and diluted earnings per share attributable to USPH shareholders $ 0.43 $ (0.07 ) $ 0.36 Shares used in computation - basic 12,448 12,448 Shares used in computation - diluted 12,448 12,448 Dividends declared per common share $ 0.17 $ 0.17 Consolidated Statement of Net Income as of September 30, 2015: For the Three Months Ended For the Nine Months Ended As Reported September 30, 2015 Adjustments As Restated September 30, 2015 As Reported September 30, 2015 Adjustments As Restated September 30, 2015 Net patient revenues $ 82,154 $ - $ 82,154 $ 239,412 $ - $ 239,412 Other revenues 1,895 - 1,895 5,166 - 5,166 Net revenues 84,049 - 84,049 244,578 - 244,578 Clinic operating costs: Salaries and related costs 46,594 - 46,594 134,044 - 134,044 Rent, clinic supplies, contract labor and other 17,428 - 17,428 50,434 - 50,434 Provision for doubtful accounts 1,067 - 1,067 3,119 - 3,119 Closure costs 88 - 88 125 - 125 Total clinic operating costs 65,177 - 65,177 187,722 - 187,722 Gross margin 18,872 - 18,872 56,856 - 56,856 Corporate office costs 6,923 - 6,923 22,173 - 22,173 Operating income 11,949 - 11,949 34,683 - 34,683 Interest and other income, net 24 - 24 48 - 48 Interest expense Mandatorily redeemable non-controlling interests - change in redemption value - (501 ) (501 ) - (697 ) (697 ) Mandatorily redeemable non-controlling interests - earnings allocable - (778 ) (778 ) - (2,674 ) (2,674 ) Debt and other (255 ) - (255 ) (765 ) - (765 ) Total interest expense (255 ) (1,279 ) (1,534 ) (765 ) (3,371 ) (4,136 ) Income before taxes 11,718 (1,279 ) 10,439 33,966 (3,371 ) 30,595 Provision for income taxes 3,654 (189 ) 3,465 10,634 (263 ) 10,371 Net income 8,064 (1,090 ) 6,974 23,332 (3,108 ) 20,224 Less: net income attributable to non-controlling interests (2,246 ) 778 (1,468 ) (7,044 ) 2,674 (4,370 ) Net income attributable to USPH shareholders $ 5,818 $ (312 ) $ 5,506 $ 16,288 $ (434 ) $ 15,854 Basic and diluted earnings per share attributable to USPH shareholders $ 0.47 $ (0.03 ) $ 0.44 $ 1.29 $ (0.01 ) $ 1.28 Shares used in computation - basic 12,421 12,421 12,382 12,382 Shares used in computation - diluted 12,421 12,421 12,382 12,382 Dividends declared per common share $ 0.15 $ 0.15 $ 0.45 $ 0.45 Consolidated Statement of Net Income as of June 30, 2015: For the Three Months Ended For the Six Months Ended As Reported June 30, 2015 Adjustments As Restated June 30, 2015 As Reported June 30, 2015 Adjustments As Restated June 30, 2015 Net patient revenues $ 81,451 $ - $ 81,451 $ 157,258 $ - $ 157,258 Other revenues 1,837 - 1,837 3,271 - 3,271 Net revenues 83,288 - 83,288 160,529 - 160,529 Clinic operating costs: Salaries and related costs 44,398 - 44,398 87,450 - 87,450 Rent, clinic supplies, contract labor and other 16,681 - 16,681 33,006 - 33,006 Provision for doubtful accounts 1,062 - 1,062 2,052 - 2,052 Closure costs 5 - 5 37 - 37 Total clinic operating costs 62,146 - 62,146 122,545 - 122,545 Gross margin 21,142 - 21,142 37,984 - 37,984 Corporate office costs 7,593 - 7,593 15,250 - 15,250 Operating income 13,549 - 13,549 22,734 - 22,734 Interest and other income, net 16 - 16 24 - 24 Interest expense Mandatorily redeemable non-controlling interests - change in redemption value - 48 48 - (196 ) (196 ) Mandatorily redeemable non-controlling interests - earnings allocable - (1,190 ) (1,190 ) - (1,896 ) (1,896 ) Debt and other (245 ) - (245 ) (510 ) - (510 ) Total interest expense (245 ) (1,142 ) (1,387 ) (510 ) (2,092 ) (2,602 ) Income before taxes 13,320 (1,142 ) 12,178 22,248 (2,092 ) 20,156 Provision for income taxes 4,203 18 4,221 6,980 (74 ) 6,906 Net income 9,117 (1,160 ) 7,957 15,268 (2,018 ) 13,250 Less: net income attributable to non-controlling interests (2,813 ) 1,190 (1,623 ) (4,798 ) 1,896 (2,902 ) Net income attributable to USPH shareholders $ 6,304 $ 30 $ 6,334 $ 10,470 $ (122 ) $ 10,348 Basic and diluted earnings per share attributable to USPH shareholders $ 0.48 $ 0.03 $ 0.51 $ 0.82 $ 0.02 $ 0.84 Shares used in computation - basic 12,409 12,409 12,362 12,362 Shares used in computation - diluted 12,409 12,409 12,362 12,362 Dividends declared per common share $ 0.15 $ 0.15 $ 0.30 $ 0.30 Consolidated Statement of Net Income as of March 31, 2015: For the Three Months Ended As Reported March 31, 2015 Adjustments As Restated March 31, 2015 Net patient revenues $ 75,807 $ - $ 75,807 Other revenues 1,434 - 1,434 Net revenues 77,241 - 77,241 Clinic operating costs: Salaries and related costs 43,052 - 43,052 Rent, clinic supplies, contract labor and other 16,325 - 16,325 Provision for doubtful accounts 990 - 990 Closure costs 32 - 32 Total clinic operating costs 60,399 - 60,399 Gross margin 16,842 - 16,842 Corporate office costs 7,657 - 7,657 Operating income 9,185 - 9,185 Interest and other income, net 8 - 8 Interest expense Mandatorily redeemable non-controlling interests - change in redemption value - (244 ) (244 ) Mandatorily redeemable non-controlling interests - earnings allocable - (706 ) (706 ) Debt and other (265 ) - (265 ) Total interest expense (265 ) (950 ) (1,215 ) Income before taxes 8,928 (950 ) 7,978 Provision for income taxes 2,777 (92 ) 2,685 Net income 6,151 (858 ) 5,293 Less: net income attributable to non-controlling interests (1,985 ) 706 (1,279 ) Net income attributable to USPH shareholders $ 4,166 $ (152 ) $ 4,014 Basic and diluted earnings per share attributable to USPH shareholders $ 0.34 $ (0.01 ) $ 0.33 Shares used in computation - basic 12,313 12,313 Shares used in computation - diluted 12,313 12,313 Dividends declared per common share $ 0.15 $ 0.15 Consolidated Statement of Cash Flows as of September 30, 2016: For the Nine Months Ended As Reported As Restated September 30, 2016 Adjustments September 30, 2016 OPERATING ACTIVITIES Net income including non-controlling interests $ 25,712 $ (5,954 ) $ 19,758 Adjustments to reconcile net income including non-controlling interests to net cash provided by operating activities: Depreciation and amortization 6,210 - 6,210 Provision for doubtful accounts 2,962 - 2,962 Equity-based awards compensation expense 3,748 - 3,748 Loss (gain) on sale of fixed assets 31 - 31 Excess tax benefit from equity-based awards (798 ) 798 - Deferred income tax 5,688 (2,450 ) 3,238 Other - - - Changes in operating assets and liabilities: - Increase in patient accounts receivable (2,548 ) - (2,548 ) (Increase) decrease in accounts receivable - other 116 - 116 Decrease (increase) in other assets (4,979 ) - (4,979 ) Increase (decrease) in accounts payable and accrued expenses 5,178 (1,596 ) 3,582 Increase (decrease) in mandatorily redeemable non-controlling interests - 5,372 5,372 (Decrease) increase in other liabilities 708 - 708 Net cash provided by operating activities 42,028 (3,830 ) 38,198 INVESTING ACTIVITIES Purchase of fixed assets (5,620 ) - (5,620 ) Purchase of businesses, net of cash acquired (12,958 ) - (12,958 ) Acquisitions of non-controlling interests (1,800 ) 1,136 (664 ) Proceeds on sale of fixed assets, net 42 - 42 Net cash used in investing activities (20,336 ) 1,136 (19,200 ) FINANCING ACTIVITIES Distributions to non-controlling interests (8,271 ) 3,830 (4,441 ) Cash dividends to shareholders - funded (6,382 ) - (6,382 ) Proceeds from revolving line of credit 128,000 - 128,000 Payments on revolving line of credit (136,000 ) - (136,000 ) Payments to settle mandatorily redeemable non-controlling interests - (1,136 ) (1,136 ) Principal payments on notes payable (592 ) - (592 ) Tax benefit from equity-based awards 798 - 798 Other 1 - 1 Net cash used in financing activities (22,446 ) 2,694 (19,752 ) Net increase in cash and cash equivalents (754 ) - (754 ) Cash and cash equivalents - beginning of period 15,778 - 15,778 Cash and cash equivalents - end of period $ 15,024 $ - $ 15,024 SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Cash paid during the period for: Income taxes $ 10,051 $ 10,051 Interest $ 770 $ 770 Non-cash investing and financing transactions during the period: Purchase of business - seller financing portion $ 500 $ 500 Acquisition of non-controlling interest - seller financing portion $ 514 $ 388 Payment to settle redeemable non-controlling interest - financing portion $ - $ 126 Sale of non-controlling interests $ (148 ) $ (148 ) Consolidated Statement of Cash Flows as of June 30, 2016: For the Six Months Ended As Reported As Restated June 30, 2016 Adjustments June 30, 2016 OPERATING ACTIVITIES Net income including non-controlling interests $ 17,740 $ (4,116 ) $ 13,624 Adjustments to reconcile net income including non-controlling interests to net cash provided by operating activities: Depreciation and amortization 4,158 - 4,158 Provision for doubtful accounts 2,045 - 2,045 Equity-based awards compensation expense 2,484 - 2,484 Loss (gain) on sale of fixed assets - - - Excess tax benefit from equity-based awards (556 ) 556 - Deferred income tax 4,170 (1,667 ) 2,503 Other - - - Changes in operating assets and liabilities: - Increase in patient accounts receivable (2,449 ) - (2,449 ) (Increase) decrease in accounts receivable - other 53 - 53 Decrease (increase) in other assets (2,443 ) - (2,443 ) Increase (decrease) in accounts payable and accrued expenses 7,715 (1,112 ) 6,603 Increase (decrease) in mandatorily redeemable non-controlling interests - 4,028 4,028 (Decrease) increase in other liabilities 447 - 447 Net cash provided by operating activities 33,364 (2,311 ) 31,053 INVESTING ACTIVITIES Purchase of fixed assets (3,453 ) - (3,453 ) Purchase of businesses, net of cash acquired (12,958 ) - (12,958 ) Acquisitions of non-controlling interests, net of sales (1,386 ) 1,136 (250 ) Proceeds on sale of fixed assets, net 42 - 42 Net cash used in investing activities (17,755 ) 1,136 (16,619 ) FINANCING ACTIVITIES Distributions to non-controlling interests (5,204 ) 2,311 (2,893 ) Cash dividends to shareholders - funded (4,254 ) - (4,254 ) Proceeds from revolving line of credit 93,000 - 93,000 Payments on revolving line of credit (94,500 ) - (94,500 ) Payments to settle mandatorily redeemable non-controlling interests - (1,136 ) (1,136 ) Principal payments on notes payable (533 ) - (533 ) Tax benefit from equity-based awards 556 - 556 Other 1 - 1 Net cash used in financing activities (10,934 ) 1,175 (9,759 ) Net increase in cash and cash equivalents 4,675 - 4,675 Cash and cash equivalents - beginning of period 15,778 - 15,778 Cash and cash equivalents - end of period $ 20,453 $ - $ 20,453 SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Cash paid during the period for: Income taxes $ 5,513 $ 5,513 Interest $ 512 $ 512 Non-cash investing and financing transactions during the period: Purchase of business - seller financing portion $ 500 $ 500 Acquisition of non-controlling interest - seller financing portion $ 514 $ 388 Payment to settle redeemable non-controlling interest - financing portion $ - $ 126 Sale of non-controlling interests $ (148 ) $ (148 ) Consolidated Statement of Cash Flows as of March 31, 2016: For the Three Months Ended As Reported As Restated March 31, 2016 Adjustments March 31, 2016 OPERATING ACTIVITIES Net income including non-controlling interests $ 7,680 $ (1,727 ) $ 5,953 Adjustments to reconcile net income including non-controlling interests to net cash provided by operating activities: Depreciation and amortization 2,091 - 2,091 Provision for doubtful accounts 1,089 - 1,089 Equity-based awards compensation expense 1,221 - 1,221 Loss (gain) on sale of fixed assets (19 ) - (19 ) Excess tax benefit from equity-based awards (323 ) 465 142 Deferred income tax 2,709 (886 ) 1,823 Other - - - Changes in operating assets and liabilities: - Increase in patient accounts receivable (2,185 ) - (2,185 ) (Increase) decrease in accounts receivable - other 43 - 43 Decrease (increase) in other assets (2,282 ) - (2,282 ) Increase (decrease) in accounts payable and accrued expenses 4,322 (930 ) 3,392 Increase (decrease) in mandatorily redeemable non-controlling interests - 2,578 2,578 (Decrease) increase in other liabilities 365 - 365 Net cash provided by operating activities 14,711 (500 ) 14,211 INVESTING ACTIVITIES Purchase of fixed assets (1,738 ) - (1,738 ) Purchase of businesses, net of cash acquired (12,899 ) - (12,899 ) Acquisitions of non-controlling interests (1,524 ) 1,136 (388 ) Proceeds on sale of fixed assets, net 42 - 42 Net cash used in investing activities (16,119 ) 1,136 (14,983 ) FINANCING ACTIVITIES Distributions to non-controlling interests (1,613 ) 500 (1,113 ) Cash dividends to shareholders - funded (2,125 ) - (2,125 ) Proceeds from revolving line of credit 49,000 - 49,000 Payments on revolving line of credit (40,500 ) - (40,500 ) Payments to settle mandatorily redeemable non-controlling interests - (1,136 ) (1,136 ) Principal payments on notes payable (250 ) - (250 ) Tax benefit from equity-based awards 323 - 323 Other 1 - 1 Net cash used in financing activities 4,836 (636 ) 4,200 Net increase in cash and cash equivalents 3,428 - 3,428 Cash and cash equivalents - beginning of period 15,778 - 15,778 Cash and cash equivalents - end of period $ 19,206 $ - $ 19,206 SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Cash paid during the period for: Income taxes $ 2,265 $ 2,265 Interest $ 248 $ 248 Non-cash investing and financing transactions during the period: Purchase of business - seller financing portion $ 500 $ 500 Acquisition of non-controlling interest - seller financing portion $ 514 $ 388 Payment to settle redeemable non-controlling interest - financing portion $ - $ 126 Consolidated Statement of Cash Flows as of September 30, 2015: For the Nine Months Ended As Reported September 30, 2015 Adjustments As Restated September 30, 2015 OPERATING ACTIVITIES Net income including non-controlling interests $ 23,332 $ (3,108 ) $ 20,224 Adjustments to reconcile net income including non-controlling interests to net

SCHEDULE II - VALUATION AND QUA

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2016
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS [Abstract]
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES Balance at Beginning of Period Additions Charged to Costs and Expenses Additions Charged to Other Accounts Deductions Balance at End of Period YEAR ENDED DECEMBER 31, 2016: Reserves and allowances deducted from asset accounts: Allowance for doubtful accounts(1) $ 1,642 $ 3,906 - $ 3,756 (2) $ 1,792 YEAR ENDED DECEMBER 31, 2015: Reserves and allowances deducted from asset accounts: Allowance for doubtful accounts $ 1,867 $ 4,170 - $ 4,395 (2) $ 1,642 YEAR ENDED DECEMBER 31, 2014: Reserves and allowances deducted from asset accounts: Allowance for doubtful accounts $ 1,628 $ 4,112 - $ 3,873 (2) $ 1,867 (1) Related to patient accounts receivable and accounts receivable—other. (2) Uncollectible accounts written off, net of recoveries. * All other schedules are omitted because of the absence of conditions under which they are required or because the required information is shown in the financial statements or notes thereto.

Significant Accounting Polici25

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Significant Accounting Policies [Abstract]
Cash Equivalents	Cash Equivalents The Company maintains its cash and cash equivalents at financial institutions. The combined account balances at several institutions typically exceed Federal Deposit Insurance Corporation (“FDIC”) insurance coverage and, as a result, there is a concentration of credit risk related to amounts on deposit in excess of FDIC insurance coverage. Management believes that this risk is not significant.
Long-Lived Assets	Long-Lived Assets Fixed assets are stated at cost. Depreciation is computed on the straight-line method over the estimated useful lives of the related assets. Estimated useful lives for furniture and equipment range from three to eight years and for software purchased from three to seven years. Leasehold improvements are amortized over the shorter of the related lease term or estimated useful lives of the assets, which is generally three to five years.
Impairment of Long-Lived Assets and Long-Lived Assets to be Disposed of	Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of The Company reviews property and equipment and intangible assets with finite lives for impairment upon the occurrence of certain events or circumstances that indicate the related amounts may be impaired. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
Goodwill	Goodwill Goodwill represents the excess of the amount paid and fair value of the non-controlling interests over the fair value of the acquired business assets, which include certain identifiable intangible assets. Historically, goodwill has been derived from acquisitions and, prior to 2009, from the purchase of some or all of a particular local management’s equity interest in an existing clinic. Effective January 1, 2009, if the purchase price of a non-controlling interest by the Company exceeds or is less than the book value at the time of purchase, any excess or shortfall is recognized as an adjustment to additional paid-in capital. The fair value of goodwill and other identifiable intangible assets with indefinite lives are tested for impairment annually and upon the occurrence of certain events, and are written down to fair value if considered impaired. The Company evaluates goodwill for impairment on at least an annual basis (in its third quarter) by comparing the fair value of its reporting units to the carrying value of each reporting unit including related goodwill. The Company operates a one segment business which is made up of various clinics within partnerships. The partnerships are components of regions and are aggregated to the operating segment level for the purpose of determining the Company’s reporting units when performing its annual goodwill impairment test. In 2016, 2015 and 2014, there were six regions. An impairment loss generally would be recognized when the carrying amount of the net assets of a reporting unit, inclusive of goodwill and other identifiable intangible assets, exceeds the estimated fair value of the reporting unit. The estimated fair value of a reporting unit is determined using two factors: (i) earnings prior to taxes, depreciation and amortization for the reporting unit multiplied by a price/earnings ratio used in the industry and (ii) a discounted cash flow analysis. A weight is assigned to each factor and the sum of each weight times the factor is considered the estimated fair value. For 2016, the factors (i.e., price/earnings ratio, discount rate and residual capitalization rate) were updated to reflect current market conditions. The evaluation of goodwill in 2016, 2015 and 2014 did not result in any goodwill amounts that were deemed impaired. The Company has not identified any triggering events occurring after the testing date that would impact the impairment testing results obtained. Factors which could result in future impairment charges include but are not limited to: • cost, risks and uncertainties associated with the Company’s recent restatement of its prior financial statements due to the correction of its accounting methodology for redeemable non-controlling partnership interests, and including any pending and future claims or proceedings relating to such matters; • changes as the result of government enacted national healthcare reform; • changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification or enrollment status; • revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction; • business and regulatory conditions including federal and state regulation; • governmental and other third party payor inspections, reviews, investigations and audits; • compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information and associated fines and penalties for failure to comply; • legal actions, which could subject us to increased operating costs and uninsured liabilities; • changes in reimbursement rates or payment methods from third party payors including government agencies and deductibles and co-pays owed by patients; • revenue and earnings expectations; • general economic conditions; • availability and cost of qualified physical and occupational therapists; • personnel productivity and retaining key personnel; • competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain operations and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets; • acquisitions, purchases of non-controlling interests (minority interests) and the successful integration of the operations of the acquired business; • maintaining necessary insurance coverage; • availability, terms, and use of capital; and • weather and other seasonal factors. The Company will continue to monitor for any triggering events or other indicators of impairment.
Mandatorily Redeemable Non-Controlling Interests	Mandatorily Redeemable Non-Controlling Interests – The non-controlling interests that are reflected as mandatorily redeemable non-controlling interests in the consolidated financial statements consist of those owners who have certain redemption rights, whether currently exercisable or not, and which currently, or in the future, require that the Company purchase the non-controlling interest of those owners at a predetermined formula based on a multiple of trailing twelve months earnings performance as defined in the respective limited partnership agreements. The redemption rights are triggered at such time as both of the following events have occurred: 1) termination of the owner’s employment, regardless of the reason for such termination, and 2) the passage of specified number of years after the closing of the transaction, typically three to five years, as defined in the limited partnership agreement. On the date the Company acquires a controlling interest in a partnership and the limited partnership agreement contains mandatory redemption rights, the fair value of the non-controlling interest is recorded in the long-term liabilities section of the consolidated balance sheet under the caption – Mandatorily redeemable non-controlling interests Interest expense – mandatorily redeemable non-controlling interests – change in redemption value and Interest expense – mandatorily redeemable non-controlling interests – earnings allocable
Non-Controlling Interests	Non-Controlling Interests The Company recognizes non-controlling interests as equity in the consolidated financial statements separate from the parent entity’s equity. The amount of net income attributable to non-controlling interests is included in consolidated net income on the face of the statements of net income. Changes in a parent entity’s ownership interest in a subsidiary that do not result in deconsolidation are treated as equity transactions if the parent entity retains its controlling financial interest. The Company recognizes a gain or loss in net income when a subsidiary is deconsolidated. Such gain or loss is measured using the fair value of the non-controlling equity investment on the deconsolidation date. When the purchase price of a non-controlling interest by the Company exceeds the book value at the time of purchase, any excess or shortfall is recognized as an adjustment to additional paid-in capital. Additionally, operating losses are allocated to non-controlling interests even when such allocation creates a deficit balance for the non-controlling interest partner.
Revenue Recognition	Revenue Recognition Revenues are recognized in the period in which services are rendered. Net patient revenues (patient revenues less estimated contractual adjustments) are reported at the estimated net realizable amounts from third-party payors, patients and others for services rendered. The Company has agreements with third-party payors that provide for payments to the Company at amounts different from its established rates. The allowance for estimated contractual adjustments is based on terms of payor contracts and historical collection and write-off experience. The Company determines allowances for doubtful accounts based on the specific agings and payor classifications at each clinic. The provision for doubtful accounts is included in clinic operating costs in the statements of net income. Patient accounts receivable, which are stated at the historical carrying amount net of contractual allowances, write-offs and allowance for doubtful accounts, includes only those amounts the Company estimates to be collectible. Medicare Reimbursement The Medicare program reimburses outpatient rehabilitation providers based on the Medicare Physician Fee Schedule (‘‘MPFS’’). The MPFS rates have historically been subject to an automatic annual update based on a formula, called the sustainable growth rate (‘‘SGR’’) formula. The use of the SGR formula would have resulted in calculated automatic reductions in rates in every year since 2002; however, for each year through September 30, 2015, Centers for Medicare & Medicaid Services (‘‘CMS’’) or Congress has taken action to prevent the implementation of SGR formula reductions. On April 16, 2015, the Medicare Access and CHIP Reauthorization Act of 2015 (‘‘MACRA’’) was signed into law, eliminating the SGR formula and the associated annual automatic rate reductions. For services provided between January 1, 2015 and June 30, 2015 a 0% payment update was applied to the Medicare physician fee schedule payment rates; for services provided between July 1, 2015 and December 31, 2015 a 0.5% increase was applied to the fee schedule payment rates; for services provided in 2016 a 0.3% decrease is being applied to the fee schedule payment rates, and for 2017 through 2019, a 0.5% increase will be applied each year to the fee schedule payment rates, unless further adjusted by CMS. The payment adjustments proposed by CMS for 2017 is a .08% reduction. In addition, the MACRA promotes the development of new payment models that focus on quality and outcomes. The Budget Control Act of 2011 increased the federal debt ceiling in connection with deficit reductions over the next ten years, and requires automatic reductions in federal spending by approximately $1.2 trillion. Payments to Medicare providers are subject to these automatic spending reductions, subject to a 2% cap. On April 1, 2013, a 2% reduction to Medicare payments was implemented. The Bipartisan Budget Act of 2015, enacted on November 2, 2015, extends the 2% reductions to Medicare payments through fiscal year 2025. As a result of the Balanced Budget Act of 1997, the formula for determining the total amount paid by Medicare in any one year for outpatient physical therapy, occupational therapy, and/or speech-language pathology services provided to any Medicare beneficiary (i.e., the ‘‘Therapy Cap’’ or ‘‘Limit’’) was established. Based on the statutory definitions which constrained how the Therapy Cap would be applied, there is one Limit for Physical Therapy and Speech Language Pathology Services combined, and one Limit for Occupational Therapy. For 2016, the annual Limit on outpatient therapy services is $1,960 for Physical and Speech Language Pathology Services combined and $1,960 for Occupational Therapy Services. Historically, these Therapy Caps applied to outpatient therapy services provided in all settings, except for services provided in departments of hospitals. However, the Protecting Access to Medicare Act of 2014, and prior legislation, extended the Therapy Caps to services furnished in hospital outpatient department settings. The application of these annual limits to hospital outpatient department settings will sunset on December 31, 2017 unless Congress extends it. In the Deficit Reduction Act of 2005, Congress implemented an exceptions process to the annual Limit for therapy expenses for therapy services above the annual Limit. Therapy services above the annual Limit that are medically necessary satisfy an exception to the annual Limit and such claims are payable by the Medicare program. The MACRA extended the exceptions process for outpatient therapy caps through December 31, 2017. Unless Congress extends the exceptions process further, the therapy caps will apply to all outpatient therapy services beginning January 1, 2018, except those services furnished and billed by outpatient hospital departments. For any claim above the annual Limit, the claim must contain a modifier indicating that the services are medically necessary and justified by appropriate documentation in the medical record. Furthermore, under the Middle Class Tax Relief and Job Creation Act of 2012 (‘‘MCTRA’’), since October 1, 2012, patients who met or exceeded $3,700 in therapy expenditures during a calendar year have been subject to a manual medical review to determine whether applicable payment criteria are satisfied. The $3,700 threshold is applied to Physical Therapy and Speech Language Pathology Services; a separate $3,700 threshold is applied to the Occupational Therapy. The MACRA directed CMS to modify the manual medical review process such that those reviews will no longer apply to all claims exceeding the $3,700 threshold and instead will be determined on a targeted basis based on a variety of factors that CMS considers appropriate. The new factors apply to exception requests for which CMS did not conduct a medical review by July 15, 2015. CMS adopted a multiple procedure payment reduction (‘‘MPPR’’) for therapy services in the final update to the MPFS for calendar year 2011. The MPPR applied to all outpatient therapy services paid under Medicare Part B — occupational therapy, physical therapy and speech-language pathology. Under the policy, the Medicare program pays 100% of the practice expense component of the Relative Value Unit (‘‘RVU’’) for the therapy procedure with the highest practice expense RVU, then reduces the payment for the practice expense component for the second and subsequent therapy procedures or units of service furnished during the same day for the same patient, regardless of whether those therapy services are furnished in separate sessions. Since 2013, the practice expense component for the second and subsequent therapy service furnished during the same day for the same patient was reduced by 50%. In addition, the MCTRA directed CMS to implement a claims-based data collection program to gather additional data on patient function during the course of therapy in order to better understand patient conditions and outcomes. All practice settings that provide outpatient therapy services are required to include this data on the claim form. Since 2013, therapists have been required to report new codes and modifiers on the claim form that reflect a patient’s functional limitations and goals at initial evaluation, periodically throughout care, and at discharge, CMS has rejected claims if the required data is not included in the claim. The Physician Quality Reporting System, or ‘‘PQRS,’’ is a CMS reporting program that uses a combination of incentive payments and payment reductions to promote reporting of quality information by ‘‘eligible professionals.’’ Although physical therapists, occupational therapists and qualified speech-language therapists are generally able to participate in the PQRS program, therapy professionals for whose services we bill through our certified rehabilitation agencies cannot participate because the Medicare claims processing systems currently cannot accommodate institutional providers such as certified rehabilitation agencies. Eligible professionals, such as those of our therapy professionals for whose services we bill using their individual Medicare provider numbers, who do not satisfactorily report data on quality measures will be subject to a 2% reduction in their Medicare payment in 2016 and 2017. As required under the MACRA, the PQRS program will be replaced with the Merit-Based Incentive Payment System (MIPS) on January 1, 2017. Physical therapists and occupational therapists are not required to participate in the MIPS program until January 1, 2019 or later, as determined by CMS. Statutes, regulations, and payment rules governing the delivery of therapy services to Medicare beneficiaries are complex and subject to interpretation. The Company believes that it is in compliance in all material respects with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing that would have a material effect on the Company’s financial statements as of September 30, 2016. Compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from the Medicare program. For the year ended December 31, 2016, net revenue from Medicare accounts for approximately $81.8 million. Management Contract Revenues Management contract revenues are derived from contractual arrangements whereby the Company manages a clinic for third party owners. The Company does not have any ownership interest in these clinics. Typically, revenues are determined based on the number of visits conducted at the clinic and recognized when services are performed. Costs, typically salaries for the Company’s employees, are recorded when incurred. Management contract revenues are included in “other revenues” in the accompanying Consolidated Statements of Net Income.
Contractual Allowances	Contractual Allowances Contractual allowances result from the differences between the rates charged for services performed and expected reimbursements by both insurance companies and government sponsored healthcare programs for such services. Medicare regulations and the various third party payors and managed care contracts are often complex and may include multiple reimbursement mechanisms payable for the services provided in Company clinics. The Company estimates contractual allowances based on its interpretation of the applicable regulations, payor contracts and historical calculations. Each month the Company estimates its contractual allowance for each clinic based on payor contracts and the historical collection experience of the clinic and applies an appropriate contractual allowance reserve percentage to the gross accounts receivable balances for each payor of the clinic. Based on the Company’s historical experience, calculating the contractual allowance reserve percentage at the payor level is sufficient to allow the Company to provide the necessary detail and accuracy with its collectability estimates. However, the services authorized and provided and related reimbursement are subject to interpretation that could result in payments that differ from the Company’s estimates. Payor terms are periodically revised necessitating continual review and assessment of the estimates made by management. The Company’s billing system does not capture the exact change in its contractual allowance reserve estimate from period to period in order to assess the accuracy of its revenues and hence its contractual allowance reserves. Management regularly compares its cash collections to corresponding net revenues measured both in the aggregate and on a clinic-by-clinic basis. In the aggregate, historically the difference between net revenues and corresponding cash collections has generally reflected a difference within approximately 1% of net revenues. Additionally, analysis of subsequent period’s contractual write-offs on a payor basis reflects a difference within approximately 1% between the actual aggregate contractual reserve percentage as compared to the estimated contractual allowance reserve percentage associated with the same period end balance. As a result, the Company believes that a change in the contractual allowance reserve estimate would not likely be more than 1% at December 31, 2016.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount to be recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company did not have any accrued interest or penalties associated with any unrecognized tax benefits nor was any interest expense recognized during the twelve months ended December 31, 2016 and 2015. The Company will book any interest or penalties, if required, in interest and/or other income/expense as appropriate. On September 13, 2013, the U.S. Treasury Department and the I.R.S. issued final regulations that address costs incurred in acquiring, producing, or improving tangible property (the “Tangible Property Regulations”). The Tangible Property Regulations are generally effective for tax years beginning on or after January 1, 2014, and may be adopted in earlier years. The Company adopted the tax treatment of expenditures to improve tangible property and the capitalization of inherently facilitative costs to acquire tangible property as of January 1, 2014. Historically, the Company has treated the expenditures to improve tangible property and the capitalization of inherently facilitative costs to acquire tangible property similar for tax and book. The impact of these changes were not material to the Company's consolidated financial statements.
Fair Values of Financial Instruments	Fair Values of Financial Instruments The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable and notes payable approximate their fair values due to the short-term maturity of these financial instruments. The carrying amount under the Amended Credit Agreement (as defined in Note 9) approximates its fair value. The interest rate on the Credit Agreement, which is tied to the Eurodollar Rate, is set at various short-term intervals, as detailed in the Credit Agreement.
Segment Reporting	Segment Reporting Operating segments are components of an enterprise for which separate financial information is available that is evaluated regularly by chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company identifies operating segments based on management responsibility and believes it meets the criteria for aggregating its operating segments into a single reporting segment.
Use of Estimates	Use of Estimates In preparing the Company’s consolidated financial statements, management makes certain estimates and assumptions, especially in relation to, but not limited to, goodwill impairment, allowance for receivables, tax provision and contractual allowances, that affect the amounts reported in the consolidated financial statements and related disclosures. Actual results may differ from these estimates.
Self-Insurance Program	Self-Insurance Program The Company utilizes a self-insurance plan for its employee group health insurance coverage administered by a third party. Predetermined loss limits have been arranged with the insurance company to minimize the Company’s maximum liability and cash outlay. Accrued expenses include the estimated incurred but unreported costs to settle unpaid claims and estimated future claims. Management believes that the current accrued amounts are sufficient to pay claims arising from self-insurance claims incurred through December 31, 2016.
Restricted Stock	Restricted Stock Restricted stock issued to employees and directors is subject to continued employment or continued service on the board, respectively. Generally, restrictions on the stock granted to employees lapse in equal annual installments on the following four anniversaries of the date of grant. For those shares granted to directors, the restrictions will lapse in equal quarterly installments during the first year after the date of grant. For those granted to executive officers, the restriction will lapse in equal quarterly installments during the four years following the date of grant. Compensation expense for grants of restricted stock is recognized based on the fair value per share on the date of grant amortized over the vesting period. The restricted stock issued is included in basic and diluted shares for the earnings per share computation.
Recently Adopted Accounting Guidance	Recently Adopted Accounting Guidance In September 2015, the FASB issued changes to the accounting for measurement-period adjustments related to business combinations. Currently, an acquiring entity is required to retrospectively adjust the balance sheet amounts of the acquiree recognized at the acquisition date with a corresponding adjustment to goodwill during the measurement period, as well as revise comparative information for prior periods presented within financial statements as needed, including revising income effects, such as depreciation and amortization, as a result of changes made to the balance sheet amounts of the acquiree. Such adjustments are required when new information is obtained about facts and circumstances that existed as of the acquisition date that if known, would have affected the measurement of the amounts initially recognized or would have resulted in the recognition of additional assets or liabilities. The measurement period is the period after the acquisition date during which the acquirer may adjust the balance sheet amounts recognized for a business combination (generally up to one year from the date of acquisition). The changes eliminate the requirement to make such retrospective adjustments, and, instead require the acquiring entity to record these adjustments in the reporting period they are determined. Additionally, the changes require the acquiring entity to present separately on the face of the income statement or disclose in the notes to the financial statements the portion of the amount recorded in current-period income by line item that would have been recorded in previous reporting periods if the adjustment to the balance sheet amounts had been recognized as of the acquisition date. These changes became effective for the Company on January 1, 2016. This change did not have a material impact on its consolidated financial statements. In March 2016, the FASB issued guidance to simplify some provisions in stock compensation accounting. The guidance amends how excess tax benefits and a company’s payments to cover tax bills for the recipients’ shares should be classified. Prior to this guidance, excess tax benefits were recorded in additional paid-in capital, but will now become a component of the income tax provision/benefit in the period in which they occur. This guidance allows companies to estimate the number of stock awards expected to vest and revises the withholding requirements for classifying stock awards as equity. For public business entities, this guidance is effective for fiscal years starting after December 15, 2016, including interim periods within those fiscal years but early adoption is allowed. The Company adopted this accounting treatment in the fourth quarter of 2016. The adoption increased earnings, by decreasing the tax provision, by $1.0 million, or $0.09 per share, for the full fiscal year 2016. The election to record forfeitures in the period they occur is consistent with the Company’s past approach, due to the immateriality of past forfeitures, and the Company believes the effect to be immaterial on the consolidated financial statements.
Recently Issued Accounting Guidance	Recently Issued Accounting Guidance In February 2016, the FASB issued amended accounting guidance which replaced most existing lease accounting guidance under U. S. generally accepted accounting principles. Among other changes, the amended guidance requires that a right-to-use asset, which is an asset that represents the lessee’s right to use, and a lease liability, which is a lessee’s obligation to make lease payments arising for a lease measured on a discounted basis, be recognized on the balance sheet by lessees for those leases with a term of greater than 12 months. The amended guidance is effective for reporting periods beginning after December 15, 2018; however, early adoption is permitted. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Since the Company leases all but one of its clinic facilities, it has been evaluating various lease management systems to capture the necessary information and the impact that this amended accounting guidance will have on its consolidated financial statements.
Subsequent Event	Subsequent Event The Company has evaluated events occurring after the balance sheet date for possible disclosure as a subsequent event through the date that these consolidated financial statements were issued. In January 2017, the Company acquired a 70% interest in a physical therapy practice that owns and operates 17 clinics and manages an additional 8 clinics. The purchase price for the 70% interest was $11.4 million. In March 2017, the Company acquired a 55% interest in a company which is a provider of workforce performance solutions. The purchase price for the 55% interest was $6.6 million. In May 2017, the Company acquired a 70% interest in a physical therapy practice that owns and operates 4 clinics. The purchase price for the 70% interest was $2.5 million. Although the restatement of prior financial statements caused the Company to be in violation of our Amended Credit Agreement dated December 5, 2013, the Company was able to obtain necessary waivers and amendments, as applicable. On March 30, 2017, the Company entered into a Third Amendment to Amended and Restated Credit Agreement and Limited Waiver with its lenders. As of the date of this report, the Company is in compliance with the covenants in the Amended and Restated Credit Agreement.

Organization, Nature of Opera26

Organization, Nature of Operations and Basis of Presentation (Tables)	12 Months Ended
	Dec. 31, 2016
Organization, Nature of Operations and Basis of Presentation [Abstract]
Schedule of Multi Clinic Acquisition	During 2016, 2015 and 2014, the Company completed the following multi-clinic acquisitions of physical therapy practices: Date % Interest Acquired Number of Clinics 2016 February 2016 Acquisition February 29 55 % 8 November 2016 Acquisition November 30 60 % 12 2015 January 2015 Acquisition January 31 60 % 9 April 2015 Acquisition April 30 70 % 3 June 2015 Acquisition June 30 70 % 4 December 2015 Acquisition December 31 59 % 4 2014 April 2014 Acquisition April 30 70 % 13 August 2014 Acquisition August 1 100 % 3
Consolidated Balance Sheet	Consolidated Balance Sheet on December 31, 2015: Description As Reported Adjustment As Restated Goodwill $ 171,457 $ 23,916 $ 195,373 Total assets $ 279,913 $ 23,844 $ 303,757 MRNCI (1) - $ 45,974 $ 45,974 Deferred taxes (liability) $ 8,355 $ 7,153 $ 15,508 Total liabilities $ 77,960 $ 53,487 $ 131,447 RNCI (2) $ 8,843 $ (8,843 ) - Additional paid-in capital $ 45,251 $ 18,987 $ 64,238 Retained earnings $ 149,016 $ (10,715 ) $ 138,301 Total liabilities and equity $ 279,913 $ 23,844 $ 303,757 (1) Mandatorily redeemable non-controlling interests (2) Redeemable non-controlling interests
Consolidated Statement of Net Income	Consolidated Statement of Net Income for the Year Ended December 31, 2015: Description As Reported Adjustment As Restated Interest expense MRNCI (1) – changes in redemption value - $ 2,670 $ 2,670 MRNCI (1) – earnings allocable - $ 3,538 $ 3,538 Total interest expense $ 1,031 $ 6,208 $ 7,239 Net income before taxes $ 46,344 $ (6,208 ) $ 40,136 Provision for income taxes $ 14,653 $ (1,006 ) $ 13,647 Net income $ 31,691 $ (5,202 ) $ 26,489 Less: net income attributable to non-controlling interests $ 9,412 $ (3,538 ) $ 5,874 Net income attributable to USPH shareholders $ 22,279 $ (1,664 ) $ 20,615 Earnings per share $ 1.77 $ (0.11 ) $ 1.66 (1) See above. Consolidated Statement of Net Income for the Year Ended December 31, 2014: Description As Reported Adjustment As Restated Interest expense MRNCI (1) – change in redemption value - $ 2,978 $ 2,978 MRNCI (1) – earnings allocable - $ 3,388 $ 3,388 Total interest expense $ 1,088 $ 6,366 $ 7,454 Net income before taxes $ 44,698 $ (6,366 ) $ 38,332 Provision for income taxes $ 14,274 $ (1,256 ) $ 13,018 Net income $ 30,424 $ (5,110 ) $ 25,314 Less: net income attributable to non-controlling interests $ 9,571 $ (3,388 ) $ 6,183 Net income attributable to USPH shareholders $ 20,853 $ (1,722 ) $ 19,131 Earnings per share $ 1.62 $ (0.05 ) $ 1.57 (1) See above.
Consolidated Statement of Cash Flows	Consolidated Statement of Cash Flows for the Year Ended December 31, 2015: Description As Reported Adjustment As Restated Net income $ 31,691 $ (5,202 ) $ 26,489 Deferred taxes $ 7,001 $ (1,048 ) $ 5,953 (Increase) decrease in other assets $ (1,477 ) $ 102 $ (1,375 ) (Decrease) increase in accounts payable and accrued expenses $ (7,013 ) $ 2 $ (7,011 ) Increase in mandatorily redeemable non-controlling interest $ - $ 2,509 $ 2,509 (Decrease) increase in other liabilities $ 1,482 $ (86 ) $ 1,396 Net cash provided by operating activities $ 41,243 $ (3,723 ) $ 37,520 Acquisitions of non-controlling interests $ (7,083 ) $ 6,115 $ (968 ) Net cash used in investing activities $ (32,240 ) $ 6,115 $ (26,125 ) Distributions to non-controlling interests (including redeemable non-controlling interests) $ (9,632 ) $ 9,632 $ - Distributions to non-controlling interests $ - $ (5,892 ) $ (5,892 ) Payments to settle mandatorily redeemable non-controlling interests $ - $ (6,115 ) $ (6,115 ) Other $ 22 $ (17 ) $ 5 Net cash used in financing activities $ (7,496 ) $ (2,392 ) $ (9,888 ) Consolidated Statement of Cash Flows for the Year Ended December 31, 2014: Description As Reported Adjustment As Restated Net income $ 30,424 $ (5,110 ) $ 25,314 Deferred taxes $ 6,275 $ (1,169 ) $ 5,106 (Increase) decrease in other assets $ (2,493 ) $ 3,648 $ 1,155 Increase in mandatorily redeemable non-controlling interest $ - $ 2,936 $ 2,936 (Decrease) increase in other liabilities $ 730 $ (4,108 ) $ (3,378 ) Net cash provided by operating activities $ 45,194 $ (3,803 ) $ 41,391 Acquisitions of non-controlling interests $ (5,490 ) $ 5,263 $ (227 ) Net cash used in investing activities $ (22,880 ) $ 5,263 $ (17,617 ) Distributions to non-controlling interests (including redeemable non-controlling interests) $ (9,913 ) $ 9,913 $ - Distributions to non-controlling interests $ - $ (5,963 ) $ (5,963 ) Payments to settle mandatorily redeemable non-controlling interests $ - $ (5,233 ) $ (5,233 ) Other $ 222 $ (177 ) $ 45 Net cash used in financing activities $ (20,941 ) $ (1,460 ) $ (22,401 )

Acquisitions of Businesses (Tab

Acquisitions of Businesses (Tables)	12 Months Ended
	Dec. 31, 2016
Acquisitions of Businesses [Abstract]
Schedule of Multi Clinic Acquisition	During 2016, 2015 and 2014, the Company completed the following multi-clinic acquisitions of physical therapy practices: Date % Interest Acquired Number of Clinics 2016 February 2016 Acquisition February 29 55 % 8 November 2016 Acquisition November 30 60 % 12 2015 January 2015 Acquisition January 31 60 % 9 April 2015 Acquisition April 30 70 % 3 June 2015 Acquisition June 30 70 % 4 December 2015 Acquisition December 31 59 % 4 2014 April 2014 Acquisition April 30 70 % 13 August 2014 Acquisition August 1 100 % 3
Schedule of Preliminary Purchase Prices Allocation	The purchase price for the 2016 acquisitions has been preliminarily allocated as follows (in thousands): Cash paid, net of cash acquired $ 23,623 Seller notes 1,000 Total consideration $ 24,623 Estimated fair value of net tangible assets acquired: Total current assets $ 1,712 Total non-current assets 1,202 Total liabilities (398 ) Net tangible assets acquired $ 2,516 Referral relationships 4,919 Non-compete 847 Tradename 3,802 Goodwill 31,419 Fair value of non-controlling interest (18,880 ) $ 24,623 The purchase prices for the 2015 acquisitions have been allocated as follows (in thousands): Cash paid, net of cash acquired $ 18,965 Seller notes 1,800 Total consideration $ 20,765 Estimated fair value of net tangible assets acquired: Total current assets $ 1,952 Total non-current assets 1,068 Total liabilities (1,067 ) Net tangible assets acquired $ 1,953 Referral relationships 3,655 Non-compete 594 Tradename 3,417 Goodwill 23,437 Fair value of non-controlling interest (12,291 ) $ 20,765 The purchase prices for the 2014 acquisitions have been allocated as follows (in thousands): Cash paid, net of cash acquired $ 12,270 Seller notes 400 Total consideration $ 12,670 Estimated fair value of net tangible assets acquired: Total current assets $ 1,213 Total non-current assets 1,051 Total liabilities (406 ) Net tangible assets acquired $ 1,858 Referral relationships 280 Non-compete 330 Tradename 1,600 Goodwill 13,327 Fair value of non-controlling interest (4,725 ) $ 12,670

Redeemable Non-Controlling In28

Redeemable Non-Controlling Interest (Tables)	12 Months Ended
	Dec. 31, 2016
Redeemable Non-Controlling Interest [Abstract]
Changes in Carrying Amount of Redeemable Non-Controlling Interest	The following table details the changes in the carrying amount of the mandatorily redeemable non-controlling interests (in thousands): Year Ended Year Ended (as restated) Beginning balance, as restated $ 45,974 $ 40,365 Operating results allocated to mandatorily redeemable non-controlling interest partners 4,057 3,538 Distributions to mandatorily redeemable non-controlling interest partners (4,628 ) (3,740 ) Changes in the redemption value of mandatorily redeemable non-controlling interest 6,169 2,670 Payments for settlement of mandatorily redeemable non-controlling interest (1,262 ) (9,192 ) Purchases of businesses - initial liability related to mandatorily redeemable non-controlling interests 18,880 12,291 Other - 42 Ending balance $ 69,190 $ 45,974
Carrying Amount of Redeemable Non-Controlling Interest	The following table details the carrying amount of the mandatorily redeemable non-controlling interests (in thousands): Year Ended Year Ended (as restated) Contractual time period has lapsed but holder's employment has not been terminated $ 24,700 $ 19,969 Contractual time period has not lapsed and holder's employment has not been terminated 46,949 27,893 Holder's employment has terminated and contractual time period has expired - - Holder's employment has terminated and contractual time period has not expired - - Redemption value prior to excess distributed earnings $ 71,649 $ 47,862 Excess distributions over earnings and losses (2,459 ) (1,888 ) $ 69,190 $ 45,974

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2016
Goodwill [Abstract]
Summary of Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill as of December 31, 2016 and 2015 consisted of the following (in thousands): Year Ended December 31, 2016 Year Ended December 31, 2015 (as restated) Beginning balance, as restated $ 195,373 $ 171,740 Goodwill acquired during the period 31,419 23,437 Goodwill adjustments for purchase price allocation of business acquired 14 376 Goodwill written-off - closed clinics - (180 ) Ending balance $ 226,806 $ 195,373

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	12 Months Ended
	Dec. 31, 2016
Intangible Assets, net [Abstract]
Intangible Assets, Net	Intangible assets, net as of December 31, 2016 and 2015 consisted of the following (in thousands): December 31, 2016 December 31, 2015 Tradenames, net of accumulated amortization of $0 and $170, respectively $ 21,234 $ 17,660 Referral relationships, net of accumulated amortization of $5,275 and $3,763, respectively 14,859 10,866 Non-compete agreements, net of accumulated amortization of $3,380 and $2,855, respectively 1,967 1,770 $ 38,060 $ 30,296
Amortization Expenses	The following table details the amount of amortization expense recorded for intangible assets for the years ended December 31, 2016, 2015 and 2014 (in thousands): Year Ended Year Ended Year Ended December 31, 2016 December 31, 2015 December 31, 2014 Tradenames $ 330 $ 84 $ 86 Referral relationships 1,512 1,153 1,028 Non-compete agreements 525 478 427 $ 2,367 $ 1,715 $ 1,541
Amortization of Referral Relationships and Non Competition Agreements	The remaining balances of the referral relationships and non-compete agreements is expected to be amortized as follows (in thousands): Referral Relationships Non-Compete Agreements Years Annual Amount Years Annual Amount 2017 1,682 2017 581 2018 1,636 2018 525 2019 1,547 2019 452 2020 1,547 2020 239 2021 1,547 2021 162 2022 1,498 2022 8 2023 1,391 2024 1,272 2025 1,166 2026 704 2027 544 2028 281 2029 44

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2016
Accrued Expenses [Abstract]
Summary of Accrued Expenses	Accrued expenses as of December 31, 2016 and 2015 consisted of the following (in thousands): December 31, 2016 December 31, 2015 Salaries and related costs $ 10,569 $ 9,414 Credit balances due to patients and payors 3,880 1,472 Group health insurance claims 2,499 2,276 Other 4,808 3,434 Total $ 21,756 $ 16,596

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Payable [Abstract]
Summary of Credit Agreement and Notes Payable	Notes payable as of December 31, 2016 and 2015 consisted of the following (dollars in thousands): December 31, 2016 December 31, 2015 Credit Agreement average effective interest rate of 2.5% inclusive of unused fee $ 46,000 $ 44,000 Various notes payable with $1,227 plus accrued interest due in the next year interest accrues in the range of 3.25% through 3.5% per annum 5,823 5,110 51,823 49,110 Less current portion (1,227 ) (775 ) Long term portion $ 50,596 $ 48,335
Summary of Aggregate Annual Payments of Principal Required to Revolving Credit Facility	Aggregate annual payments of principal required pursuant to the Credit Agreement and the above notes payable subsequent to December 31, 2016 are as follows (in thousands): During the twelve months ended December 31, 2017 $ 1,227 During the twelve months ended December 31, 2018 48,750 During the twelve months ended December 31, 2019 1,846 $ 51,823

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Taxes [Abstract]
Schedule of Components of Deferred Tax Assets Included in Consolidated Balance Sheets	Significant components of deferred tax assets included in the consolidated balance sheets at December 31, 2016 and 2015 were as follows (in thousands): December 31, 2016 December 31, 2015 (as restated) Deferred tax assets: Compensation $ 1,914 $ 1,830 Allowance for doubtful accounts 572 472 Lease obligations - closed clinics 57 50 Deferred tax assets $ 2,543 $ 2,352 Deferred tax liabilities: Depreciation and amortization $ (17,896 ) $ (16,142 ) Other (383 ) (1,718 ) Deferred tax liabilities (18,279 ) (17,860 ) Net deferred tax liability $ (15,736 ) $ (15,508 )
Schedule of Differences Between Federal Tax Rate and Company's Effective Tax Rate for Results of Continuing Operations	The differences between the federal tax rate and the Company’s effective tax rate for results of continuing operations for the years ended December 31, 2016, 2015 and 2014 were as follows (in thousands): December 31, 2016 December 31, 2015 December 31, 2014 (as restated) (as restated) U. S. tax at statutory rate $ 11,351 35.0 % $ 11,991 35.0 % $ 11,252 35.0 % State income taxes, net of federal benefit 945 2.9 % 1,337 3.9 % 1,474 4.6 % Excess equity compensation deduction (911 ) -2.8 % - 0.0 % - 0.0 % Non-deductible expenses 495 1.5 % 319 0.9 % 292 0.9 % $ 11,880 36.6 % $ 13,647 39.8 % $ 13,018 40.5 %
Schedule of Significant Components of Provision for Income Taxes for Continuing Operations	Significant components of the provision for income taxes for continuing operations for the years ended December 31, 2016, 2015 and 2014 were as follows (in thousands): December 31, 2016 December 31, 2015 December 31, 2014 (as restated) (as restated) Current: Federal $ 7,620 $ 6,502 $ 6,972 State 1,281 1,192 940 Total current 8,901 7,694 7,912 Deferred: Federal 2,548 5,302 4,224 State 431 651 882 Total deferred 2,979 5,953 5,106 Total income tax provision for continuing operations $ 11,880 $ 13,647 $ 13,018

Equity Based Plans (Tables)

Equity Based Plans (Tables)	12 Months Ended
	Dec. 31, 2016
Equity Based Plans [Abstract]
Summary of Cumulative Summary of Equity Plans	A cumulative summary of equity plans as of December 31, 2016 follows: Authorized Restricted Outstanding Stock Options Stock Options Shares Available Equity Plans Amended 1999 Plan 600,000 416,402 - 139,791 - 7,775 Amended 2003 Plan 2,100,000 763,357 - 778,300 - 558,343 2,700,000 1,179,759 - 918,091 - 566,118
Summary of Restricted Stock Granted and Cancelled	During 2016, 2015 and 2014, the Company granted the following shares of restricted stock to directors, officers and employees pursuant to its equity plans as follows: Year Granted Number of Shares Weighted Average Fair 2014 159,443 $ 33.29 2015 147,928 $ 41.66 2016 101,790 $ 51.59 During 2016, 2015 and 2014, the following shares were cancelled due to employee terminations prior to restrictions lapsing: Year Cancelled Number of Shares Weighted Average Fair 2014 8,120 $ 23.49 2015 - - 2016 4,965 $ 35.78

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies [Abstract]
Future Minimum Operating Lease Commitments	The future minimum operating lease commitments for each of the next five years and thereafter and in the aggregate as of December 31, 2016 are as follows (in thousands): December 31, 2016 2017 $ 30,376 2018 23,907 2019 17,041 2020 15,164 2021 6,850 Thereafter 3,095 Total $ 96,433

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Computations of Basic and Diluted Earnings Per Share	The computations of basic and diluted earnings per share for the years ended December 31, 2016, 2015 and 2014 are as follows (in thousands, except per share data): Year Ended Year Ended Year Ended December 31, 2016 December 31, 2015 December 31, 2014 (as restated) (as restated) Net income attributable to USPh shareholders $ 20,551 $ 20,615 $ 19,131 Basic and diluted net income per share attributable to USPH shareholders $ 1.64 $ 1.66 $ 1.57 Shares used in computation: Basic earnings per share - weighted-average shares 12,500 12,392 12,217 Effect of dilutive securities - stock options - - 4 Denominator for diluted earnings per share - adjusted weighted-average shares 12,500 12,392 12,221

Selected Quarterly Financial 37

Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2016
Selected Quarterly Financial Data (Unaudited) [Abstract]
Summary of Selected Quarterly Financial Data	Q1 2016 Q2 2016 Q3 2016 Q4 2016 Net patient revenues $ 85,049 $ 88,433 $ 86,411 $ 88,946 Net revenues $ 86,908 $ 90,430 $ 88,344 $ 90,864 Operating income $ 11,491 $ 15,033 $ 12,055 $ 10,954 Net income $ 5,953 $ 7,671 $ 6,134 $ 6,510 Net income attributable to USPH shareholders $ 4,488 $ 6,012 $ 4,804 $ 5,247 Basic and diluted earnings per share attributable to common shareholders: $ 0.36 $ 0.48 $ 0.38 $ 0.42 Shares used in computation - basic and diluted 12,448 12,511 12,520 12,519 Q1 2015 Q2 2015 Q3 2015 Q4 2015 Net patient revenues $ 75,807 $ 81,451 $ 82,154 $ 84,881 Net revenues $ 77,241 $ 83,288 $ 84,049 $ 86,724 Operating income $ 9,185 $ 13,549 $ 11,949 $ 12,611 Net income $ 5,293 $ 7,957 $ 6,974 $ 6,265 Net income attributable to USPH shareholders $ 4,014 $ 6,334 $ 5,506 $ 4,761 Basic and diluted earnings per share attributable to common shareholders: $ 0.33 $ 0.51 $ 0.44 $ 0.38 Shares used in computation - basic and diluted 12,313 12,409 12,421 12,421
Error Corrections and Prior Period Adjustments	Consolidated Balance Sheet as of September 30, 2016: As Reported September 30, 2016 Adjustments As Restated September 30, 2016 ASSETS Current assets: Cash and cash equivalents $ 15,024 $ - $ 15,024 Patient accounts receivable, less allowance for doubtful accounts of $1,770 38,522 - 38,522 Accounts receivable - other 2,272 - 2,272 Other current assets 10,800 816 11,616 Total current assets 66,618 816 67,434 Fixed assets: Furniture and equipment 46,996 - 46,996 Leasehold improvements 26,206 - 26,206 Fixed assets, gross 73,202 - 73,202 Less accumulated depreciation and amortization 55,760 - 55,760 Fixed assets, net 17,442 - 17,442 Goodwill 191,231 23,826 215,057 Other identifiable intangible assets, net 33,389 - 33,389 Other assets 1,221 - 1,221 Total assets $ 309,901 $ 24,642 $ 334,543 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable - trade $ 2,181 $ - $ 2,181 Accrued expenses 23,216 - 23,216 Current portion of notes payable 986 - 986 Total current liabilities 26,383 - 26,383 Notes payable 4,546 - 4,546 Revolving line of credit 36,000 - 36,000 Mandatorily redeemable non-controlling interests - 61,276 61,276 Deferred rent 1,313 - 1,313 Deferred taxes 13,727 5,009 18,736 Other long-term liabilities 860 54 914 Total liabilities 82,829 66,339 149,168 Commitments and contingencies Redeemable non-controlling interests 8,334 (8,334 ) - U.S. Physical Therapy, Inc. ("USPH") shareholders’ equity: Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding - - - Common stock, $.01 par value, 20,000,000 shares authorized, 14,734,963 shares issued 147 - 147 Additional paid-in capital 49,506 18,987 68,493 Retained earnings 160,746 (13,523 ) 147,223 Treasury stock at cost, 2,214,737 shares (31,628 ) - (31,628 ) Total USPH shareholders’ equity 178,771 5,464 184,235 Non-controlling interests 39,967 (38,827 ) 1,140 Total equity 218,738 (33,363 ) 185,375 Total liabilities and equity $ 309,901 $ 24,642 $ 334,543 Consolidated Balance Sheet as of June 30, 2016: As Reported June 30, 2016 Adjustments As Restated June 30, 2016 ASSETS Current assets: Cash and cash equivalents $ 20,453 $ - $ 20,453 Patient accounts receivable, less allowance for doubtful accounts of $1,672 39,356 - 39,356 Accounts receivable - other 2,335 - 2,335 Other current assets 8,220 574 8,794 Total current assets 70,364 574 70,938 Fixed assets: Furniture and equipment 46,747 - 46,747 Leasehold improvements 25,733 - 25,733 Fixed assets, gross 72,480 - 72,480 Less accumulated depreciation and amortization 55,642 - 55,642 Fixed assets, net 16,838 - 16,838 Goodwill 191,268 23,826 215,094 Other identifiable intangible assets, net 33,909 - 33,909 Other assets 1,219 - 1,219 Total assets $ 313,598 $ 24,400 $ 337,998 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable - trade $ 1,668 $ - $ 1,668 Accrued expenses 26,273 - 26,273 Current portion of notes payable 1,044 - 1,044 Total current liabilities 28,985 - 28,985 Notes payable 4,547 - 4,547 Revolving line of credit 42,500 - 42,500 Mandatorily redeemable non-controlling interests - 59,932 59,932 Deferred rent 1,285 - 1,285 Deferred taxes 12,361 5,792 18,153 Other long-term liabilities 869 54 923 Total liabilities 90,547 65,778 156,325 Commitments and contingencies Redeemable non-controlling interests 8,641 (8,641 ) - U.S. Physical Therapy, Inc. ("USPH") shareholders’ equity: Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding - - - Common stock, $.01 par value, 20,000,000 shares authorized, 14,734,963 shares issued 147 - 147 Additional paid-in capital 48,236 18,987 67,223 Retained earnings 157,161 (12,614 ) 144,547 Treasury stock at cost, 2,214,737 shares (31,628 ) - (31,628 ) Total USPH shareholders’ equity 173,916 6,373 180,289 Non-controlling interests 40,494 (39,110 ) 1,384 Total equity 214,410 (32,737 ) 181,673 Total liabilities and equity $ 313,598 $ 24,400 $ 337,998 Consolidated Balance Sheet as of March 31, 2016: As Reported March 31, 2016 Adjustments As Restated March 31, 2016 ASSETS Current assets: Cash and cash equivalents $ 19,206 $ - $ 19,206 Patient accounts receivable, less allowance for doubtful accounts of $1,568 38,217 - 38,217 Accounts receivable - other 2,345 - 2,345 Other current assets 8,298 483 8,781 Total current assets 68,066 483 68,549 Fixed assets: Furniture and equipment 45,654 - 45,654 Leasehold improvements 25,547 - 25,547 Fixed assets, gross 71,201 - 71,201 Less accumulated depreciation and amortization 54,512 - 54,512 Fixed assets, net 16,689 - 16,689 Goodwill 191,051 23,826 214,877 Other identifiable intangible assets, net 34,428 - 34,428 Other assets 1,200 - 1,200 Total assets $ 311,434 $ 24,309 $ 335,743 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable - trade $ 2,244 $ - $ 2,244 Accrued expenses 20,684 - 20,684 Current portion of notes payable 1,253 - 1,253 Total current liabilities 24,181 - 24,181 Notes payable 4,621 - 4,621 Revolving line of credit 52,500 - 52,500 Mandatorily redeemable non-controlling interests - 58,481 58,481 Deferred rent 1,391 - 1,391 Deferred taxes 10,789 6,573 17,362 Other long-term liabilities 914 54 968 Total liabilities 94,396 65,108 159,504 Commitments and contingencies Redeemable non-controlling interests 7,591 (7,591 ) - U.S. Physical Therapy, Inc. ("USPH") shareholders’ equity: Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding - - - Common stock, $.01 par value, 20,000,000 shares authorized, 14,717,463 shares issued 147 - 147 Additional paid-in capital 46,563 18,987 65,550 Retained earnings 152,219 (11,555 ) 140,664 Treasury stock at cost, 2,214,737 shares (31,628 ) - (31,628 ) Total USPH shareholders’ equity 167,301 7,432 174,733 Non-controlling interests 42,146 (40,640 ) 1,506 Total equity 209,447 (33,208 ) 176,239 Total liabilities and equity $ 311,434 $ 24,309 $ 335,743 Consolidated Balance Sheet as of September 30, 2015: As Reported September 30, 2015 Adjustments As Restated September 30, 2015 ASSETS Current assets: Cash and cash equivalents $ 20,558 $ - $ 20,558 Patient accounts receivable, less allowance for doubtful accounts of $1,556 35,106 - 35,106 Accounts receivable - other 1,939 - 1,939 Other current assets 6,058 - 6,058 Total current assets 63,661 - 63,661 Fixed assets: Furniture and equipment 44,157 - 44,157 Leasehold improvements 25,006 - 25,006 Fixed assets, gross 69,163 - 69,163 Less accumulated depreciation and amortization 52,501 - 52,501 Fixed assets, net 16,662 - 16,662 Goodwill 170,849 23,826 194,675 Other identifiable intangible assets, net 23,798 - 23,798 Other assets 1,175 - 1,175 Total assets $ 276,145 $ 23,826 $ 299,971 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable - trade $ 1,662 $ - $ 1,662 Accrued expenses 18,287 - 18,287 Current portion of notes payable 1,412 - 1,412 Total current liabilities 21,361 - 21,361 Notes payable 1,679 - 1,679 Revolving line of credit 46,000 - 46,000 Mandatorily redeemable non-controlling interests - 45,323 45,323 Deferred rent 1,192 - 1,192 Deferred taxes - 13,276 13,276 Other long-term liabilities 10,769 (7,995 ) 2,774 Total liabilities 81,001 50,604 131,605 Commitments and contingencies Redeemable non-controlling interests 9,024 (9,024 ) - U.S. Physical Therapy, Inc. ("USPH") shareholders’ equity: Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding - - - Common stock, $.01 par value, 20,000,000 shares authorized, 14,635,874 shares issued 146 - 146 Additional paid-in capital 45,536 17,382 62,918 Retained earnings 144,888 (9,485 ) 135,403 Treasury stock at cost, 2,214,737 shares (31,628 ) - (31,628 ) Total USPH shareholders’ equity 158,942 7,897 166,839 Non-controlling interests 27,178 (25,651 ) 1,527 Total equity 186,120 (17,754 ) 168,366 Total liabilities and equity $ 276,145 $ 23,826 $ 299,971 Consolidated Balance Sheet as of June 30, 2015: As Reported June 30, 2015 Adjustments As Restated June 30, 2015 ASSETS Current assets: Cash and cash equivalents $ 12,972 $ - $ 12,972 Patient accounts receivable, less allowance for doubtful accounts of $1,618 34,830 - 34,830 Accounts receivable - other 1,338 - 1,338 Other current assets 6,509 - 6,509 Total current assets 55,649 - 55,649 Fixed assets: Furniture and equipment 43,495 - 43,495 Leasehold improvements 24,107 - 24,107 Fixed assets, gross 67,602 - 67,602 Less accumulated depreciation and amortization 51,098 - 51,098 Fixed assets, net 16,504 - 16,504 Goodwill 170,914 23,826 194,740 Other identifiable intangible assets, net 24,167 - 24,167 Other assets 1,086 - 1,086 Total assets $ 268,320 $ 23,826 $ 292,146 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable - trade $ 1,451 $ - $ 1,451 Accrued expenses 19,446 - 19,446 Current portion of notes payable 800 - 800 Total current liabilities 21,697 - 21,697 Notes payable 1,059 - 1,059 Revolving line of credit 41,000 - 41,000 Mandatorily redeemable non-controlling interests - 49,166 49,166 Deferred rent 1,040 - 1,040 Deferred taxes - 12,027 12,027 Other long-term liabilities 10,925 (7,995 ) 2,930 Total liabilities 75,721 53,198 128,919 Commitments and contingencies Redeemable non-controlling interests 10,585 (10,585 ) - U.S. Physical Therapy, Inc. ("USPH") shareholders’ equity: Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding - - - Common stock, $.01 par value, 20,000,000 shares authorized, 14,635,674 shares issued 146 - 146 Additional paid-in capital 45,829 15,222 61,051 Retained earnings 140,933 (9,173 ) 131,760 Treasury stock at cost, 2,214,737 shares (31,628 ) - (31,628 ) Total USPH shareholders’ equity 155,280 6,049 161,329 Non-controlling interests 26,734 (24,836 ) 1,898 Total equity 182,014 (18,787 ) 163,227 Total liabilities and equity $ 268,320 $ 23,826 $ 292,146 Consolidated Balance Sheet as of March 31, 2015: As Reported March 31, 2015 Adjustments As Restated March 31, 2015 ASSETS Current assets: Cash and cash equivalents $ 14,557 $ - $ 14,557 Patient accounts receivable, less allowance for doubtful accounts of $1,633 34,673 - 34,673 Accounts receivable - other 1,378 - 1,378 Other current assets 5,291 - 5,291 Total current assets 55,899 - 55,899 Fixed assets: Furniture and equipment 42,542 - 42,542 Leasehold improvements 23,565 - 23,565 Fixed assets, gross 66,107 - 66,107 Less accumulated depreciation and amortization 50,212 - 50,212 Fixed assets, net 15,895 - 15,895 Goodwill 159,176 23,826 183,002 Other identifiable intangible assets, net 24,537 - 24,537 Other assets 1,916 - 1,916 Total assets $ 257,423 $ 23,826 $ 281,249 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable - trade $ 2,292 $ - $ 2,292 Accrued expenses 18,178 - 18,178 Current portion of notes payable 932 - 932 Total current liabilities 21,402 - 21,402 Notes payable 483 - 483 Revolving line of credit 41,500 - 41,500 Mandatorily redeemable non-controlling interests - 45,578 45,578 Deferred rent 984 - 984 Deferred taxes - 12,009 12,009 Other long-term liabilities 9,480 (7,995 ) 1,485 Total liabilities 73,849 49,592 123,441 Commitments and contingencies Redeemable non-controlling interests 7,373 (7,373 ) - U.S. Physical Therapy, Inc. ("USPH") shareholders’ equity: Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding - - - Common stock, $.01 par value, 20,000,000 shares authorized, 14,613,374 shares issued 145 - 145 Additional paid-in capital 45,080 15,222 60,302 Retained earnings 136,491 (9,203 ) 127,288 Treasury stock at cost, 2,214,737 shares (31,628 ) - (31,628 ) Total USPH shareholders’ equity 150,088 6,019 156,107 Non-controlling interests 26,113 (24,412 ) 1,701 Total equity 176,201 (18,393 ) 157,808 Total liabilities and equity $ 257,423 $ 23,826 $ 281,249 Consolidated Statement of Net Income as of September 30, 2016: For the Three Months Ended For the Nine Months Ended As Reported September 30, 2016 Adjustments As Restated September 30, 2016 As Reported September 30, 2016 Adjustments As Restated September 30, 2016 Net patient revenues $ 86,411 $ - $ 86,411 $ 259,893 $ - $ 259,893 Other revenues 1,933 - 1,933 5,789 - 5,789 Net revenues 88,344 - 88,344 265,682 - 265,682 Clinic operating costs: Salaries and related costs 49,868 - 49,868 146,509 - 146,509 Rent, clinic supplies, contract labor and other 17,885 - 17,885 52,938 - 52,938 Provision for doubtful accounts 917 - 917 2,962 - 2,962 Closure costs 9 - 9 54 - 54 Total clinic operating costs 68,679 - 68,679 202,463 - 202,463 Gross margin 19,665 - 19,665 63,219 - 63,219 Corporate office costs 7,610 - 7,610 24,640 - 24,640 Operating income 12,055 - 12,055 38,579 - 38,579 Interest and other income, net 21 - 21 62 - 62 Interest expense Mandatorily redeemable non-controlling interests - change in redemption value - (1,934 ) (1,934 ) - (6,056 ) (6,056 ) Mandatorily redeemable non-controlling interests - earnings allocable - (929 ) (929 ) - (3,146 ) (3,146 ) Debt and other (326 ) - (326 ) (954 ) - (954 ) Total interest expense (326 ) (2,863 ) (3,189 ) (954 ) (9,202 ) (10,156 ) Income before taxes 11,750 (2,863 ) 8,887 37,687 (9,202 ) 28,485 Provision for income taxes 3,778 (1,025 ) 2,753 11,975 (3,248 ) 8,727 Net income 7,972 (1,838 ) 6,134 25,712 (5,954 ) 19,758 Less: net income attributable to non-controlling interests (2,259 ) 929 (1,330 ) (7,600 ) 3,146 (4,454 ) Net income attributable to USPH shareholders $ 5,713 $ (909 ) $ 4,804 $ 18,112 $ (2,808 ) $ 15,304 Basic and diluted earnings per share attributable to USPH shareholders $ 0.46 $ (0.08 ) $ 0.38 $ 1.45 $ (0.23 ) $ 1.22 Shares used in computation - basic 12,520 12,520 12,494 12,494 Shares used in computation - diluted 12,520 12,520 12,494 12,494 Dividends declared per common share $ 0.17 $ 0.17 $ 0.51 $ 0.51 Consolidated Statement of Net Income as of June 30, 2016: For the Three Months Ended For the Six Months Ended As Reported June 30, 2016 Adjustments As Restated June 30, 2016 As Reported June 30, 2016 Adjustments As Restated June 30, 2016 Net patient revenues $ 88,433 $ - $ 88,433 $ 173,482 $ - $ 173,482 Other revenues 1,997 - 1,997 3,856 - 3,856 Net revenues 90,430 - 90,430 177,338 - 177,338 Clinic operating costs: Salaries and related costs 48,837 - 48,837 96,641 - 96,641 Rent, clinic supplies, contract labor and other 17,546 - 17,546 35,053 - 35,053 Provision for doubtful accounts 956 - 956 2,045 - 2,045 Closure costs 32 - 32 45 - 45 Total clinic operating costs 67,371 - 67,371 133,784 - 133,784 Gross margin 23,059 - 23,059 43,554 - 43,554 Corporate office costs 8,026 - 8,026 17,030 - 17,030 Operating income 15,033 - 15,033 26,524 - 26,524 Interest and other income, net 21 - 21 41 - 41 Interest expense Mandatorily redeemable non-controlling interests - change in redemption value - (1,931 ) (1,931 ) - (4,122 ) (4,122 ) Mandatorily redeemable non-controlling interests - earnings allocable - (1,330 ) (1,330 ) - (2,217 ) (2,217 ) Debt and other (320 ) - (320 ) (628 ) - (628 ) Total interest expense (320 ) (3,261 ) (3,581 ) (628 ) (6,339 ) (6,967 ) Income before taxes 14,734 (3,261 ) 11,473 25,937 (6,339 ) 19,598 Provision for income taxes 4,674 (872 ) 3,802 8,197 (2,223 ) 5,974 Net income 10,060 (2,389 ) 7,671 17,740 (4,116 ) 13,624 Less: net income attributable to non-controlling interests (2,989 ) 1,330 (1,659 ) (5,341 ) 2,217 (3,124 ) Net income attributable to USPH shareholders $ 7,071 $ (1,059 ) $ 6,012 $ 12,399 $ (1,899 ) $ 10,500 Basic and diluted earnings per share attributable to USPH shareholders $ 0.57 $ (0.09 ) $ 0.48 $ 0.99 $ (0.15 ) $ 0.84 Shares used in computation - basic 12,511 12,511 12,480 12,480 Shares used in computation - diluted 12,511 12,511 12,480 12,480 Dividends declared per common share $ 0.17 $ 0.17 $ 0.34 $ 0.34 Consolidated Statement of Net Income as of March 31, 2016: For the Three Months Ended As Reported March 31, 2016 Adjustments As Restated March 31, 2016 Net patient revenues $ 85,049 $ - $ 85,049 Other revenues 1,859 - 1,859 Net revenues 86,908 - 86,908 Clinic operating costs: Salaries and related costs 47,804 - 47,804 Rent, clinic supplies, contract labor and other 17,507 - 17,507 Provision for doubtful accounts 1,089 - 1,089 Closure costs 13 - 13 Total clinic operating costs 66,413 - 66,413 Gross margin 20,495 - 20,495 Corporate office costs 9,004 - 9,004 Operating income 11,491 - 11,491 Interest and other income, net 20 - 20 Interest expense Mandatorily redeemable non-controlling interests - change in redemption value - (2,191 ) (2,191 ) Mandatorily redeemable non-controlling interests - earnings allocable - (887 ) (887 ) Debt and other (308 ) - (308 ) Total interest expense (308 ) (3,078 ) (3,386 ) Income before taxes 11,203 (3,078 ) 8,125 Provision for income taxes 3,523 (1,351 ) 2,172 Net income 7,680 (1,727 ) 5,953 Less: net income attributable to non-controlling interests (2,352 ) 887 (1,465 ) Net income attributable to USPH shareholders $ 5,328 $ (840 ) $ 4,488 Basic and diluted earnings per share attributable to USPH shareholders $ 0.43 $ (0.07 ) $ 0.36 Shares used in computation - basic 12,448 12,448 Shares used in computation - diluted 12,448 12,448 Dividends declared per common share $ 0.17 $ 0.17 Consolidated Statement of Net Income as of September 30, 2015: For the Three Months Ended For the Nine Months Ended As Reported September 30, 2015 Adjustments As Restated September 30, 2015 As Reported September 30, 2015 Adjustments As Restated September 30, 2015 Net patient revenues $ 82,154 $ - $ 82,154 $ 239,412 $ - $ 239,412 Other revenues 1,895 - 1,895 5,166 - 5,166 Net revenues 84,049 - 84,049 244,578 - 244,578 Clinic operating costs: Salaries and related costs 46,594 - 46,594 134,044 - 134,044 Rent, clinic supplies, contract labor and other 17,428 - 17,428 50,434 - 50,434 Provision for doubtful accounts 1,067 - 1,067 3,119 - 3,119 Closure costs 88 - 88 125 - 125 Total clinic operating costs 65,177 - 65,177 187,722 - 187,722 Gross margin 18,872 - 18,872 56,856 - 56,856 Corporate office costs 6,923 - 6,923 22,173 - 22,173 Operating income 11,949 - 11,949 34,683 - 34,683 Interest and other income, net 24 - 24 48 - 48 Interest expense Mandatorily redeemable non-controlling interests - change in redemption value - (501 ) (501 ) - (697 ) (697 ) Mandatorily redeemable non-controlling interests - earnings allocable - (778 ) (778 ) - (2,674 ) (2,674 ) Debt and other (255 ) - (255 ) (765 ) - (765 ) Total interest expense (255 ) (1,279 ) (1,534 ) (765 ) (3,371 ) (4,136 ) Income before taxes 11,718 (1,279 ) 10,439 33,966 (3,371 ) 30,595 Provision for income taxes 3,654 (189 ) 3,465 10,634 (263 ) 10,371 Net income 8,064 (1,090 ) 6,974 23,332 (3,108 ) 20,224 Less: net income attributable to non-controlling interests (2,246 ) 778 (1,468 ) (7,044 ) 2,674 (4,370 ) Net income attributable to USPH shareholders $ 5,818 $ (312 ) $ 5,506 $ 16,288 $ (434 ) $ 15,854 Basic and diluted earnings per share attributable to USPH shareholders $ 0.47 $ (0.03 ) $ 0.44 $ 1.29 $ (0.01 ) $ 1.28 Shares used in computation - basic 12,421 12,421 12,382 12,382 Shares used in computation - diluted 12,421 12,421 12,382 12,382 Dividends declared per common share $ 0.15 $ 0.15 $ 0.45 $ 0.45 Consolidated Statement of Net Income as of June 30, 2015: For the Three Months Ended For the Six Months Ended As Reported June 30, 2015 Adjustments As Restated June 30, 2015 As Reported June 30, 2015 Adjustments As Restated June 30, 2015 Net patient revenues $ 81,451 $ - $ 81,451 $ 157,258 $ - $ 157,258 Other revenues 1,837 - 1,837 3,271 - 3,271 Net revenues 83,288 - 83,288 160,529 - 160,529 Clinic operating costs: Salaries and related costs 44,398 - 44,398 87,450 - 87,450 Rent, clinic supplies, contract labor and other 16,681 - 16,681 33,006 - 33,006 Provision for doubtful accounts 1,062 - 1,062 2,052 - 2,052 Closure costs 5 - 5 37 - 37 Total clinic operating costs 62,146 - 62,146 122,545 - 122,545 Gross margin 21,142 - 21,142 37,984 - 37,984 Corporate office costs 7,593 - 7,593 15,250 - 15,250 Operating income 13,549 - 13,549 22,734 - 22,734 Interest and other income, net 16 - 16 24 - 24 Interest expense Mandatorily redeemable non-controlling interests - change in redemption value - 48 48 - (196 ) (196 ) Mandatorily redeemable non-controlling interests - earnings allocable - (1,190 ) (1,190 ) - (1,896 ) (1,896 ) Debt and other (245 ) - (245 ) (510 ) - (510 ) Total interest expense (245 ) (1,142 ) (1,387 ) (510 ) (2,092 ) (2,602 ) Income before taxes 13,320 (1,142 ) 12,178 22,248 (2,092 ) 20,156 Provision for income taxes 4,203 18 4,221 6,980 (74 ) 6,906 Net income 9,117 (1,160 ) 7,957 15,268 (2,018 ) 13,250 Less: net income attributable to non-controlling interests (2,813 ) 1,190 (1,623 ) (4,798 ) 1,896 (2,902 ) Net income attributable to USPH shareholders $ 6,304 $ 30 $ 6,334 $ 10,470 $ (122 ) $ 10,348 Basic and diluted earnings per share attributable to USPH shareholders $ 0.48 $ 0.03 $ 0.51 $ 0.82 $ 0.02 $ 0.84 Shares used in computation - basic 12,409 12,409 12,362 12,362 Shares used in computation - diluted 12,409 12,409 12,362 12,362 Dividends declared per common share $ 0.15 $ 0.15 $ 0.30 $ 0.30 Consolidated Statement of Net Income as of March 31, 2015: For the Three Months Ended As Reported March 31, 2015 Adjustments As Restated March 31, 2015 Net patient revenues $ 75,807 $ - $ 75,807 Other revenues 1,434 - 1,434 Net revenues 77,241 - 77,241 Clinic operating costs: Salaries and related costs 43,052 - 43,052 Rent, clinic supplies, contract labor and other 16,325 - 16,325 Provision for doubtful accounts 990 - 990 Closure costs 32 - 32 Total clinic operating costs 60,399 - 60,399 Gross margin 16,842 - 16,842 Corporate office costs 7,657 - 7,657 Operating income 9,185 - 9,185 Interest and other income, net 8 - 8 Interest expense Mandatorily redeemable non-controlling interests - change in redemption value - (244 ) (244 ) Mandatorily redeemable non-controlling interests - earnings allocable - (706 ) (706 ) Debt and other (265 ) - (265 ) Total interest expense (265 ) (950 ) (1,215 ) Income before taxes 8,928 (950 ) 7,978 Provision for income taxes 2,777 (92 ) 2,685 Net income 6,151 (858 ) 5,293 Less: net income attributable to non-controlling interests (1,985 ) 706 (1,279 ) Net income attributable to USPH shareholders $ 4,166 $ (152 ) $ 4,014 Basic and diluted earnings per share attributable to USPH shareholders $ 0.34 $ (0.01 ) $ 0.33 Shares used in computation - basic 12,313 12,313 Shares used in computation - diluted 12,313 12,313 Dividends declared per common share $ 0.15 $ 0.15 Consolidated Statement of Cash Flows as of September 30, 2016: For the Nine Months Ended As Reported As Restated September 30, 2016 Adjustments September 30, 2016 OPERATING ACTIVITIES Net income including non-controlling interests $ 25,712 $ (5,954 ) $ 19,758 Adjustments to reconcile net income including non-controlling interests to net cash provided by operating activities: Depreciation and amortization 6,210 - 6,210 Provision for doubtful accounts 2,962 - 2,962 Equity-based awards compensation expense 3,748 - 3,748 Loss (gain) on sale of fixed assets 31 - 31 Excess tax benefit from equity-based awards (798 ) 798 - Deferred income tax 5,688 (2,450 ) 3,238 Other - - - Changes in operating assets and liabilities: - Increase in patient accounts receivable (2,548 ) - (2,548 ) (Increase) decrease in accounts receivable - other 116 - 116 Decrease (increase) in other assets (4,979 ) - (4,979 ) Increase (decrease) in accounts payable and accrued expenses 5,178 (1,596 ) 3,582 Increase (decrease) in mandatorily redeemable non-controlling interests - 5,372 5,372 (Decrease) increase in other liabilities 708 - 708 Net cash provided by operating activities 42,028 (3,830 ) 38,198 INVESTING ACTIVITIES Purchase of fixed assets (5,620 ) - (5,620 ) Purchase of businesses, net of cash acquired (12,958 ) - (12,958 ) Acquisitions of non-controlling interests (1,800 ) 1,136 (664 ) Proceeds on sale of fixed assets, net 42 - 42 Net cash used in investing activities (20,336 ) 1,136 (19,200 ) FINANCING ACTIVITIES Distributions to non-controlling interests (8,271 ) 3,830 (4,441 ) Cash dividends to shareholders - funded (6,382 ) - (6,382 ) Proceeds from revolving line of credit 128,000 - 128,000 Payments on revolving line of credit (136,000 ) - (136,000 ) Payments to settle mandatorily redeemable non-controlling interests - (1,136 ) (1,136 ) Principal payments on notes payable (592 ) - (592 ) Tax benefit from equity-based awards 798 - 798 Other 1 - 1 Net cash used in financing activities (22,446 ) 2,694 (19,752 ) Net increase in cash and cash equivalents (754 ) - (754 ) Cash and cash equivalents - beginning of period 15,778 - 15,778 Cash and cash equivalents - end of period $ 15,024 $ - $ 15,024 SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Cash paid during the period for: Income taxes $ 10,051 $ 10,051 Interest $ 770 $ 770 Non-cash investing and financing transactions during the period: Purchase of business - seller financing portion $ 500 $ 500 Acquisition of non-controlling interest - seller financing portion $ 514 $ 388 Payment to settle redeemable non-controlling interest - financing portion $ - $ 126 Sale of non-controlling interests $ (148 ) $ (148 ) Consolidated Statement of Cash Flows as of June 30, 2016: For the Six Months Ended As Reported As Restated June 30, 2016 Adjustments June 30, 2016 OPERATING ACTIVITIES Net income including non-controlling interests $ 17,740 $ (4,116 ) $ 13,624 Adjustments to reconcile net income including non-controlling interests to net cash provided by operating activities: Depreciation and amortization 4,158 - 4,158 Provision for doubtful accounts 2,045 - 2,045 Equity-based awards compensation expense 2,484 - 2,484 Loss (gain) on sale of fixed assets - - - Excess tax benefit from equity-based awards (556 ) 556 - Deferred income tax 4,170 (1,667 ) 2,503 Other - - - Changes in operating assets and liabilities: - Increase in patient accounts receivable (2,449 ) - (2,449 ) (Increase) decrease in accounts receivable - other 53 - 53 Decrease (increase) in other assets (2,443 ) - (2,443 ) Increase (decrease) in accounts payable and accrued expenses 7,715 (1,112 ) 6,603 Increase (decrease) in mandatorily redeemable non-controlling interests - 4,028 4,028 (Decrease) increase in other liabilities 447 - 447 Net cash provided by operating activities 33,364 (2,311 ) 31,053 INVESTING ACTIVITIES Purchase of fixed assets (3,453 ) - (3,453 ) Purchase of businesses, net of cash acquired (12,958 ) - (12,958 ) Acquisitions of non-controlling interests, net of sales (1,386 ) 1,136 (250 ) Proceeds on sale of fixed assets, net 42 - 42 Net cash used in investing activities (17,755 ) 1,136 (16,619 ) FINANCING ACTIVITIES Distributions to non-controlling interests (5,204 ) 2,311 (2,893 ) Cash dividends to shareholders - funded (4,254 ) - (4,254 ) Proceeds from revolving line of credit 93,000 - 93,000 Payments on revolving line of credit (94,500 ) - (94,500 ) Payments to settle mandatorily redeemable non-controlling interests - (1,136 ) (1,136 ) Principal payments on notes payable (533 ) - (533 ) Tax benefit from equity-based awards 556 - 556 Other 1 - 1 Net cash used in financing activities (10,934 ) 1,175 (9,759 ) Net increase in cash and cash equivalents 4,675 - 4,675 Cash and cash equivalents - beginning of period 15,778 - 15,778 Cash and cash equivalents - end of period $ 20,453 $ - $ 20,453 SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Cash paid during the period for: Income taxes $ 5,513 $ 5,513 Interest $ 512 $ 512 Non-cash investing and financing transactions during the period: Purchase of business - seller financing portion $ 500 $ 500 Acquisition of non-controlling interest - seller financing portion $ 514 $ 388 Payment to settle redeemable non-controlling interest - financing portion $ - $ 126 Sale of non-controlling interests $ (148 ) $ (148 ) Consolidated Statement of Cash Flows as of March 31, 2016: For the Three Months Ended As Reported As Restated March 31, 2016 Adjustments March 31, 2016 OPERATING ACTIVITIES Net income including non-controlling interests $ 7,680 $ (1,727 ) $ 5,953 Adjustments to reconcile net income including non-controlling interests to net cash provided by operating activities: Depreciation and amortization 2,091 - 2,091 Provision for doubtful accounts 1,089 - 1,089 Equity-based awards compensation expense 1,221 - 1,221 Loss (gain) on sale of fixed assets (19 ) - (19 ) Excess tax benefit from equity-based awards (323 ) 465 142 Deferred income tax 2,709 (886 ) 1,823 Other - - - Changes in operating assets and liabilities: - Increase in patient accounts receivable (2,185 ) - (2,185 ) (Increase) decrease in accounts receivable - other 43 - 43 Decrease (increase) in other assets (2,282 ) - (2,282 ) Increase (decrease) in accounts payable and accrued expenses 4,322 (930 ) 3,392 Increase (decrease) in mandatorily redeemable non-controlling interests - 2,578 2,578 (Decrease) increase in other liabilities 365 - 365 Net cash provided by operating activities 14,711 (500 ) 14,211 INVESTING ACTIVITIES Purchase of fixed assets (1,738 ) - (1,738 ) Purchase of businesses, net of cash acquired (12,899 ) - (12,899 ) Acquisitions of non-controlling interests (1,524 ) 1,136 (388 ) Proceeds on sale of fixed assets, net 42 - 42 Net cash used in investing activities (16,119 ) 1,136 (14,983 ) FINANCING ACTIVITIES Distributions to non-controlling interests (1,613 ) 500 (1,113 ) Cash dividends to shareholders - funded (2,125 ) - (2,125 ) Proceeds from revolving line of credit 49,000 - 49,000 Payments on revolving line of credit (40,500 ) - (40,500 ) Payments to settle mandatorily redeemable non-controlling interests - (1,136 ) (1,136 ) Principal payments on notes payable (250 ) - (250 ) Tax benefit from equity-based awards 323 - 323 Other 1 - 1 Net cash used in financing activities 4,836 (636 ) 4,200 Net increase in cash and cash equivalents 3,428 - 3,428 Cash and cash equivalents - beginning of period 15,778 - 15,778 Cash and cash equivalents - end of period $ 19,206 $ - $ 19,206 SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Cash paid during the period for: Income taxes $ 2,265 $ 2,265 Interest $ 248 $ 248 Non-cash investing and financing transactions during the period: Purchase of business - seller financing portion $ 500 $ 500 Acquisition of non-controlling interest - seller financing portion $ 514 $ 388 Payment to settle redeemable non-controlling interest - financing portion $ - $ 126 Consolidated Statement of Cash Flows as of September 30, 2015: For the Nine Months Ended As Reported September 30, 2015 Adjustments As Restated September 30, 2015 OPERATING ACTIVITIES Net income including non-controlling interests $ 23,332 $ (3,108 ) $ 20,224 Adjustments to reconcile net income including non-controlling interests to net cash provided by operating activities: Depreciation and amortization 5,656 - 5,656 Provision for doubtful accounts 3,119 - 3,119 Equity-based awards compensation expense 3,368 - 3,368 Loss (gain) on sale of fixed assets 3 - 3 Excess tax benefit from equity-based awards (816 ) - (816 ) Deferred income tax 3,181 (263 ) 2,918 Other 180 - 180 Changes in operating assets and liabilities: - Increase in patient accounts receivable (4,148 ) - (4,148 ) (Increase) decrease in accounts receivable - other (145 ) - (145 ) Decrease (increase) in other assets (1,485 ) - (1,485 ) Increase (decrease) in accounts payable and accrued expenses (3,766 ) - (3,766 ) Increase (decrease) in mandatorily redeemable non-controlling interests - 683 683 (Decrease) increase in other liabilities 380 - 380 Net cash provided by operating activities 28,859 (2,688 ) 26,171 INVESTING ACTIVITIES Purchase of fixed assets (4,690 ) - (4,690 ) Purchase of businesses, net of cash acquired (14,434 ) - (14,434 ) Acquisitions of non-controlling interests (2,802 ) 1,860 (942 ) Proceeds on sale of fixed assets, net 71 - 71 Net cash used in investing activities (21,855 ) 1,860 (19,995 ) FINANCING ACTIVITIES Distributions to non-controlling interests (6,836 ) 2,688 (4,148 ) Cash dividends to shareholders - funded (5,586 ) - (5,586 ) Proceeds from revolving line of credit 75,000 - 75,000 Payments on revolving line of credit (63,500 ) - (63,500 ) Payments to settle mandatorily redeemable non-controlling interests - (1,860 ) (1,860 ) Principal payments on notes payable (616 ) - (616 ) Tax benefit from equity-based awards 816 - 816 Other 5 - 5 Net cash (used) in provided by financing activities (717 ) 828 111 Net increase in cash and cash equivalents 6,287 - 6,287 Cash and cash equivalents - beginning of period 14,271 - 14,271 Cash and cash equivalents - end of period $ 20,558 $ - $ 20,558 SUPPLEMENTAL DISCLOS

Organization, Nature of Opera38

Organization, Nature of Operations and Basis of Presentation (Details)	12 Months Ended
	Dec. 31, 2016ClinicStateFacility	Dec. 31, 2015Clinic	Dec. 31, 2014Clinic
Organization, Nature of Operations and Basis of Presentation [Abstract]
Number of clinics operated	540
Number of states where clinics are operated | State	42
Number of third party facilities | Facility	20
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Percentage of general partnership interest owned	1.00%
Percentage of interest acquired in a single clinic	60.00%
Number of clinic practices acquired	2	1	4
Minimum [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Percentage of limited partnership interest owned	49.00%
Maximum [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Percentage of limited partnership interest owned	99.00%

Organization, Nature of Opera39

Organization, Nature of Operations and Basis of Presentation - Schedule of Multi Clinic Acquisition (Details) - Clinic	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
February 2016 Acquisition [Member]
Business Acquisition [Line Items]
Acquisition date	Feb. 29, 2016
Percentage of interest acquired	55.00%
Number of clinics	8
November 2016 Acquisition [Member]
Business Acquisition [Line Items]
Acquisition date	Nov. 30, 2016
Percentage of interest acquired	60.00%
Number of clinics	12
January 2015 Acquisition [Member]
Business Acquisition [Line Items]
Acquisition date		Jan. 31, 2015
Percentage of interest acquired		60.00%
Number of clinics		9
April 2015 Acquisition [Member]
Business Acquisition [Line Items]
Acquisition date		Apr. 30, 2015
Percentage of interest acquired		70.00%
Number of clinics		3
June 2015 Acquisition [Member]
Business Acquisition [Line Items]
Acquisition date		Jun. 30, 2015
Percentage of interest acquired		70.00%
Number of clinics		4
December 2015 Acquisition [Member]
Business Acquisition [Line Items]
Acquisition date		Dec. 31, 2015
Percentage of interest acquired		59.00%
Number of clinics		4
April 2014 Acquisition [Member]
Business Acquisition [Line Items]
Acquisition date			Apr. 30, 2014
Percentage of interest acquired			70.00%
Number of clinics			13
August 2014 Acquisition [Member]
Business Acquisition [Line Items]
Acquisition date			Aug. 1, 2014
Percentage of interest acquired			100.00%
Number of clinics			3

Organization, Nature of Opera40

Organization, Nature of Operations and Basis of Presentation, Restatement of Prior Year Financial Statements (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended															6 Months Ended				9 Months Ended				12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016		Jun. 30, 2016		Mar. 31, 2016		Dec. 31, 2015		Sep. 30, 2015		Jun. 30, 2015		Mar. 31, 2015		Jun. 30, 2016		Jun. 30, 2015		Sep. 30, 2016		Sep. 30, 2015		Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Consolidated Balance Sheet [Abstract]
Goodwill	$ 226,806	$ 215,057	[1]	$ 215,094	[1]	$ 214,877	[1]	$ 195,373	[1]	$ 194,675	[1]	$ 194,740	[1]	$ 183,002	[1]	$ 215,094	[1]	$ 194,740	[1]	$ 215,057	[1]	$ 194,675	[1]	$ 226,806	$ 195,373	[1]	$ 171,740	[1]
Total assets	351,231	334,543	[1]	337,998	[1]	335,743	[1]	303,757	[1]	299,971	[1]	292,146	[1]	281,249	[1]	337,998	[1]	292,146	[1]	334,543	[1]	299,971	[1]	351,231	303,757	[1]
MRNCI	69,190	61,276	[1]	59,932	[1]	58,481	[1]	45,974	[1],[2]	45,323	[1]	49,166	[1]	45,578	[1]	59,932	[1]	49,166	[1]	61,276	[1]	45,323	[1]	69,190	45,974	[1],[2]	40,365	[1]
Deferred taxes (liability)	15,736	18,736	[1]	18,153	[1]	17,362	[1]	15,508	[1]	13,276	[1]	12,027	[1]	12,009	[1]	18,153	[1]	12,027	[1]	18,736	[1]	13,276	[1]	15,736	15,508	[1]
Total liabilities	162,543	149,168	[1]	156,325	[1]	159,504	[1]	131,447	[1]	131,605	[1]	128,919	[1]	123,441	[1]	156,325	[1]	128,919	[1]	149,168	[1]	131,605	[1]	162,543	131,447	[1]
RNCI		0	[1]	0	[1]	0	[1]	0	[3]	0	[1]	0	[1]	0	[1]	0	[1]	0	[1]	0	[1]	0	[1]		0	[3]
Additional paid-in capital	68,687	68,493	[1]	67,223	[1]	65,550	[1]	64,238	[1]	62,918	[1]	61,051	[1]	60,302	[1]	67,223	[1]	61,051	[1]	68,493	[1]	62,918	[1]	68,687	64,238	[1]
Retained earnings	150,342	147,223	[1]	144,547	[1]	140,664	[1]	138,301	[1]	135,403	[1]	131,760	[1]	127,288	[1]	144,547	[1]	131,760	[1]	147,223	[1]	135,403	[1]	150,342	138,301	[1]
Total liabilities and equity	$ 351,231	334,543	[1]	337,998	[1]	335,743	[1]	$ 303,757	[1]	299,971	[1]	292,146	[1]	281,249	[1]	337,998	[1]	292,146	[1]	334,543	[1]	299,971	[1]	351,231	303,757	[1]
Interest expense [Abstract]
MRNCI (1) - change in redemption value		1,934	[1]	1,931	[1]	2,191	[1]			501	[1]	(48)	[1]	244	[1]	4,122	[1]	196	[1]	6,056	[1]	697	[1]	6,169	2,670	[1],[2]	2,978	[1],[2]
MRNCI (1) - earnings allocable		929	[1]	1,330	[1]	887	[1]			778	[1]	1,190	[1]	706	[1]	2,217	[1]	1,896	[1]	3,146	[1]	2,674	[1]	4,057	3,538	[1],[2]	3,388	[1],[2]
Total interest expense		3,189	[1]	3,581	[1]	3,386	[1]			1,534	[1]	1,387	[1]	1,215	[1]	6,967	[1]	2,602	[1]	10,156	[1]	4,136	[1]	11,478	7,239	[1]	7,454	[1]
Net income before taxes		8,887	[1]	11,473	[1]	8,125	[1]			10,439	[1]	12,178	[1]	7,978	[1]	19,598	[1]	20,156	[1]	28,485	[1]	30,595	[1]	38,148	40,136	[1]	38,332	[1]
Provision for income taxes		2,753	[1]	3,802	[1]	2,172	[1]			3,465	[1]	4,221	[1]	2,685	[1]	5,974	[1]	6,906	[1]	8,727	[1]	10,371	[1]	11,880	13,647	[1]	13,018	[1]
Net income		6,134	[1]	7,671	[1]	5,953	[1]			6,974	[1]	7,957	[1]	5,293	[1]	13,624	[1]	13,250	[1]	19,758	[1]	20,224	[1]	26,268	26,489	[1]	25,314	[1]
Less: net income attributable to non-controlling interests		1,330	[1]	1,659	[1]	1,465	[1]			1,468	[1]	1,623	[1]	1,279	[1]	3,124	[1]	2,902	[1]	4,454	[1]	4,370	[1]	5,717	5,874	[1]	6,183	[1]
Net income attributable to USPH shareholders		$ 4,804	[1]	$ 6,012	[1]	$ 4,488	[1]			$ 5,506	[1]	$ 6,334	[1]	$ 4,014	[1]	$ 10,500	[1]	$ 10,348	[1]	$ 15,304	[1]	$ 15,854	[1]	$ 20,551	$ 20,615	[1]	$ 19,131	[1]
Earnings per share (in dollars per share)	$ 0.42	$ 0.38	[1]	$ 0.48	[1]	$ 0.36	[1]	$ 0.38	[1]	$ 0.44	[1]	$ 0.51	[1]	$ 0.33	[1]	$ 0.84	[1]	$ 0.84	[1]	$ 1.22	[1]	$ 1.28	[1]	$ 1.64	$ 1.66	[1]	$ 1.57	[1]
Consolidated Statement of Cash Flows [Abstract]
Net income		$ 6,134	[1]	$ 7,671	[1]	$ 5,953	[1]			$ 6,974	[1]	$ 7,957	[1]	$ 5,293	[1]	$ 13,624	[1]	$ 13,250	[1]	$ 19,758	[1]	$ 20,224	[1]	$ 26,268	$ 26,489	[1]	$ 25,314	[1]
Deferred taxes						1,823	[1]							473	[1]	2,503	[1]	2,056	[1]	3,238	[1]	2,918	[1]	2,979	5,953	[1]	5,106	[1]
(Increase) decrease in other assets						(2,282)	[1]							106	[1]	(2,443)	[1]	(13)	[1]	(4,979)	[1]	(1,485)	[1]	(1,399)	(1,375)	[1]	1,155	[1]
(Decrease) increase in accounts payable and accrued expenses						3,392	[1]							(5,976)	[1]	6,603	[1]	(3,958)	[1]	3,582	[1]	(3,766)	[1]	2,994	(7,011)	[1]	1,868	[1]
Increase in mandatorily redeemable non-controlling interests						2,578	[1]							406	[1]	4,028	[1]	90	[1]	5,372	[1]	683	[1]	5,598	2,509	[1]	2,936	[1]
(Decrease) increase in other liabilities						365	[1]							665	[1]	447	[1]	927	[1]	708	[1]	380	[1]	352	1,396	[1]	(3,378)	[1]
Net cash provided by operating activities						14,211	[1]							2,475	[1]	31,053	[1]	17,237	[1]	38,198	[1]	26,171	[1]	51,050	37,520	[1]	41,391	[1]
Acquisitions of non-controlling interests																									(968)		(227)
Net cash used in investing activities						(14,983)	[1]							(8,215)	[1]	(16,619)	[1]	(18,236)	[1]	(19,200)	[1]	(19,995)	[1]	(32,492)	(26,125)	[1]	(17,617)	[1]
Distributions to non-controlling interests (including redeemable non-controlling interests)																									0		0
Distributions to non-controlling interests						(1,113)	[1]							(1,045)	[1]	(2,893)	[1]	(2,904)	[1]	(4,441)	[1]	(4,148)	[1]	(5,718)	(5,892)	[1]	(5,963)	[1]
Payments to settle mandatorily redeemable non-controlling interests						(1,136)	[1]									(1,136)	[1]			(1,136)	[1]	(1,860)	[1]	(1,262)	(6,115)	[1]	(5,233)	[1]
Other						1	[1]									1	[1]	5	[1]	1	[1]	5	[1]	1	5	[1]	45	[1]
Net cash used in financing activities						4,200	[1]							6,026	[1]	(9,759)	[1]	(300)	[1]	(19,752)	[1]	111	[1]	$ (14,289)	(9,888)	[1]	(22,401)	[1]
As Reported [Member]
Consolidated Balance Sheet [Abstract]
Goodwill		191,231		191,268		191,051		$ 171,457		170,849		170,914		159,176		191,268		170,914		191,231		170,849			171,457
Total assets		309,901		313,598		311,434		279,913		276,145		268,320		257,423		313,598		268,320		309,901		276,145			279,913
MRNCI		0		0		0		0	[2]	0		0		0		0		0		0		0			0	[2]
Deferred taxes (liability)		13,727		12,361		10,789		8,355		0		0		0		12,361		0		13,727		0			8,355
Total liabilities		82,829		90,547		94,396		77,960		81,001		75,721		73,849		90,547		75,721		82,829		81,001			77,960
RNCI		8,334		8,641		7,591		8,843	[3]	9,024		10,585		7,373		8,641		10,585		8,334		9,024			8,843	[3]
Additional paid-in capital		49,506		48,236		46,563		45,251		45,536		45,829		45,080		48,236		45,829		49,506		45,536			45,251
Retained earnings		160,746		157,161		152,219		149,016		144,888		140,933		136,491		157,161		140,933		160,746		144,888			149,016
Total liabilities and equity		309,901		313,598		311,434		279,913		276,145		268,320		257,423		313,598		268,320		309,901		276,145			279,913
Interest expense [Abstract]
MRNCI (1) - change in redemption value		0		0		0				0		0		0		0		0		0		0			0	[2]	0	[2]
MRNCI (1) - earnings allocable		0		0		0				0		0		0		0		0		0		0			0	[2]	0	[2]
Total interest expense		326		320		308				255		245		265		628		510		954		765			1,031		1,088
Net income before taxes		11,750		14,734		11,203				11,718		13,320		8,928		25,937		22,248		37,687		33,966			46,344		44,698
Provision for income taxes		3,778		4,674		3,523				3,654		4,203		2,777		8,197		6,980		11,975		10,634			14,653		14,274
Net income		7,972		10,060		7,680				8,064		9,117		6,151		17,740		15,268		25,712		23,332			31,691		30,424
Less: net income attributable to non-controlling interests		2,259		2,989		2,352				2,246		2,813		1,985		5,341		4,798		7,600		7,044			9,412		9,571
Net income attributable to USPH shareholders		$ 5,713		$ 7,071		$ 5,328				$ 5,818		$ 6,304		$ 4,166		$ 12,399		$ 10,470		$ 18,112		$ 16,288			$ 22,279		$ 20,853
Earnings per share (in dollars per share)		$ 0.46		$ 0.57		$ 0.43				$ 0.47		$ 0.48		$ 0.34		$ 0.99		$ 0.82		$ 1.45		$ 1.29			$ 1.77		$ 1.62
Consolidated Statement of Cash Flows [Abstract]
Net income		$ 7,972		$ 10,060		$ 7,680				$ 8,064		$ 9,117		$ 6,151		$ 17,740		$ 15,268		$ 25,712		$ 23,332			$ 31,691		$ 30,424
Deferred taxes						2,709								565		4,170		2,130		5,688		3,181			7,001		6,275
(Increase) decrease in other assets						(2,282)								106		(2,443)		(13)		(4,979)		(1,485)			(1,477)		(2,493)
(Decrease) increase in accounts payable and accrued expenses						4,322								(5,976)		7,715		(3,958)		5,178		(3,766)			(7,013)
Increase in mandatorily redeemable non-controlling interests						0								0		0		0		0		0			0		0
(Decrease) increase in other liabilities						365								665		447		927		708		380			1,482		730
Net cash provided by operating activities						14,711								3,019		33,364		19,239		42,028		28,859			41,243		45,194
Acquisitions of non-controlling interests																									(7,083)		(5,490)
Net cash used in investing activities						(16,119)								(8,215)		(17,755)		(18,236)		(20,336)		(21,855)			(32,240)		(22,880)
Distributions to non-controlling interests (including redeemable non-controlling interests)																									(9,632)		(9,913)
Distributions to non-controlling interests						(1,613)								(1,589)		(5,204)		(4,906)		(8,271)		(6,836)			0		0
Payments to settle mandatorily redeemable non-controlling interests						0										0				0		0			0		0
Other						1										1		5		1		5			22		222
Net cash used in financing activities						4,836								5,482		(10,934)		(2,302)		(22,446)		(717)			(7,496)		(20,941)
Adjustment [Member]
Consolidated Balance Sheet [Abstract]
Goodwill		23,826		23,826		23,826		23,916		23,826		23,826		23,826		23,826		23,826		23,826		23,826			23,916
Total assets		24,642		24,400		24,309		23,844		23,826		23,826		23,826		24,400		23,826		24,642		23,826			23,844
MRNCI		61,276		59,932		58,481		45,974	[2]	45,323		49,166		45,578		59,932		49,166		61,276		45,323			45,974	[2]
Deferred taxes (liability)		5,009		5,792		6,573		7,153		13,276		12,027		12,009		5,792		12,027		5,009		13,276			7,153
Total liabilities		66,339		65,778		65,108		53,487		50,604		53,198		49,592		65,778		53,198		66,339		50,604			53,487
RNCI		(8,334)		(8,641)		(7,591)		(8,843)	[3]	(9,024)		(10,585)		(7,373)		(8,641)		(10,585)		(8,334)		(9,024)			(8,843)	[3]
Additional paid-in capital		18,987		18,987		18,987		18,987		17,382		15,222		15,222		18,987		15,222		18,987		17,382			18,987
Retained earnings		(13,523)		(12,614)		(11,555)		(10,715)		(9,485)		(9,173)		(9,203)		(12,614)		(9,173)		(13,523)		(9,485)			(10,715)
Total liabilities and equity		24,642		24,400		24,309		$ 23,844		23,826		23,826		23,826		24,400		23,826		24,642		23,826			23,844
Interest expense [Abstract]
MRNCI (1) - change in redemption value		1,934		1,931		2,191				501		(48)		244		4,122		196		6,056		697			2,670	[2]	2,978	[2]
MRNCI (1) - earnings allocable		929		1,330		887				778		1,190		706		2,217		1,896		3,146		2,674			3,538	[2]	3,388	[2]
Total interest expense		2,863		3,261		3,078				1,279		1,142		950		6,339		2,092		9,202		3,371			6,208		6,366
Net income before taxes		(2,863)		(3,261)		(3,078)				(1,279)		(1,142)		(950)		(6,339)		(2,092)		(9,202)		(3,371)			(6,208)		(6,366)
Provision for income taxes		(1,025)		(872)		(1,351)				(189)		18		(92)		(2,223)		(74)		(3,248)		(263)			(1,006)		(1,256)
Net income		(1,838)		(2,389)		(1,727)				(1,090)		(1,160)		(858)		(4,116)		(2,018)		(5,954)		(3,108)			(5,202)		(5,110)
Less: net income attributable to non-controlling interests		(929)		(1,330)		(887)				(778)		(1,190)		(706)		(2,217)		(1,896)		(3,146)		(2,674)			(3,538)		(3,388)
Net income attributable to USPH shareholders		$ (909)		$ (1,059)		$ (840)				$ (312)		$ 30		$ (152)		$ (1,899)		$ (122)		$ (2,808)		$ (434)			$ (1,664)		$ (1,722)
Earnings per share (in dollars per share)		$ (0.08)		$ (0.09)		$ (0.07)				$ (0.03)		$ 0.03		$ (0.01)		$ (0.15)		$ 0.02		$ (0.23)		$ (0.01)			$ (0.11)		$ (0.05)
Consolidated Statement of Cash Flows [Abstract]
Net income		$ (1,838)		$ (2,389)		$ (1,727)				$ (1,090)		$ (1,160)		$ (858)		$ (4,116)		$ (2,018)		$ (5,954)		$ (3,108)			$ (5,202)		$ (5,110)
Deferred taxes						(886)								(92)		(1,667)		(74)		(2,450)		(263)			(1,048)		(1,169)
(Increase) decrease in other assets						0								0		0		0		0		0			102		3,648
(Decrease) increase in accounts payable and accrued expenses						(930)								0		(1,112)		0		(1,596)		0			2
Increase in mandatorily redeemable non-controlling interests						2,578								406		4,028		90		5,372		683			2,509		2,936
(Decrease) increase in other liabilities						0								0		0		0		0		0			(86)		(4,108)
Net cash provided by operating activities						(500)								(544)		(2,311)		(2,002)		(3,830)		(2,688)			(3,723)		(3,803)
Acquisitions of non-controlling interests																									6,115		5,263
Net cash used in investing activities						1,136								0		1,136		0		1,136		1,860			6,115		5,263
Distributions to non-controlling interests (including redeemable non-controlling interests)																									9,632		9,913
Distributions to non-controlling interests						500								544		2,311		2,002		3,830		2,688			(5,892)		(5,963)
Payments to settle mandatorily redeemable non-controlling interests						(1,136)										(1,136)				(1,136)		(1,860)			(6,115)		(5,233)
Other						0										0		0		0		0			(17)		(177)
Net cash used in financing activities						$ (636)								$ 544		$ 1,175		$ 2,002		$ 2,694		$ 828			$ (2,392)		$ (1,460)
[1]	as restated
[2]	Mandatorily redeemable non-controlling interests
[3]	Redeemable non-controlling interests

Significant Accounting Polici41

Significant Accounting Policies (Details)

1 Months Ended

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

May 31, 2017USD ($)Clinic

Mar. 31, 2017USD ($)

Jan. 31, 2017USD ($)Clinic

Sep. 30, 2016USD ($)

[1]

Jun. 30, 2016USD ($)

[1]

Mar. 31, 2016USD ($)

[1]

Sep. 30, 2015USD ($)

[1]

Jun. 30, 2015USD ($)

[1]

Mar. 31, 2015USD ($)

[1]

Jun. 30, 2016USD ($)

[1]

Jun. 30, 2015USD ($)

[1]

Sep. 30, 2016USD ($)

[1]

Sep. 30, 2015USD ($)

[1]

Dec. 31, 2016USD ($)SegmentRegion$ / shares

Dec. 31, 2015USD ($)Region

Dec. 31, 2014USD ($)Region

Depreciation Amortization Impairment [Line Items]

Number of business segments | Segment

1

Number of regions | Region

6

6

6

Federal debt ceiling in connection with deficit reductions

10 years

Reductions in federal spending

$ 1,200,000,000,000

Medicare spending cut percentage

2.00%

Expected reduction in Medicare spending percentage

2.00%

Combined physical therapy/speech language pathology expenses

$ 3,700

Percentage of practice expense component

100.00%

Percentage reduction for service

50.00%

Net revenue from Medicare accounts

$ 81,800,000

Difference between net revenues and corresponding cash collections, approximately of net revenues

1.00%

Difference between actual aggregate contractual reserve and estimated contractual allowance reserve percentage

1.00%

Maximum contractual allowance reserve estimate

1.00%

Minimum percentage of fair value reporting unit less than carrying amount

50.00%

Unrecognized tax benefit

$ 0

$ 0

Accrued interest and penalties associated with any unrecognized tax benefits

0

0

$ 0

Interest expense recognized

0

0

Increase in earnings by decreasing the tax provision due to adoption of new accounting treatment

$ 2,753,000

$ 3,802,000

$ 2,172,000

$ 3,465,000

$ 4,221,000

$ 2,685,000

$ 5,974,000

$ 6,906,000

$ 8,727,000

$ 10,371,000

11,880,000

$ 13,647,000

[1]

$ 13,018,000

[1]

Accounting Standards Update 2016-09 [Member]

Depreciation Amortization Impairment [Line Items]

Increase in earnings by decreasing the tax provision due to adoption of new accounting treatment

$ 1,000,000

Increase in earnings by decreasing the tax provision due to adoption of new accounting treatment (in dollars per share) | $ / shares

$ 0.09

Physical Therapy Practice [Member] | Subsequent Event [Member]

Depreciation Amortization Impairment [Line Items]

Percentage of interest acquired

70.00%

70.00%

Number of clinics owned and operated | Clinic

4

17

Number of additional clinics managed | Clinic

8

Purchase price

$ 2,500,000

$ 11,400,000

Workforce Performance Solutions [Member] | Subsequent Event [Member]

Depreciation Amortization Impairment [Line Items]

Percentage of interest acquired

55.00%

Purchase price

$ 6,600,000

Year 2016 [Member]

Depreciation Amortization Impairment [Line Items]

Percentage of medicare payment

(0.30%)

Expected reduction in Medicare spending percentage

2.00%

Year 2017 [Member]

Depreciation Amortization Impairment [Line Items]

Percentage of payment adjustments proposed by CMS

(0.08%)

Expected reduction in Medicare spending percentage

2.00%

January 1, 2015 through June 30, 2015 [Member]

Depreciation Amortization Impairment [Line Items]

Percentage of medicare payment

0.00%

July 1, 2015 through December 31, 2015 [Member]

Depreciation Amortization Impairment [Line Items]

Percentage of medicare payment

0.50%

From 2017 through 2019 [Member]

Depreciation Amortization Impairment [Line Items]

Percentage of medicare payment

0.50%

Minimum [Member]

Depreciation Amortization Impairment [Line Items]

Redemption period in the limited partnership agreement

3 years

Percentage of interest acquired

2.00%

5.00%

Minimum [Member] | Furniture & Equipment [Member]

Depreciation Amortization Impairment [Line Items]

Estimated useful lives

3 years

Minimum [Member] | Computer Software, Intangible Asset [Member]

Depreciation Amortization Impairment [Line Items]

Estimated useful lives

3 years

Minimum [Member] | Leasehold Improvements [Member]

Depreciation Amortization Impairment [Line Items]

Estimated useful lives

3 years

Maximum [Member]

Depreciation Amortization Impairment [Line Items]

Redemption period in the limited partnership agreement

5 years

Percentage of interest acquired

35.00%

35.00%

Maximum [Member] | Year 2016 [Member]

Depreciation Amortization Impairment [Line Items]

Annual limit on physical therapy and speech language pathology services

$ 1,960

Annual limit occupational therapy services

$ 1,960

Maximum [Member] | Furniture & Equipment [Member]

Depreciation Amortization Impairment [Line Items]

Estimated useful lives

8 years

Maximum [Member] | Computer Software, Intangible Asset [Member]

Depreciation Amortization Impairment [Line Items]

Estimated useful lives

7 years

Maximum [Member] | Leasehold Improvements [Member]

Depreciation Amortization Impairment [Line Items]

Estimated useful lives

5 years

[1]

as restated

Acquisitions of Businesses (Det

Acquisitions of Businesses (Details)	Nov. 30, 2016USD ($)Installment	Feb. 29, 2016USD ($)Installment	Dec. 31, 2015USD ($)Installment	Aug. 31, 2015USD ($)	Jun. 30, 2015USD ($)	Apr. 30, 2015USD ($)Installment	Jan. 31, 2015USD ($)Installment	Aug. 31, 2014USD ($)	Apr. 30, 2014USD ($)Installment	Mar. 31, 2016USD ($)	[1]	Mar. 31, 2015USD ($)	[1]	Jun. 30, 2016USD ($)	[1]	Jun. 30, 2015USD ($)		Sep. 30, 2016USD ($)	[1]	Sep. 30, 2015USD ($)	[1]	Dec. 31, 2016USD ($)ClinicSubsidiaryOperation	Dec. 31, 2015USD ($)Clinic		Dec. 31, 2014USD ($)Clinic
Business Acquisition [Line Items]
Seller notes issued for acquisition of interest in clinic			$ 1,800,000																			$ 1,000,000	$ 1,800,000		$ 400,000
Number of acquired operations combined | Operation																						2
Cash paid, net of cash acquired										$ 12,899,000		$ 6,445,000		$ 12,958,000		$ 14,467,000	[1]	$ 12,958,000		$ 14,434,000		$ 23,623,000	18,965,000	[1]	12,270,000	[1]
Seller notes			1,800,000																			1,000,000	1,800,000		400,000
Total consideration			20,765,000																			24,623,000	20,765,000		12,670,000
Estimated fair value of net tangible assets acquired: [Abstract]
Total current assets			1,952,000																			1,712,000	1,952,000		1,213,000
Total non-current assets			1,068,000																			1,202,000	1,068,000		1,051,000
Total liabilities			(1,067,000)																			(398,000)	(1,067,000)		(406,000)
Net tangible assets acquired			1,953,000																			2,516,000	1,953,000		1,858,000
Referral relationships			3,655,000																			4,919,000	3,655,000		280,000
Non-compete			594,000																			847,000	594,000		330,000
Tradename			3,417,000																			3,802,000	3,417,000		1,600,000
Goodwill			23,437,000																			31,419,000	23,437,000		13,327,000
Fair value of noncontrolling interest			(12,291,000)																			(18,880,000)	(12,291,000)		(4,725,000)
Total consideration			$ 20,765,000																			$ 24,623,000	$ 20,765,000		$ 12,670,000
Minimum [Member]
Business Acquisition [Line Items]
Percentage of interest acquired			5.00%																			2.00%	5.00%
Maximum [Member]
Business Acquisition [Line Items]
Percentage of interest acquired			35.00%																			35.00%	35.00%
Referral Relationships [Member] | Minimum [Member]
Business Acquisition [Line Items]
Estimated useful lives of acquired intangibles																						4 years 6 months
Referral Relationships [Member] | Maximum [Member]
Business Acquisition [Line Items]
Estimated useful lives of acquired intangibles																						13 years
Non-compete Agreements [Member] | Minimum [Member]
Business Acquisition [Line Items]
Estimated useful lives of acquired intangibles																						5 years
Non-compete Agreements [Member] | Maximum [Member]
Business Acquisition [Line Items]
Estimated useful lives of acquired intangibles																						6 years
Tradenames [Member]
Business Acquisition [Line Items]
Estimated useful lives of acquired intangibles																						6 years
February 2017 [Member]
Business Acquisition [Line Items]
Acquisition cost payable in two principal installments including accrued interest																						$ 194,000
February 2018 [Member]
Business Acquisition [Line Items]
Acquisition cost payable in two principal installments including accrued interest																						$ 194,000
February 2016 Acquisition [Member]
Business Acquisition [Line Items]
Acquisition date																						Feb. 29, 2016
Percentage of interest acquired																						55.00%
Number of clinics | Clinic																						8
November 2016 Acquisition [Member]
Business Acquisition [Line Items]
Acquisition date																						Nov. 30, 2016
Percentage of interest acquired																						60.00%
Number of clinics | Clinic																						12
January 2015 Acquisition [Member]
Business Acquisition [Line Items]
Acquisition date																							Jan. 31, 2015
Percentage of interest acquired			60.00%																				60.00%
Number of clinics | Clinic																							9
April 2015 Acquisition [Member]
Business Acquisition [Line Items]
Acquisition date																							Apr. 30, 2015
Percentage of interest acquired			70.00%																				70.00%
Number of clinics | Clinic																							3
June 2015 Acquisition [Member]
Business Acquisition [Line Items]
Acquisition date																							Jun. 30, 2015
Percentage of interest acquired			70.00%																				70.00%
Number of clinics | Clinic																							4
December 2015 Acquisition [Member]
Business Acquisition [Line Items]
Acquisition date																							Dec. 31, 2015
Percentage of interest acquired			59.00%																				59.00%
Number of clinics | Clinic																							4
April 2014 Acquisition [Member]
Business Acquisition [Line Items]
Acquisition date																									Apr. 30, 2014
Percentage of interest acquired																									70.00%
Number of clinics | Clinic																									13
August 2014 Acquisition [Member]
Business Acquisition [Line Items]
Acquisition date																									Aug. 1, 2014
Percentage of interest acquired																									100.00%
Number of clinics | Clinic																									3
Acquisition Of Single Clinic Practices [Member]
Business Acquisition [Line Items]
Percentage of interest acquired			60.00%	60.00%																			60.00%
Number of clinics | Clinic																						2	1		4
Cash paid for acquisition of interest in clinic				$ 150,000
Seller notes issued for acquisition of interest in clinic				50,000
Aggregate purchase price for the acquired clinic practices																						$ 75,000
Number of subsidiaries acquired clinic practices | Subsidiary																						2
Seller notes				50,000
Acquisition Of Single Clinic Practices [Member] | August 2016 [Member]
Business Acquisition [Line Items]
Acquisition cost payable in two principal installments including accrued interest				$ 50,000
Acquisition Of Three Clinic Practices [Member]
Business Acquisition [Line Items]
Percentage of interest acquired						70.00%
Cash paid for acquisition of interest in clinic						$ 4,700,000		$ 1,000,000
Seller notes issued for acquisition of interest in clinic						$ 150,000																			$ 595,000
Business acquisition number of installments to payment of purchase consideration | Installment						2
Seller notes						$ 150,000																			$ 595,000
Acquisition Of Three Clinic Practices [Member] | April 2016 [Member]
Business Acquisition [Line Items]
Acquisition cost payable in two principal installments including accrued interest						75,000
Acquisition Of Three Clinic Practices [Member] | April 2017 [Member]
Business Acquisition [Line Items]
Acquisition cost payable in two principal installments including accrued interest						$ 75,000
Acquisition Of Four Clinic Practices [Member]
Business Acquisition [Line Items]
Percentage of interest acquired			59.00%		70.00%											70.00%							59.00%
Cash paid for acquisition of interest in clinic			$ 4,600,000		$ 3,600,000
Seller notes issued for acquisition of interest in clinic			$ 400,000		700,000											$ 700,000							$ 400,000
Business acquisition number of installments to payment of purchase consideration | Installment			2
Seller notes			$ 400,000		700,000											$ 700,000							$ 400,000
Acquisition Of Four Clinic Practices [Member] | December 2016 [Member]
Business Acquisition [Line Items]
Acquisition cost payable in two principal installments including accrued interest			200,000
Acquisition Of Four Clinic Practices [Member] | December 2017 [Member]
Business Acquisition [Line Items]
Acquisition cost payable in two principal installments including accrued interest			$ 200,000
Acquisition Of Four Clinic Practices [Member] | June 2018 [Member]
Business Acquisition [Line Items]
Acquisition cost payable in two principal installments including accrued interest					$ 700,000
Acquisition Of Eight Clinic Practices [Member]
Business Acquisition [Line Items]
Percentage of interest acquired		55.00%
Cash paid for acquisition of interest in clinic		$ 13,200,000
Seller notes issued for acquisition of interest in clinic		$ 500,000
Business acquisition number of installments to payment of purchase consideration | Installment		2
Seller notes		$ 500,000
Acquisition Of Eight Clinic Practices [Member] | February 2017 [Member]
Business Acquisition [Line Items]
Acquisition cost payable in two principal installments including accrued interest		250,000
Acquisition Of Eight Clinic Practices [Member] | February 2018 [Member]
Business Acquisition [Line Items]
Acquisition cost payable in two principal installments including accrued interest		$ 250,000
Acquisition Of Nine Clinic Practices [Member]
Business Acquisition [Line Items]
Percentage of interest acquired							60.00%
Cash paid for acquisition of interest in clinic							$ 6,700,000
Seller notes issued for acquisition of interest in clinic							$ 500,000
Business acquisition number of installments to payment of purchase consideration | Installment							2
Seller notes							$ 500,000
Acquisition Of Nine Clinic Practices [Member] | January 2016 [Member]
Business Acquisition [Line Items]
Acquisition cost payable in two principal installments including accrued interest							250,000
Acquisition Of Nine Clinic Practices [Member] | January 2017 [Member]
Business Acquisition [Line Items]
Acquisition cost payable in two principal installments including accrued interest							$ 250,000
Acquisition Of Twelve Clinic Practices [Member]
Business Acquisition [Line Items]
Percentage of interest acquired	60.00%
Cash paid for acquisition of interest in clinic	$ 11,000,000
Seller notes issued for acquisition of interest in clinic	$ 500,000
Business acquisition number of installments to payment of purchase consideration | Installment	2
Seller notes	$ 500,000
Acquisition Of Twelve Clinic Practices [Member] | November 2017 [Member]
Business Acquisition [Line Items]
Acquisition cost payable in two principal installments including accrued interest	250,000
Acquisition Of Twelve Clinic Practices [Member] | November 2018 [Member]
Business Acquisition [Line Items]
Acquisition cost payable in two principal installments including accrued interest	$ 250,000
Acquisition Of Thirteen Clinic Practices [Member]
Business Acquisition [Line Items]
Percentage of interest acquired									70.00%
Cash paid for acquisition of interest in clinic									$ 10,600,000
Seller notes issued for acquisition of interest in clinic									$ 400,000
Business acquisition number of installments to payment of purchase consideration | Installment									2
Seller notes									$ 400,000
Acquisition Of Thirteen Clinic Practices [Member] | April 2016 [Member]
Business Acquisition [Line Items]
Acquisition cost payable in two principal installments including accrued interest									200,000
Acquisition Of Thirteen Clinic Practices [Member] | April 2015 [Member]
Business Acquisition [Line Items]
Acquisition cost payable in two principal installments including accrued interest									$ 200,000
[1]	as restated

Non-Controlling Interests (Deta

Non-Controlling Interests (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)InstallmentPartnership	Dec. 31, 2015USD ($)Partnership
Business Acquisition [Line Items]
Number of partnership in which interest acquired | Partnership	6	6
Number of partnership in which interest sold | Partnership	1
Purchase price for additional non controlling interest	$ 900	$ 900
Seller notes	$ 400
Number of installments | Installment	2
Book value of purchase price	$ 112	217
Remaining purchase price	1,200	700
Future tax benefits	$ 500	$ 300
Sale of non-controlling interest percentage in partnership one	4.00%
Sale of non-controlling interest percentage in partnership two	35.00%
Cash proceeds from sale of non-controlling interest	$ 138
Amount of notes receivable from sale of non-controlling interest	148
Total sale price	286
Tax effect on sale price	110
February 2017 [Member]
Business Acquisition [Line Items]
Acquisition cost payable in two principal installments including accrued interest	194
February 2018 [Member]
Business Acquisition [Line Items]
Acquisition cost payable in two principal installments including accrued interest	$ 194
Minimum [Member]
Business Acquisition [Line Items]
Percentage of interest acquired	2.00%	5.00%
Maximum [Member]
Business Acquisition [Line Items]
Percentage of interest acquired	35.00%	35.00%

Redeemable Non-Controlling In44

Redeemable Non-Controlling Interest (Details) $ in Thousands

12 Months Ended

Dec. 31, 2016USD ($)

Dec. 31, 2015USD ($)

Dec. 31, 2016USD ($)Installment

Sep. 30, 2016USD ($)

[2]

Jun. 30, 2016USD ($)

[2]

Mar. 31, 2016USD ($)

[2]

Dec. 31, 2015USD ($)

Sep. 30, 2015USD ($)

[2]

Jun. 30, 2015USD ($)

[2]

Mar. 31, 2015USD ($)

[2]

Changes in Carrying Amount of Mandatorily Redeemable Non-Controlling Interests [Roll Forward]

Beginning balance

[2]

$ 45,974

[1]

$ 40,365

Operating results allocated to mandatorily redeemable non-controlling interest partners

4,057

3,538

[2]

Distributions to mandatorily redeemable non-controlling interest partners

(4,628)

(3,740)

[2]

Changes in the redemption value of mandatorily redeemable non-controlling interest

6,169

2,670

[2]

Payments for settlement of mandatorily redeemable non-controlling interest

(1,262)

(9,192)

[2]

Purchases of businesess - initial liability related to mandatorily redeemable non-controlling interests

18,880

12,291

[2]

Other

0

42

[2]

Ending balance

69,190

45,974

[1],[2]

Carrying Amount of Redeemable Non-Controlling Interest [Abstract]

Contractual time period has lapsed but holder's employment has not been terminated

$ 24,700

$ 19,969

[2]

Contractual time period has not lapsed and holder's employment has not been terminated

46,949

27,893

[2]

Holder's employment has terminated and contractual time period has expired

0

0

[2]

Holder's employment has terminated and contractual time period has not expired

0

0

[2]

Redemption value prior to excess distributed earnings

71,649

47,862

[2]

Excess distributions over earnings and losses

(2,459)

(1,888)

[2]

Redeemable non-controlling interests

$ 69,190

$ 45,974

[1],[2]

$ 69,190

$ 61,276

$ 59,932

$ 58,481

45,974

[1],[2]

$ 45,323

$ 49,166

$ 45,578

Debt Instrument [Line Items]

Number of installments | Installment

2

Aggregate principal payment due in 2018

$ 48,750

Aggregate principal payment due in 2019

1,846

Notes Payable [Member]

Debt Instrument [Line Items]

Aggregate amount of notes payable

$ 100

$ 3,100

Number of installments | Installment

2

Average effective interest rate

3.25%

Aggregate principal payment due in 2018

$ 1,200

Aggregate principal payment due in 2019

$ 1,900

Therapy Practice [Member]

Business Acquisition [Line Items]

Business acquisition, consideration payable, term of note

2 years

Therapy Practice [Member] | Minimum [Member]

Business Acquisition [Line Items]

Business acquisition, percentage of limited partnership acquired

50.00%

Therapy Practice [Member] | Maximum [Member]

Business Acquisition [Line Items]

Business acquisition, percentage of limited partnership acquired

90.00%

Therapy Practice [Member] | NewCo. [Member]

Business Acquisition [Line Items]

Percentage of equity interest of subsidiary contributed for acquisition

100.00%

Business acquisition, percentage of general partnership interest acquired

100.00%

Employment agreement renewal term

1 year

Non-Compete agreement term under condition of termination of employment of employed selling shareholder

2 years

Therapy Practice [Member] | NewCo. [Member] | Minimum [Member]

Business Acquisition [Line Items]

Employment agreement term

3 years

Non-Compete agreement term regardless of whether the selling shareholder is employed

5 years

Required redemption term, under condition of termination of employment of employed selling shareholders

3 years

Therapy Practice [Member] | NewCo. [Member] | Maximum [Member]

Business Acquisition [Line Items]

Employment agreement term

5 years

Non-Compete agreement term regardless of whether the selling shareholder is employed

6 years

Required redemption term, under condition of termination of employment of employed selling shareholders

5 years

[1]

Mandatorily redeemable non-controlling interests

[2]

as restated

Goodwill (Details)

Goodwill (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015
Goodwill [Roll Forward]
Beginning balance, as restated	[1]	$ 195,373	$ 171,740
Goodwill acquired during the period		31,419	23,437	[1]
Goodwill adjustments for purchase price allocation of business acquired		14	376	[1]
Goodwill written-off - closed clinics		0	(180)	[1]
Ending balance		$ 226,806	$ 195,373	[1]
[1]	as restated

Intangible Assets, net (Details

Intangible Assets, net (Details) $ in Thousands

12 Months Ended

Dec. 31, 2016USD ($)Operation

Sep. 30, 2016USD ($)

[1]

Jun. 30, 2016USD ($)

[1]

Mar. 31, 2016USD ($)

[1]

Dec. 31, 2015USD ($)

Sep. 30, 2015USD ($)

[1]

Jun. 30, 2015USD ($)

[1]

Mar. 31, 2015USD ($)

[1]

Dec. 31, 2014USD ($)

Finite-Lived Intangible Assets [Line Items]

Total

$ 38,060

$ 33,389

$ 33,909

$ 34,428

$ 30,296

[1]

$ 23,798

$ 24,167

$ 24,537

Number of acquired operations | Operation

2

Tradenames [Member]

Finite-Lived Intangible Assets [Line Items]

Total

$ 21,234

17,660

Accumulated amortization

$ 0

170

Estimated useful life

6 years

Referral Relationships [Member]

Finite-Lived Intangible Assets [Line Items]

Total

$ 14,859

10,866

Accumulated amortization

$ 5,275

3,763

Referral Relationships [Member] | Minimum [Member]

Finite-Lived Intangible Assets [Line Items]

Estimated useful life

6 years

Referral Relationships [Member] | Maximum [Member]

Finite-Lived Intangible Assets [Line Items]

Estimated useful life

16 years

Referral Relationships [Member] | Physician Services [Member]

Finite-Lived Intangible Assets [Line Items]

Accumulated amortization

$ 156

Non-compete Agreements [Member]

Finite-Lived Intangible Assets [Line Items]

Total

$ 1,967

1,770

Accumulated amortization

$ 3,380

$ 2,855

Non-compete Agreements [Member] | Minimum [Member]

Finite-Lived Intangible Assets [Line Items]

Estimated useful life

5 years

Non-compete Agreements [Member] | Maximum [Member]

Finite-Lived Intangible Assets [Line Items]

Estimated useful life

6 years

Non-compete Agreements [Member] | Physician Services [Member]

Finite-Lived Intangible Assets [Line Items]

Accumulated amortization

$ 270

[1]

as restated

Intangible Assets, net - Amorti

Intangible Assets, net - Amortization Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Total amortization expenses	$ 2,367	$ 1,715	$ 1,541
Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Total amortization expenses	330	84	86
Referral Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Total amortization expenses	1,512	1,153	1,028
Non-compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Total amortization expenses	$ 525	$ 478	$ 427

Intangible Assets, net - Amor48

Intangible Assets, net - Amortization of Referral Relationships and Non-Competition Agreements (Details) $ in Thousands	Dec. 31, 2016USD ($)
Referral Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
2,017	$ 1,682
2,018	1,636
2,019	1,547
2,020	1,547
2,021	1,547
2,022	1,498
2,023	1,391
2,024	1,272
2,025	1,166
2,026	704
2,027	544
2,028	281
2,029	44
Non-compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
2,017	581
2,018	525
2,019	452
2,020	239
2,021	162
2,022	$ 8

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016	[1]	Jun. 30, 2016	[1]	Mar. 31, 2016	[1]	Dec. 31, 2015		Sep. 30, 2015	[1]	Jun. 30, 2015	[1]	Mar. 31, 2015	[1]
Payables and Accruals [Abstract]
Salaries and related costs	$ 10,569							$ 9,414
Credit balances and overpayments due to patients and payors	3,880							1,472
Group health insurance claims	2,499							2,276
Other	4,808							3,434
Total	$ 21,756	$ 23,216		$ 26,273		$ 20,684		$ 16,596	[1]	$ 18,287		$ 19,446		$ 18,178
[1]	as restated

Notes Payable - Summary of Note

Notes Payable - Summary of Notes Payable (Details) - USD ($) $ in Thousands

12 Months Ended

Dec. 31, 2016

Sep. 30, 2016

[1]

Jun. 30, 2016

[1]

Mar. 31, 2016

[1]

Dec. 31, 2015

Sep. 30, 2015

[1]

Jun. 30, 2015

[1]

Mar. 31, 2015

[1]

Debt Instrument [Line Items]

Payments/Long term debt, Total

$ 51,823

$ 49,110

Less current portion

(1,227)

$ (986)

$ (1,044)

$ (1,253)

(775)

[1]

$ (1,412)

$ (800)

$ (932)

Long term portion

50,596

48,335

Credit Facility [Member]

Debt Instrument [Line Items]

Payments/Long term debt, Total

$ 46,000

44,000

Average effective interest rate

2.50%

3.25 % through 3.5 % notes payable due in next year [Member]

Debt Instrument [Line Items]

Payments/Long term debt, Total

$ 5,823

$ 5,110

Annual installments

$ 1,227

3.25 % through 3.5 % notes payable due in next year [Member] | Maximum [Member]

Debt Instrument [Line Items]

Percentage of interest accrued

3.50%

3.25 % through 3.5 % notes payable due in next year [Member] | Minimum [Member]

Debt Instrument [Line Items]

Percentage of interest accrued

3.25%

[1]

as restated

Notes Payable (Details)

Notes Payable (Details) - USD ($)	Jan. 11, 2016	Dec. 31, 2016	Dec. 05, 2013
Debt Instrument [Line Items]
Aggregate principal payment due in 2017		$ 1,227,000
Aggregate principal payment due in 2018		48,750,000
Notes Payable [Member]
Debt Instrument [Line Items]
Aggregate amount of notes payable		1,500,000
Aggregate principal payment due in 2017		694,000
Aggregate principal payment due in 2018		$ 819,000
Minimum [Member]
Debt Instrument [Line Items]
Spread on Libor variable rate		1.50%
Spread on variable rate		0.10%
Percentage of unused commitment fee		0.10%
Minimum [Member] | Notes Payable [Member]
Debt Instrument [Line Items]
Average effective interest rate		3.25%
Maximum [Member]
Debt Instrument [Line Items]
Spread on Libor variable rate		2.50%
Spread on variable rate		1.00%
Percentage of unused commitment fee		0.25%
Maximum [Member] | Notes Payable [Member]
Debt Instrument [Line Items]
Average effective interest rate		3.50%
Credit Agreement [Member]
Debt Instrument [Line Items]
Cash and noncash consideration with respect to acquisition after amendment	$ 50,000,000
Cash dividends after amendment	$ 10,000,000
Credit Facility [Member]
Debt Instrument [Line Items]
Revolving credit facility commitment			$ 125,000,000
Revolving credit facility maturity date		Nov. 30, 2018
Remaining revolving credit outstanding		$ 79,000,000

Notes Payable - Summary of Aggr

Notes Payable - Summary of Aggregate Annual Payments of Principal Required to Revolving Credit Facility (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Long Term Debt By Maturity [Abstract]
During the twelve months ended December 30, 2017	$ 1,227
During the twelve months ended December 30, 2018	48,750
During the twelve months ended December 30, 2019	1,846
Payments/Long term debt, Total	$ 51,823	$ 49,110

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Deferred Tax Assets Included in Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	[1]
Deferred tax assets [Abstract]
Compensation	$ 1,914	$ 1,830
Allowance for doubtful accounts	572	472
Lease obligations - closed clinics	57	50
Deferred tax assets	2,543	2,352
Deferred tax liabilities [Abstract]
Depreciation and amortization	(17,896)	(16,142)
Other	(383)	(1,718)
Deferred tax liabilities	(18,279)	(17,860)
Net deferred tax liability	$ (15,736)	$ (15,508)
[1]	as restated

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Examination [Line Items]
Deferred tax assets related to acquisitions of non controlling interests	$ 400,000
Revaluation of redeemable non-controlling interests	2,400,000
Deferred tax assets related to acquired interests	7,400,000
Adjustment to the deferred tax assets related to acquisitions of non controlling interests	2,700,000
Offset to adjustment, reduction in the previously reported tax receivable	2,900,000
Additional-paid-in-capital	200,000
Tax receivable included in other current assets	2,300,000	$ 3,400,000
Reduction of the income tax provision	1,000,000
Increase in current state income tax provision	34,000	147,000	$ 223,000
Accrued interest and penalties associated with any unrecognized tax benefits	0	0	0
Interest expense recognized	$ 0	$ 0	$ 0
Federal [Member] | Maximum [Member]
Income Tax Examination [Line Items]
Periods open for examination	2,015
Federal [Member] | Minimum [Member]
Income Tax Examination [Line Items]
Periods open for examination	2,013
State [Member] | Maximum [Member]
Income Tax Examination [Line Items]
Periods open for examination	2,015
State [Member] | Minimum [Member]
Income Tax Examination [Line Items]
Periods open for examination	2,012

Income Taxes - Schedule of Diff

Income Taxes - Schedule of Differences Between Federal Tax Rate and Company's Effective Tax Rate for Results of Continuing Operations (Details) - USD ($) $ in Thousands	3 Months Ended												6 Months Ended				9 Months Ended				12 Months Ended
	Sep. 30, 2016	[1]	Jun. 30, 2016	[1]	Mar. 31, 2016	[1]	Sep. 30, 2015	[1]	Jun. 30, 2015	[1]	Mar. 31, 2015	[1]	Jun. 30, 2016	[1]	Jun. 30, 2015	[1]	Sep. 30, 2016	[1]	Sep. 30, 2015	[1]	Dec. 31, 2016	Dec. 31, 2015	[1]	Dec. 31, 2014	[1]
Income Taxes [Abstract]
U.S. tax at statutory rate																					$ 11,351	$ 11,991		$ 11,252
State income taxes, net of federal benefit																					945	1,337		1,474
Excess equity compensation deduction																					(911)	0		0
Non-deductible expenses																					495	319		292
Total income tax provision for continuing operations	$ 2,753		$ 3,802		$ 2,172		$ 3,465		$ 4,221		$ 2,685		$ 5,974		$ 6,906		$ 8,727		$ 10,371		$ 11,880	$ 13,647		$ 13,018
U.S. tax at statutory rate																					35.00%	35.00%		35.00%
State income taxes, net of federal benefit																					2.90%	3.90%		4.60%
Excess equity compensation deduction																					(2.80%)	0.00%		0.00%
Nondeductible expenses																					1.50%	0.90%		0.90%
Total																					36.60%	39.80%		40.50%
[1]	as restated

Income Taxes - Schedule of Sign

Income Taxes - Schedule of Significant Components of Provision for Income Taxes for Continuing Operations (Details) - USD ($) $ in Thousands	3 Months Ended												6 Months Ended				9 Months Ended				12 Months Ended
	Sep. 30, 2016	[1]	Jun. 30, 2016	[1]	Mar. 31, 2016	[1]	Sep. 30, 2015	[1]	Jun. 30, 2015	[1]	Mar. 31, 2015	[1]	Jun. 30, 2016	[1]	Jun. 30, 2015	[1]	Sep. 30, 2016	[1]	Sep. 30, 2015	[1]	Dec. 31, 2016	Dec. 31, 2015	[1]	Dec. 31, 2014	[1]
Current [Abstract]
Federal																					$ 7,620	$ 6,502		$ 6,972
State																					1,281	1,192		940
Total current																					8,901	7,694		7,912
Deferred [Abstract]
Federal																					2,548	5,302		4,224
State																					431	651		882
Total deferred					$ 1,823						$ 473		$ 2,503		$ 2,056		$ 3,238		$ 2,918		2,979	5,953		5,106
Total income tax provision for continuing operations	$ 2,753		$ 3,802		$ 2,172		$ 3,465		$ 4,221		$ 2,685		$ 5,974		$ 6,906		$ 8,727		$ 10,371		$ 11,880	$ 13,647		$ 13,018
[1]	as restated

Equity Based Plans (Details)

Equity Based Plans (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Mar. 17, 2016	Mar. 16, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)	2,700,000
Number of common shares available for grant (in shares)	566,118
Shares outstanding for which restrictions had not lapsed (in shares)	232,997
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense	$ 4,962	$ 4,491	$ 3,363
Compensation not yet recognized	$ 6,700
Amended 2003 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)	2,100,000			2,100,000	1,750,000
Number of common shares available for grant (in shares)	558,343
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted period on the stock granted	4 years
Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted period on the stock granted	4 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restrictions will lapse in	2,020
Maximum [Member] | Non Qualified Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)	600,000
Maximum [Member] | Amended 2003 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common shares available for grant (in shares)	2,100,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restrictions will lapse in	2,017

Equity Based Plans - Summary of

Equity Based Plans - Summary of Cumulative Summary of Equity Plans (Details) - shares	Dec. 31, 2016	Mar. 17, 2016	Mar. 16, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized (in shares)	2,700,000
Restricted stock issued (in shares)	1,179,759
Outstanding stock options (in shares)	0
Stock options exercised (in shares)	918,091
Stock options exercisable (in shares)	0
Shares available for grant (in shares)	566,118
Amended 1999 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized (in shares)	600,000
Restricted stock issued (in shares)	416,402
Outstanding stock options (in shares)	0
Stock options exercised (in shares)	139,791
Stock options exercisable (in shares)	0
Shares available for grant (in shares)	7,775
Amended 2003 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized (in shares)	2,100,000	2,100,000	1,750,000
Restricted stock issued (in shares)	763,357
Outstanding stock options (in shares)	0
Stock options exercised (in shares)	778,300
Stock options exercisable (in shares)	0
Shares available for grant (in shares)	558,343

Equity Based Plans - Summary 59

Equity Based Plans - Summary of Restricted Stock Granted to Directors, Officers and Employees Pursuant to Its Equity Plans (Details) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares (in shares)	101,790	147,928	159,443
Weighted average fair value (in dollars per share)	$ 51.59	$ 41.66	$ 33.29

Equity Based Plans, Summary of

Equity Based Plans, Summary of Restricted Stock Cancelled Due to Employee Terminations Prior to Restrictions Lapsing (Details) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares (in shares)	4,965	0	8,120
Weighted average fair value (in dollars per share)	$ 35.78	$ 0	$ 23.49

Common Stock (Details)

Common Stock (Details) - USD ($)	1 Months Ended	12 Months Ended
	Mar. 31, 2009	Dec. 31, 2016	Dec. 31, 2008
Common Stock [Abstract]
Common stock authorized by the Board of Directors (in shares)	1,200,000		2,250,000
Maximum percentage of repurchase of common stock	10.00%
Bank credit agreement to permit share repurchases of common stock	$ 15,000,000
Total purchased shares (in shares)	859,499	0
Additional estimated shares (in shares)		213,675
Closing price (in dollars per share)		$ 70.20

Defined Contribution Plan (Deta

Defined Contribution Plan (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Defined Contribution Plan [Abstract]
Required time period for employees for profit sharing plan	3 months
Maximum employer contribution as a percentage of employee contribution	50.00%
Contribution expense recognized	$ 0	$ 0	$ 0
Employer matching contribution amount	$ 1.1	$ 0.9	$ 0.7

Commitments and Contingencies63

Commitments and Contingencies (Details) $ in Millions	12 Months Ended
	Dec. 31, 2016USD ($)Officer	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Operating Leased Assets [Line Items]
Rent expense	$ 30.3	$ 28.3	$ 25.6
Renewal period of employment agreements	2 years
Expiration date	Dec. 31, 2019
Future compensation - 2017	$ 23.2
Future compensation - 2018 through 2021	$ 14.8
Executive Officer [Member]
Operating Leased Assets [Line Items]
Number of officers with the company had employee agreement | Officer	3
Minimum [Member]
Operating Leased Assets [Line Items]
Operating leases renewal period	1 year
Maximum [Member]
Operating Leased Assets [Line Items]
Operating leases renewal period	5 years

Commitments and Contingencies -

Commitments and Contingencies - Future Minimum Operating Lease Commitments (Details) $ in Thousands	Dec. 31, 2016USD ($)
Commitments and Contingencies [Abstract]
2,017	$ 30,376
2,018	23,907
2,019	17,041
2,020	15,164
2,021	6,850
Thereafter	3,095
Total	$ 96,433

Earnings Per Share - Computatio

Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended															6 Months Ended				9 Months Ended				12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	[1]	Jun. 30, 2016	[1]	Mar. 31, 2016	[1]	Dec. 31, 2015	[1]	Sep. 30, 2015	[1]	Jun. 30, 2015	[1]	Mar. 31, 2015	[1]	Jun. 30, 2016	[1]	Jun. 30, 2015	[1]	Sep. 30, 2016	[1]	Sep. 30, 2015	[1]	Dec. 31, 2016	Dec. 31, 2015	[1]	Dec. 31, 2014	[1]
Earnings Per Share [Abstract]
Net income attributable to USPh shareholders		$ 4,804		$ 6,012		$ 4,488				$ 5,506		$ 6,334		$ 4,014		$ 10,500		$ 10,348		$ 15,304		$ 15,854		$ 20,551	$ 20,615		$ 19,131
Basic and diluted net income per share attributable to common shareholders (in dollars per share)	$ 0.42	$ 0.38		$ 0.48		$ 0.36		$ 0.38		$ 0.44		$ 0.51		$ 0.33		$ 0.84		$ 0.84		$ 1.22		$ 1.28		$ 1.64	$ 1.66		$ 1.57
Shares used in computation [Abstract]
Basic earnings per share - weighted-average shares (in shares)		12,520		12,511		12,448				12,421		12,409		12,313		12,480		12,362		12,494		12,382		12,500	12,392		12,217
Effect of dilutive securities - stock options (in shares)																								0	0		4
Denominator for diluted earnings per share - adjusted weighted-average shares (in shares)		12,520		12,511		12,448				12,421		12,409		12,313		12,480		12,362		12,494		12,382		12,500	12,392		12,221
[1]	as restated

Selected Quarterly Financial 66

Selected Quarterly Financial Data (Unaudited) - Summary of Selected Quarterly Financial Data (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended															6 Months Ended				9 Months Ended				12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	[1]	Jun. 30, 2016	[1]	Mar. 31, 2016	[1]	Dec. 31, 2015	[1]	Sep. 30, 2015	[1]	Jun. 30, 2015	[1]	Mar. 31, 2015	[1]	Jun. 30, 2016	[1]	Jun. 30, 2015	[1]	Sep. 30, 2016	[1]	Sep. 30, 2015	[1]	Dec. 31, 2016	Dec. 31, 2015	[1]	Dec. 31, 2014	[1]
Selected Quarterly Financial Data (Unaudited) [Abstract]
Net patient revenues	$ 88,946	$ 86,411		$ 88,433		$ 85,049		$ 84,881		$ 82,154		$ 81,451		$ 75,807		$ 173,482		$ 157,258		$ 259,893		$ 239,412		$ 348,839	$ 324,293		$ 299,009
Net revenues	90,864	88,344		90,430		86,908		86,724		84,049		83,288		77,241		177,338		160,529		265,682		244,578		356,546	331,302		305,074
Operating income	10,954	12,055		15,033		11,491		12,611		11,949		13,549		9,185		$ 26,524		$ 22,734		$ 38,579		$ 34,683		$ 49,533	$ 47,294		$ 45,768
Net income	6,510	6,134		7,671		5,953		6,265		6,974		7,957		5,293
Net income attributable to USPH shareholders	$ 5,247	$ 4,804		$ 6,012		$ 4,488		$ 4,761		$ 5,506		$ 6,334		$ 4,014
Basic and diluted net income per share attributable to common shareholders (in dollars per share)	$ 0.42	$ 0.38		$ 0.48		$ 0.36		$ 0.38		$ 0.44		$ 0.51		$ 0.33		$ 0.84		$ 0.84		$ 1.22		$ 1.28		$ 1.64	$ 1.66		$ 1.57
Shares used in computation - basic and diluted (in shares)	12,519	12,520		12,511		12,448		12,421		12,421		12,409		12,313
[1]	as restated

Selected Quarterly Financial 67

Selected Quarterly Financial Data (Unaudited) - Restated Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016		Jun. 30, 2016		Mar. 31, 2016		Dec. 31, 2015		Sep. 30, 2015		Jun. 30, 2015		Mar. 31, 2015		Dec. 31, 2014		Dec. 31, 2013
Current assets [Abstract]
Cash and cash equivalents	$ 20,047	$ 15,024	[1]	$ 20,453	[1]	$ 19,206	[1]	$ 15,778	[1]	$ 20,558	[1]	$ 12,972	[1]	$ 14,557	[1]	$ 14,271	[1]	$ 12,898	[1]
Patient accounts receivable, less allowance for doubtful accounts	38,840	38,522	[1]	39,356	[1]	38,217	[1]	36,231	[1]	35,106	[1]	34,830	[1]	34,673	[1]
Accounts receivable - other	2,649	2,272	[1]	2,335	[1]	2,345	[1]	2,388	[1]	1,939	[1]	1,338	[1]	1,378	[1]
Other current assets	4,428	11,616	[1]	8,794	[1]	8,781	[1]	5,803	[1]	6,058	[1]	6,509	[1]	5,291	[1]
Total current assets	65,964	67,434	[1]	70,938	[1]	68,549	[1]	60,200	[1]	63,661	[1]	55,649	[1]	55,899	[1]
Fixed assets [Abstract]
Furniture and equipment	48,426	46,996	[1]	46,747	[1]	45,654	[1]	44,749	[1]	44,157	[1]	43,495	[1]	42,542	[1]
Leasehold improvements	26,765	26,206	[1]	25,733	[1]	25,547	[1]	25,160	[1]	25,006	[1]	24,107	[1]	23,565	[1]
Fixed assets, gross	75,191	73,202	[1]	72,480	[1]	71,201	[1]	69,909	[1]	69,163	[1]	67,602	[1]	66,107	[1]
Less accumulated depreciation and amortization	56,018	55,760	[1]	55,642	[1]	54,512	[1]	53,255	[1]	52,501	[1]	51,098	[1]	50,212	[1]
Fixed assets, net	19,173	17,442	[1]	16,838	[1]	16,689	[1]	16,654	[1]	16,662	[1]	16,504	[1]	15,895	[1]
Goodwill	226,806	215,057	[1]	215,094	[1]	214,877	[1]	195,373	[1]	194,675	[1]	194,740	[1]	183,002	[1]	171,740	[1]
Other identifiable intangible assets, net	38,060	33,389	[1]	33,909	[1]	34,428	[1]	30,296	[1]	23,798	[1]	24,167	[1]	24,537	[1]
Other assets	1,228	1,221	[1]	1,219	[1]	1,200	[1]	1,234	[1]	1,175	[1]	1,086	[1]	1,916	[1]
Total assets	351,231	334,543	[1]	337,998	[1]	335,743	[1]	303,757	[1]	299,971	[1]	292,146	[1]	281,249	[1]
Current liabilities [Abstract]
Accounts payable - trade	1,634	2,181	[1]	1,668	[1]	2,244	[1]	1,636	[1]	1,662	[1]	1,451	[1]	2,292	[1]
Accrued expenses	21,756	23,216	[1]	26,273	[1]	20,684	[1]	16,596	[1]	18,287	[1]	19,446	[1]	18,178	[1]
Current portion of notes payable	1,227	986	[1]	1,044	[1]	1,253	[1]	775	[1]	1,412	[1]	800	[1]	932	[1]
Total current liabilities	24,617	26,383	[1]	28,985	[1]	24,181	[1]	19,007	[1]	21,361	[1]	21,697	[1]	21,402	[1]
Notes payable	4,596	4,546	[1]	4,547	[1]	4,621	[1]	4,335	[1]	1,679	[1]	1,059	[1]	483	[1]
Revolving line of credit	46,000	36,000	[1]	42,500	[1]	52,500	[1]	44,000	[1]	46,000	[1]	41,000	[1]	41,500	[1]
Mandatorily redeemable non-controlling interests	69,190	61,276	[1]	59,932	[1]	58,481	[1]	45,974	[1],[2]	45,323	[1]	49,166	[1]	45,578	[1]	40,365	[1]
Deferred rent	1,575	1,313	[1]	1,285	[1]	1,391	[1]	1,395	[1]	1,192	[1]	1,040	[1]	984	[1]
Deferred taxes	15,736	18,736	[1]	18,153	[1]	17,362	[1]	15,508	[1]	13,276	[1]	12,027	[1]	12,009	[1]
Other long-term liabilities	829	914	[1]	923	[1]	968	[1]	1,228	[1]	2,774	[1]	2,930	[1]	1,485	[1]
Total liabilities	162,543	149,168	[1]	156,325	[1]	159,504	[1]	131,447	[1]	131,605	[1]	128,919	[1]	123,441	[1]
Commitments and contingencies			[1]		[1]		[1]		[1]		[1]		[1]		[1]
Redeemable non-controlling interests		0	[1]	0	[1]	0	[1]	0	[3]	0	[1]	0	[1]	0	[1]
U.S. Physical Therapy, Inc. ("USPH") shareholders' equity [Abstract]
Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding	0	0	[1]	0	[1]	0	[1]	0	[1]	0	[1]	0	[1]	0	[1]
Common stock, $.01 par value, 20,000,000 shares authorized, 14,734,963 shares issued	147	147	[1]	147	[1]	147	[1]	146	[1]	146	[1]	146	[1]	145	[1]
Additional paid-in capital	68,687	68,493	[1]	67,223	[1]	65,550	[1]	64,238	[1]	62,918	[1]	61,051	[1]	60,302	[1]
Retained earnings	150,342	147,223	[1]	144,547	[1]	140,664	[1]	138,301	[1]	135,403	[1]	131,760	[1]	127,288	[1]
Treasury stock at cost, 2,214,737 shares	(31,628)	(31,628)	[1]	(31,628)	[1]	(31,628)	[1]	(31,628)	[1]	(31,628)	[1]	(31,628)	[1]	(31,628)	[1]
Total USPH shareholders' equity	187,548	184,235	[1]	180,289	[1]	174,733	[1]	171,057	[1]	166,839	[1]	161,329	[1]	156,107	[1]
Non-controlling interests	1,140	1,140	[1]	1,384	[1]	1,506	[1]	1,253	[1]	1,527	[1]	1,898	[1]	1,701	[1]
Total USPH shareholders' equity and non-controlling interests	188,688	185,375	[1]	181,673	[1]	176,239	[1]	172,310	[1]	168,366	[1]	163,227	[1]	157,808	[1]	153,939	[1]	136,234	[1]
Total liabilities, USPH shareholders' equity and non-controlling interests	$ 351,231	334,543	[1]	337,998	[1]	335,743	[1]	303,757	[1]	299,971	[1]	292,146	[1]	281,249	[1]
As Reported [Member]
Current assets [Abstract]
Cash and cash equivalents		15,024		20,453		19,206		15,778		20,558		12,972		14,557		14,271
Patient accounts receivable, less allowance for doubtful accounts		38,522		39,356		38,217				35,106		34,830		34,673
Accounts receivable - other		2,272		2,335		2,345				1,939		1,338		1,378
Other current assets		10,800		8,220		8,298				6,058		6,509		5,291
Total current assets		66,618		70,364		68,066				63,661		55,649		55,899
Fixed assets [Abstract]
Furniture and equipment		46,996		46,747		45,654				44,157		43,495		42,542
Leasehold improvements		26,206		25,733		25,547				25,006		24,107		23,565
Fixed assets, gross		73,202		72,480		71,201				69,163		67,602		66,107
Less accumulated depreciation and amortization		55,760		55,642		54,512				52,501		51,098		50,212
Fixed assets, net		17,442		16,838		16,689				16,662		16,504		15,895
Goodwill		191,231		191,268		191,051		171,457		170,849		170,914		159,176
Other identifiable intangible assets, net		33,389		33,909		34,428				23,798		24,167		24,537
Other assets		1,221		1,219		1,200				1,175		1,086		1,916
Total assets		309,901		313,598		311,434		279,913		276,145		268,320		257,423
Current liabilities [Abstract]
Accounts payable - trade		2,181		1,668		2,244				1,662		1,451		2,292
Accrued expenses		23,216		26,273		20,684				18,287		19,446		18,178
Current portion of notes payable		986		1,044		1,253				1,412		800		932
Total current liabilities		26,383		28,985		24,181				21,361		21,697		21,402
Notes payable		4,546		4,547		4,621				1,679		1,059		483
Revolving line of credit		36,000		42,500		52,500				46,000		41,000		41,500
Mandatorily redeemable non-controlling interests		0		0		0		0	[2]	0		0		0
Deferred rent		1,313		1,285		1,391				1,192		1,040		984
Deferred taxes		13,727		12,361		10,789		8,355		0		0		0
Other long-term liabilities		860		869		914				10,769		10,925		9,480
Total liabilities		82,829		90,547		94,396		77,960		81,001		75,721		73,849
Commitments and contingencies
Redeemable non-controlling interests		8,334		8,641		7,591		8,843	[3]	9,024		10,585		7,373
U.S. Physical Therapy, Inc. ("USPH") shareholders' equity [Abstract]
Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding		0		0		0				0		0		0
Common stock, $.01 par value, 20,000,000 shares authorized, 14,734,963 shares issued		147		147		147				146		146		145
Additional paid-in capital		49,506		48,236		46,563		45,251		45,536		45,829		45,080
Retained earnings		160,746		157,161		152,219		149,016		144,888		140,933		136,491
Treasury stock at cost, 2,214,737 shares		(31,628)		(31,628)		(31,628)				(31,628)		(31,628)		(31,628)
Total USPH shareholders' equity		178,771		173,916		167,301				158,942		155,280		150,088
Non-controlling interests		39,967		40,494		42,146				27,178		26,734		26,113
Total USPH shareholders' equity and non-controlling interests		218,738		214,410		209,447				186,120		182,014		176,201				151,017
Total liabilities, USPH shareholders' equity and non-controlling interests		309,901		313,598		311,434		279,913		276,145		268,320		257,423
Adjustment [Member]
Current assets [Abstract]
Cash and cash equivalents		0		0		0		0		0		0		0		$ 0
Patient accounts receivable, less allowance for doubtful accounts		0		0		0				0		0		0
Accounts receivable - other		0		0		0				0		0		0
Other current assets		816		574		483				0		0		0
Total current assets		816		574		483				0		0		0
Fixed assets [Abstract]
Furniture and equipment		0		0		0				0		0		0
Leasehold improvements		0		0		0				0		0		0
Fixed assets, gross		0		0		0				0		0		0
Less accumulated depreciation and amortization		0		0		0				0		0		0
Fixed assets, net		0		0		0				0		0		0
Goodwill		23,826		23,826		23,826		23,916		23,826		23,826		23,826
Other identifiable intangible assets, net		0		0		0				0		0		0
Other assets		0		0		0				0		0		0
Total assets		24,642		24,400		24,309		23,844		23,826		23,826		23,826
Current liabilities [Abstract]
Accounts payable - trade		0		0		0				0		0		0
Accrued expenses		0		0		0				0		0		0
Current portion of notes payable		0		0		0				0		0		0
Total current liabilities		0		0		0				0		0		0
Notes payable		0		0		0				0		0		0
Revolving line of credit		0		0		0				0		0		0
Mandatorily redeemable non-controlling interests		61,276		59,932		58,481		45,974	[2]	45,323		49,166		45,578
Deferred rent		0		0		0				0		0		0
Deferred taxes		5,009		5,792		6,573		7,153		13,276		12,027		12,009
Other long-term liabilities		54		54		54				(7,995)		(7,995)		(7,995)
Total liabilities		66,339		65,778		65,108		53,487		50,604		53,198		49,592
Commitments and contingencies
Redeemable non-controlling interests		(8,334)		(8,641)		(7,591)		(8,843)	[3]	(9,024)		(10,585)		(7,373)
U.S. Physical Therapy, Inc. ("USPH") shareholders' equity [Abstract]
Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding		0		0		0				0		0		0
Common stock, $.01 par value, 20,000,000 shares authorized, 14,734,963 shares issued		0		0		0				0		0		0
Additional paid-in capital		18,987		18,987		18,987		18,987		17,382		15,222		15,222
Retained earnings		(13,523)		(12,614)		(11,555)		(10,715)		(9,485)		(9,173)		(9,203)
Treasury stock at cost, 2,214,737 shares		0		0		0				0		0		0
Total USPH shareholders' equity		5,464		6,373		7,432				7,897		6,049		6,019
Non-controlling interests		(38,827)		(39,110)		(40,640)				(25,651)		(24,836)		(24,412)
Total USPH shareholders' equity and non-controlling interests		(33,363)		(32,737)		(33,208)				(17,754)		(18,787)		(18,393)				$ (14,783)
Total liabilities, USPH shareholders' equity and non-controlling interests		$ 24,642		$ 24,400		$ 24,309		$ 23,844		$ 23,826		$ 23,826		$ 23,826
[1]	as restated
[2]	Mandatorily redeemable non-controlling interests
[3]	Redeemable non-controlling interests

Selected Quarterly Financial 68

Selected Quarterly Financial Data (Unaudited) - Restated Consolidated Balance Sheets (Parenthetical) (Details) - USD ($) $ / shares in Units, $ in Thousands	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015
Current assets [Abstract]
Allowance for doubtful accounts, patient accounts receivable	$ 1,792	$ 1,770	$ 1,672	$ 1,568	$ 1,444	$ 1,556	$ 1,618	$ 1,633
U.S. Physical Therapy, Inc. ("USPH") shareholders' equity [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	500,000	500,000	500,000	500,000	500,000	500,000	500,000	500,000
Preferred stock, shares issued (in shares)	0	0	0	0	0	0	0	0
Preferred stock, shares outstanding (in shares)	0	0	0	0	0	0	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	20,000,000	20,000,000	20,000,000	20,000,000	20,000,000	20,000,000	20,000,000	20,000,000
Common stock, shares issued (in shares)	14,732,699	14,734,963	14,734,963	14,717,463	14,635,874	14,635,874	14,635,674	14,613,374
Treasury stock, shares (in shares)	2,214,737	2,214,737	2,214,737	2,214,737	2,214,737	2,214,737	2,214,737	2,214,737

Selected Quarterly Financial 69

Selected Quarterly Financial Data (Unaudited) - Restated Consolidated Statement of Net Income (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended															6 Months Ended				9 Months Ended				12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016		Jun. 30, 2016		Mar. 31, 2016		Dec. 31, 2015	[1]	Sep. 30, 2015		Jun. 30, 2015		Mar. 31, 2015		Jun. 30, 2016		Jun. 30, 2015		Sep. 30, 2016		Sep. 30, 2015		Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Income Statement [Abstract]
Net patient revenues	$ 88,946	$ 86,411	[1]	$ 88,433	[1]	$ 85,049	[1]	$ 84,881		$ 82,154	[1]	$ 81,451	[1]	$ 75,807	[1]	$ 173,482	[1]	$ 157,258	[1]	$ 259,893	[1]	$ 239,412	[1]	$ 348,839	$ 324,293	[1]	$ 299,009	[1]
Other revenues		1,933	[1]	1,997	[1]	1,859	[1]			1,895	[1]	1,837	[1]	1,434	[1]	3,856	[1]	3,271	[1]	5,789	[1]	5,166	[1]	7,707	7,009	[1]	6,065	[1]
Net revenues	90,864	88,344	[1]	90,430	[1]	86,908	[1]	86,724		84,049	[1]	83,288	[1]	77,241	[1]	177,338	[1]	160,529	[1]	265,682	[1]	244,578	[1]	356,546	331,302	[1]	305,074	[1]
Clinic operating costs [Abstract]
Salaries and related costs		49,868	[1]	48,837	[1]	47,804	[1]			46,594	[1]	44,398	[1]	43,052	[1]	96,641	[1]	87,450	[1]	146,509	[1]	134,044	[1]	198,495	180,514	[1]	163,417	[1]
Rent, clinic supplies, contract labor and other		17,885	[1]	17,546	[1]	17,507	[1]			17,428	[1]	16,681	[1]	16,325	[1]	35,053	[1]	33,006	[1]	52,938	[1]	50,434	[1]	71,868	68,046	[1]	61,209	[1]
Provision for doubtful accounts		917	[1]	956	[1]	1,089	[1]			1,067	[1]	1,062	[1]	990	[1]	2,045	[1]	2,052	[1]	2,962	[1]	3,119	[1]	4,040	4,170	[1]	4,112	[1]
Closure costs		9	[1]	32	[1]	13	[1]			88	[1]	5	[1]	32	[1]	45	[1]	37	[1]	54	[1]	125	[1]	131	211	[1]	169	[1]
Total clinic operating costs		68,679	[1]	67,371	[1]	66,413	[1]			65,177	[1]	62,146	[1]	60,399	[1]	133,784	[1]	122,545	[1]	202,463	[1]	187,722	[1]	274,534	252,941	[1]	228,907	[1]
Gross margin		19,665	[1]	23,059	[1]	20,495	[1]			18,872	[1]	21,142	[1]	16,842	[1]	43,554	[1]	37,984	[1]	63,219	[1]	56,856	[1]	82,012	78,361	[1]	76,167	[1]
Corporate office costs		7,610	[1]	8,026	[1]	9,004	[1]			6,923	[1]	7,593	[1]	7,657	[1]	17,030	[1]	15,250	[1]	24,640	[1]	22,173	[1]	32,479	31,067	[1]	30,399	[1]
Operating income	$ 10,954	12,055	[1]	15,033	[1]	11,491	[1]	$ 12,611		11,949	[1]	13,549	[1]	9,185	[1]	26,524	[1]	22,734	[1]	38,579	[1]	34,683	[1]	49,533	47,294	[1]	45,768	[1]
Interest and other income, net		21	[1]	21	[1]	20	[1]			24	[1]	16	[1]	8	[1]	41	[1]	24	[1]	62	[1]	48	[1]	93	81	[1]	18	[1]
Interest expense [Abstract]
Mandatorily redeemable non-controlling interests - change in redemption value		(1,934)	[1]	(1,931)	[1]	(2,191)	[1]			(501)	[1]	48	[1]	(244)	[1]	(4,122)	[1]	(196)	[1]	(6,056)	[1]	(697)	[1]	(6,169)	(2,670)	[1],[2]	(2,978)	[1],[2]
Mandatorily redeemable non-controlling interests - earnings allocable		(929)	[1]	(1,330)	[1]	(887)	[1]			(778)	[1]	(1,190)	[1]	(706)	[1]	(2,217)	[1]	(1,896)	[1]	(3,146)	[1]	(2,674)	[1]	(4,057)	(3,538)	[1],[2]	(3,388)	[1],[2]
Debt and other		(326)	[1]	(320)	[1]	(308)	[1]			(255)	[1]	(245)	[1]	(265)	[1]	(628)	[1]	(510)	[1]	(954)	[1]	(765)	[1]	(1,252)	(1,031)	[1]	(1,088)	[1]
Total interest expense		(3,189)	[1]	(3,581)	[1]	(3,386)	[1]			(1,534)	[1]	(1,387)	[1]	(1,215)	[1]	(6,967)	[1]	(2,602)	[1]	(10,156)	[1]	(4,136)	[1]	(11,478)	(7,239)	[1]	(7,454)	[1]
Income before taxes		8,887	[1]	11,473	[1]	8,125	[1]			10,439	[1]	12,178	[1]	7,978	[1]	19,598	[1]	20,156	[1]	28,485	[1]	30,595	[1]	38,148	40,136	[1]	38,332	[1]
Provision for income taxes		2,753	[1]	3,802	[1]	2,172	[1]			3,465	[1]	4,221	[1]	2,685	[1]	5,974	[1]	6,906	[1]	8,727	[1]	10,371	[1]	11,880	13,647	[1]	13,018	[1]
Net income		6,134	[1]	7,671	[1]	5,953	[1]			6,974	[1]	7,957	[1]	5,293	[1]	13,624	[1]	13,250	[1]	19,758	[1]	20,224	[1]	26,268	26,489	[1]	25,314	[1]
Less: net income attributable to non-controlling interests		(1,330)	[1]	(1,659)	[1]	(1,465)	[1]			(1,468)	[1]	(1,623)	[1]	(1,279)	[1]	(3,124)	[1]	(2,902)	[1]	(4,454)	[1]	(4,370)	[1]	(5,717)	(5,874)	[1]	(6,183)	[1]
Net income attributable to USPH shareholders		$ 4,804	[1]	$ 6,012	[1]	$ 4,488	[1]			$ 5,506	[1]	$ 6,334	[1]	$ 4,014	[1]	$ 10,500	[1]	$ 10,348	[1]	$ 15,304	[1]	$ 15,854	[1]	$ 20,551	$ 20,615	[1]	$ 19,131	[1]
Basic and diluted earnings per share attributable to USPH shareholders (in dollars per share)	$ 0.42	$ 0.38	[1]	$ 0.48	[1]	$ 0.36	[1]	$ 0.38		$ 0.44	[1]	$ 0.51	[1]	$ 0.33	[1]	$ 0.84	[1]	$ 0.84	[1]	$ 1.22	[1]	$ 1.28	[1]	$ 1.64	$ 1.66	[1]	$ 1.57	[1]
Shares used in computation - basic (in shares)		12,520	[1]	12,511	[1]	12,448	[1]			12,421	[1]	12,409	[1]	12,313	[1]	12,480	[1]	12,362	[1]	12,494	[1]	12,382	[1]	12,500	12,392	[1]	12,217	[1]
Shares used in computation - diluted (in shares)		12,520	[1]	12,511	[1]	12,448	[1]			12,421	[1]	12,409	[1]	12,313	[1]	12,480	[1]	12,362	[1]	12,494	[1]	12,382	[1]	12,500	12,392	[1]	12,221	[1]
Dividends declared per common share (in dollars per share)		$ 0.17	[1]	$ 0.17	[1]	$ 0.17	[1]			$ 0.15	[1]	$ 0.15	[1]	$ 0.15	[1]	$ 0.34	[1]	$ 0.30	[1]	$ 0.51	[1]	$ 0.45	[1]	$ 0.68	$ 0.60	[1]	$ 0.48	[1]
As Reported [Member]
Income Statement [Abstract]
Net patient revenues		$ 86,411		$ 88,433		$ 85,049				$ 82,154		$ 81,451		$ 75,807		$ 173,482		$ 157,258		$ 259,893		$ 239,412
Other revenues		1,933		1,997		1,859				1,895		1,837		1,434		3,856		3,271		5,789		5,166
Net revenues		88,344		90,430		86,908				84,049		83,288		77,241		177,338		160,529		265,682		244,578
Clinic operating costs [Abstract]
Salaries and related costs		49,868		48,837		47,804				46,594		44,398		43,052		96,641		87,450		146,509		134,044
Rent, clinic supplies, contract labor and other		17,885		17,546		17,507				17,428		16,681		16,325		35,053		33,006		52,938		50,434
Provision for doubtful accounts		917		956		1,089				1,067		1,062		990		2,045		2,052		2,962		3,119
Closure costs		9		32		13				88		5		32		45		37		54		125
Total clinic operating costs		68,679		67,371		66,413				65,177		62,146		60,399		133,784		122,545		202,463		187,722
Gross margin		19,665		23,059		20,495				18,872		21,142		16,842		43,554		37,984		63,219		56,856
Corporate office costs		7,610		8,026		9,004				6,923		7,593		7,657		17,030		15,250		24,640		22,173
Operating income		12,055		15,033		11,491				11,949		13,549		9,185		26,524		22,734		38,579		34,683
Interest and other income, net		21		21		20				24		16		8		41		24		62		48
Interest expense [Abstract]
Mandatorily redeemable non-controlling interests - change in redemption value		0		0		0				0		0		0		0		0		0		0			$ 0	[2]	$ 0	[2]
Mandatorily redeemable non-controlling interests - earnings allocable		0		0		0				0		0		0		0		0		0		0			0	[2]	0	[2]
Debt and other		(326)		(320)		(308)				(255)		(245)		(265)		(628)		(510)		(954)		(765)
Total interest expense		(326)		(320)		(308)				(255)		(245)		(265)		(628)		(510)		(954)		(765)			(1,031)		(1,088)
Income before taxes		11,750		14,734		11,203				11,718		13,320		8,928		25,937		22,248		37,687		33,966			46,344		44,698
Provision for income taxes		3,778		4,674		3,523				3,654		4,203		2,777		8,197		6,980		11,975		10,634			14,653		14,274
Net income		7,972		10,060		7,680				8,064		9,117		6,151		17,740		15,268		25,712		23,332			31,691		30,424
Less: net income attributable to non-controlling interests		(2,259)		(2,989)		(2,352)				(2,246)		(2,813)		(1,985)		(5,341)		(4,798)		(7,600)		(7,044)			(9,412)		(9,571)
Net income attributable to USPH shareholders		$ 5,713		$ 7,071		$ 5,328				$ 5,818		$ 6,304		$ 4,166		$ 12,399		$ 10,470		$ 18,112		$ 16,288			$ 22,279		$ 20,853
Basic and diluted earnings per share attributable to USPH shareholders (in dollars per share)		$ 0.46		$ 0.57		$ 0.43				$ 0.47		$ 0.48		$ 0.34		$ 0.99		$ 0.82		$ 1.45		$ 1.29			$ 1.77		$ 1.62
Shares used in computation - basic (in shares)		12,520		12,511		12,448				12,421		12,409		12,313		12,480		12,362		12,494		12,382
Shares used in computation - diluted (in shares)		12,520		12,511		12,448				12,421		12,409		12,313		12,480		12,362		12,494		12,382
Dividends declared per common share (in dollars per share)		$ 0.17		$ 0.17		$ 0.17				$ 0.15		$ 0.15		$ 0.15		$ 0.34		$ 0.30		$ 0.51		$ 0.45
Adjustment [Member]
Income Statement [Abstract]
Net patient revenues		$ 0		$ 0		$ 0				$ 0		$ 0		$ 0		$ 0		$ 0		$ 0		$ 0
Other revenues		0		0		0				0		0		0		0		0		0		0
Net revenues		0		0		0				0		0		0		0		0		0		0
Clinic operating costs [Abstract]
Salaries and related costs		0		0		0				0		0		0		0		0		0		0
Rent, clinic supplies, contract labor and other		0		0		0				0		0		0		0		0		0		0
Provision for doubtful accounts		0		0		0				0		0		0		0		0		0		0
Closure costs		0		0		0				0		0		0		0		0		0		0
Total clinic operating costs		0		0		0				0		0		0		0		0		0		0
Gross margin		0		0		0				0		0		0		0		0		0		0
Corporate office costs		0		0		0				0		0		0		0		0		0		0
Operating income		0		0		0				0		0		0		0		0		0		0
Interest and other income, net		0		0		0				0		0		0		0		0		0		0
Interest expense [Abstract]
Mandatorily redeemable non-controlling interests - change in redemption value		(1,934)		(1,931)		(2,191)				(501)		48		(244)		(4,122)		(196)		(6,056)		(697)			$ (2,670)	[2]	$ (2,978)	[2]
Mandatorily redeemable non-controlling interests - earnings allocable		(929)		(1,330)		(887)				(778)		(1,190)		(706)		(2,217)		(1,896)		(3,146)		(2,674)			(3,538)	[2]	(3,388)	[2]
Debt and other		0		0		0				0		0		0		0		0		0		0
Total interest expense		(2,863)		(3,261)		(3,078)				(1,279)		(1,142)		(950)		(6,339)		(2,092)		(9,202)		(3,371)			(6,208)		(6,366)
Income before taxes		(2,863)		(3,261)		(3,078)				(1,279)		(1,142)		(950)		(6,339)		(2,092)		(9,202)		(3,371)			(6,208)		(6,366)
Provision for income taxes		(1,025)		(872)		(1,351)				(189)		18		(92)		(2,223)		(74)		(3,248)		(263)			(1,006)		(1,256)
Net income		(1,838)		(2,389)		(1,727)				(1,090)		(1,160)		(858)		(4,116)		(2,018)		(5,954)		(3,108)			(5,202)		(5,110)
Less: net income attributable to non-controlling interests		929		1,330		887				778		1,190		706		2,217		1,896		3,146		2,674			3,538		3,388
Net income attributable to USPH shareholders		$ (909)		$ (1,059)		$ (840)				$ (312)		$ 30		$ (152)		$ (1,899)		$ (122)		$ (2,808)		$ (434)			$ (1,664)		$ (1,722)
Basic and diluted earnings per share attributable to USPH shareholders (in dollars per share)		$ (0.08)		$ (0.09)		$ (0.07)				$ (0.03)		$ 0.03		$ (0.01)		$ (0.15)		$ 0.02		$ (0.23)		$ (0.01)			$ (0.11)		$ (0.05)
[1]	as restated
[2]	Mandatorily redeemable non-controlling interests

Selected Quarterly Financial 70

Selected Quarterly Financial Data (Unaudited) - Restated Consolidated Statement of Cash Flows (Details) - USD ($) $ in Thousands		3 Months Ended												6 Months Ended				9 Months Ended				12 Months Ended
		Sep. 30, 2016		Jun. 30, 2016		Mar. 31, 2016		Sep. 30, 2015		Jun. 30, 2015		Mar. 31, 2015		Jun. 30, 2016		Jun. 30, 2015		Sep. 30, 2016		Sep. 30, 2015		Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
OPERATING ACTIVITIES
Net income including non-controlling interests		$ 6,134	[1]	$ 7,671	[1]	$ 5,953	[1]	$ 6,974	[1]	$ 7,957	[1]	$ 5,293	[1]	$ 13,624	[1]	$ 13,250	[1]	$ 19,758	[1]	$ 20,224	[1]	$ 26,268	$ 26,489	[1]	$ 25,314	[1]
Adjustments to reconcile net income including non-controlling interests to net cash provided by operating activities: [Abstract]
Depreciation and amortization						2,091	[1]					1,807	[1]	4,158	[1]	3,674	[1]	6,210	[1]	5,656	[1]	8,779	7,952	[1]	6,740	[1]
Provision for doubtful accounts		917	[1]	956	[1]	1,089	[1]	1,067	[1]	1,062	[1]	990	[1]	2,045	[1]	2,052	[1]	2,962	[1]	3,119	[1]	4,040	4,170	[1]	4,112	[1]
Equity-based awards compensation expense						1,221	[1]					991	[1]	2,484	[1]	2,206	[1]	3,748	[1]	3,368	[1]	4,962	4,491	[1]	3,363	[1]
Loss on sale of fixed assets						(19)	[1]					17	[1]	0	[1]	(13)	[1]	31	[1]	3	[1]	152	84	[1]	35	[1]
Excess tax benefit from equity-based awards						142	[1]					(271)	[1]	0	[1]	(430)	[1]	0	[1]	(816)	[1]	0	(947)	[1]	(948)	[1]
Deferred income tax						1,823	[1]					473	[1]	2,503	[1]	2,056	[1]	3,238	[1]	2,918	[1]	2,979	5,953	[1]	5,106	[1]
Other						0	[1]					34	[1]	0	[1]	111	[1]	0	[1]	180	[1]	0	180	[1]	135	[1]
Changes in operating assets and liabilities: [Abstract]
Increase in patient accounts receivable						(2,185)	[1]					(2,185)	[1]	(2,449)	[1]	(2,880)	[1]	(2,548)	[1]	(4,148)	[1]	(3,275)	(5,519)	[1]	(5,388)	[1]
(Increase) decrease in accounts receivable - other						43	[1]					125	[1]	53	[1]	165	[1]	116	[1]	(145)	[1]	(400)	(852)	[1]	341	[1]
(Increase) decrease in other assets						(2,282)	[1]					106	[1]	(2,443)	[1]	(13)	[1]	(4,979)	[1]	(1,485)	[1]	(1,399)	(1,375)	[1]	1,155	[1]
Increase (decrease) in accounts payable and accrued expenses						3,392	[1]					(5,976)	[1]	6,603	[1]	(3,958)	[1]	3,582	[1]	(3,766)	[1]	2,994	(7,011)	[1]	1,868	[1]
Increase (decrease) in mandatorily redeemable non-controlling interests						2,578	[1]					406	[1]	4,028	[1]	90	[1]	5,372	[1]	683	[1]	5,598	2,509	[1]	2,936	[1]
(Decrease) increase in other liabilities						365	[1]					665	[1]	447	[1]	927	[1]	708	[1]	380	[1]	352	1,396	[1]	(3,378)	[1]
Net cash provided by operating activities						14,211	[1]					2,475	[1]	31,053	[1]	17,237	[1]	38,198	[1]	26,171	[1]	51,050	37,520	[1]	41,391	[1]
INVESTING ACTIVITIES [Abstract]
Purchase of fixed assets						(1,738)	[1]					(1,419)	[1]	(3,453)	[1]	(2,873)	[1]	(5,620)	[1]	(4,690)	[1]	(8,260)	(6,263)	[1]	(5,167)	[1]
Purchase of businesses, net of cash acquired						(12,899)	[1]					(6,445)	[1]	(12,958)	[1]	(14,467)	[1]	(12,958)	[1]	(14,434)	[1]	(23,623)	(18,965)	[1]	(12,270)	[1]
Acquisitions of non-controlling interests						(388)	[1]					(359)	[1]	(250)	[1]	(968)	[1]	(664)	[1]	(942)	[1]	(670)	(968)	[1]	(227)	[1]
Proceeds on sale of fixed assets, net						42	[1]					8	[1]	42	[1]	72	[1]	42	[1]	71	[1]	61	71	[1]	47	[1]
Net cash used in investing activities						(14,983)	[1]					(8,215)	[1]	(16,619)	[1]	(18,236)	[1]	(19,200)	[1]	(19,995)	[1]	(32,492)	(26,125)	[1]	(17,617)	[1]
FINANCING ACTIVITIES [Abstract]
Distributions to non-controlling interests						(1,113)	[1]					(1,045)	[1]	(2,893)	[1]	(2,904)	[1]	(4,441)	[1]	(4,148)	[1]	(5,718)	(5,892)	[1]	(5,963)	[1]
Cash dividends to shareholders - funded						(2,125)	[1]							(4,254)	[1]	(3,723)	[1]	(6,382)	[1]	(5,586)	[1]	(8,510)	(7,449)	[1]	(5,873)	[1]
Proceeds from revolving line of credit						49,000	[1]					34,000	[1]	93,000	[1]	51,000	[1]	128,000	[1]	75,000	[1]	168,000	103,000	[1]	134,300	[1]
Payments on revolving line of credit						(40,500)	[1]					(27,000)	[1]	(94,500)	[1]	(44,500)	[1]	(136,000)	[1]	(63,500)	[1]	(166,000)	(93,500)	[1]	(139,800)	[1]
Payments to settle mandatorily redeemable non-controlling interests						(1,136)	[1]							(1,136)	[1]			(1,136)	[1]	(1,860)	[1]	(1,262)	(6,115)	[1]	(5,233)	[1]
Principal payments on notes payable						(250)	[1]					(200)	[1]	(533)	[1]	(608)	[1]	(592)	[1]	(616)	[1]	(800)	(884)	[1]	(825)	[1]
Tax benefit from equity-based awards						323	[1]					271	[1]	556	[1]	430	[1]	798	[1]	816	[1]	0	947	[1]	948	[1]
Other						1	[1]							1	[1]	5	[1]	1	[1]	5	[1]	1	5	[1]	45	[1]
Net cash (used in) provided by financing activities						4,200	[1]					6,026	[1]	(9,759)	[1]	(300)	[1]	(19,752)	[1]	111	[1]	(14,289)	(9,888)	[1]	(22,401)	[1]
Net increase in cash and cash equivalents						3,428	[1]					286	[1]	4,675	[1]	(1,299)	[1]	(754)	[1]	6,287	[1]	4,269	1,507	[1]	1,373	[1]
Cash and cash equivalents - beginning of period	[1]	20,453		19,206		15,778		12,972		14,557		14,271		15,778		14,271		15,778		14,271		15,778	14,271		12,898
Cash and cash equivalents - end of period		15,024	[1]	20,453	[1]	19,206	[1]	20,558	[1]	12,972	[1]	14,557	[1]	20,453	[1]	12,972	[1]	15,024	[1]	20,558	[1]	20,047	15,778	[1]	14,271	[1]
Cash paid during the period for: [Abstract]
Income taxes						2,265	[1]					1,275	[1]	5,513	[1]	3,835	[1]	10,051	[1]	5,659	[1]	10,584	7,779	[1]	9,253	[1]
Interest						248	[1]					235	[1]	512	[1]	460	[1]	770	[1]	616	[1]	784	884	[1]	1,103	[1]
Non-cash investing and financing transactions during the period: [Abstract]
Purchase of business - seller financing portion						500	[1]					500	[1]	500	[1]	1,350	[1]	500	[1]	1,350	[1]	1,000	1,800	[1]	400	[1]
Acquisition of noncontrolling interest - seller financing portion						388	[1]							388	[1]			388	[1]	0	[1]	387	0	[1]	0	[1]
Payment to settle redeemable non-controlling interest - financing portion						126	[1]							126	[1]			126	[1]	1,240	[1]	127	3,077	[1]	67	[1]
Revaluation of mandatorily redeemable non-controlling interests	[1]					2,191						244		0		196		6,056		697
Receivable from sale of non-controlling interests														(148)	[1]			(148)	[1]			(138)	0	[1]	0	[1]
As Reported [Member]
OPERATING ACTIVITIES
Net income including non-controlling interests		7,972		10,060		7,680		8,064		9,117		6,151		17,740		15,268		25,712		23,332			31,691		30,424
Adjustments to reconcile net income including non-controlling interests to net cash provided by operating activities: [Abstract]
Depreciation and amortization						2,091						1,807		4,158		3,674		6,210		5,656
Provision for doubtful accounts		917		956		1,089		1,067		1,062		990		2,045		2,052		2,962		3,119
Equity-based awards compensation expense						1,221						991		2,484		2,206		3,748		3,368
Loss on sale of fixed assets						(19)						17		0		(13)		31		3
Excess tax benefit from equity-based awards						(323)						(271)		(556)		(430)		(798)		(816)
Deferred income tax						2,709						565		4,170		2,130		5,688		3,181			7,001		6,275
Other						0						34		0		111		0		180
Changes in operating assets and liabilities: [Abstract]
Increase in patient accounts receivable						(2,185)						(2,185)		(2,449)		(2,880)		(2,548)		(4,148)
(Increase) decrease in accounts receivable - other						43						125		53		165		116		(145)
(Increase) decrease in other assets						(2,282)						106		(2,443)		(13)		(4,979)		(1,485)			(1,477)		(2,493)
Increase (decrease) in accounts payable and accrued expenses						4,322						(5,976)		7,715		(3,958)		5,178		(3,766)			(7,013)
Increase (decrease) in mandatorily redeemable non-controlling interests						0						0		0		0		0		0			0		0
(Decrease) increase in other liabilities						365						665		447		927		708		380			1,482		730
Net cash provided by operating activities						14,711						3,019		33,364		19,239		42,028		28,859			41,243		45,194
INVESTING ACTIVITIES [Abstract]
Purchase of fixed assets						(1,738)						(1,419)		(3,453)		(2,873)		(5,620)		(4,690)
Purchase of businesses, net of cash acquired						(12,899)						(6,445)		(12,958)		(14,467)		(12,958)		(14,434)
Acquisitions of non-controlling interests						(1,524)						(359)		(1,386)		(968)		(1,800)		(2,802)
Proceeds on sale of fixed assets, net						42						8		42		72		42		71
Net cash used in investing activities						(16,119)						(8,215)		(17,755)		(18,236)		(20,336)		(21,855)			(32,240)		(22,880)
FINANCING ACTIVITIES [Abstract]
Distributions to non-controlling interests						(1,613)						(1,589)		(5,204)		(4,906)		(8,271)		(6,836)			0		0
Cash dividends to shareholders - funded						(2,125)								(4,254)		(3,723)		(6,382)		(5,586)
Proceeds from revolving line of credit						49,000						34,000		93,000		51,000		128,000		75,000
Payments on revolving line of credit						(40,500)						(27,000)		(94,500)		(44,500)		(136,000)		(63,500)
Payments to settle mandatorily redeemable non-controlling interests						0								0				0		0			0		0
Principal payments on notes payable						(250)						(200)		(533)		(608)		(592)		(616)
Tax benefit from equity-based awards						323						271		556		430		798		816
Other						1								1		5		1		5			22		222
Net cash (used in) provided by financing activities						4,836						5,482		(10,934)		(2,302)		(22,446)		(717)			(7,496)		(20,941)
Net increase in cash and cash equivalents						3,428						286		4,675		(1,299)		(754)		6,287
Cash and cash equivalents - beginning of period		20,453		19,206		15,778		12,972		14,557		14,271		15,778		14,271		15,778		14,271		15,778	14,271
Cash and cash equivalents - end of period		15,024		20,453		19,206		20,558		12,972		14,557		20,453		12,972		15,024		20,558			15,778		14,271
Cash paid during the period for: [Abstract]
Income taxes						2,265						1,275		5,513		3,835		10,051		5,659
Interest						248						235		512		460		770		616
Non-cash investing and financing transactions during the period: [Abstract]
Purchase of business - seller financing portion						500						500		500		1,350		500		1,350
Acquisition of noncontrolling interest - seller financing portion						514								514				514		1,240
Payment to settle redeemable non-controlling interest - financing portion						0								0				0		0
Revaluation of mandatorily redeemable non-controlling interests						0						0		0		627		0		627
Receivable from sale of non-controlling interests														(148)				(148)
Adjustment [Member]
OPERATING ACTIVITIES
Net income including non-controlling interests		(1,838)		(2,389)		(1,727)		(1,090)		(1,160)		(858)		(4,116)		(2,018)		(5,954)		(3,108)			(5,202)		(5,110)
Adjustments to reconcile net income including non-controlling interests to net cash provided by operating activities: [Abstract]
Depreciation and amortization						0						0		0		0		0		0
Provision for doubtful accounts		0		0		0		0		0		0		0		0		0		0
Equity-based awards compensation expense						0						0		0		0		0		0
Loss on sale of fixed assets						0						0		0		0		0		0
Excess tax benefit from equity-based awards						465						0		556		0		798		0
Deferred income tax						(886)						(92)		(1,667)		(74)		(2,450)		(263)			(1,048)		(1,169)
Other						0						0		0		0		0		0
Changes in operating assets and liabilities: [Abstract]
Increase in patient accounts receivable						0						0		0		0		0		0
(Increase) decrease in accounts receivable - other						0						0		0		0		0		0
(Increase) decrease in other assets						0						0		0		0		0		0			102		3,648
Increase (decrease) in accounts payable and accrued expenses						(930)						0		(1,112)		0		(1,596)		0			2
Increase (decrease) in mandatorily redeemable non-controlling interests						2,578						406		4,028		90		5,372		683			2,509		2,936
(Decrease) increase in other liabilities						0						0		0		0		0		0			(86)		(4,108)
Net cash provided by operating activities						(500)						(544)		(2,311)		(2,002)		(3,830)		(2,688)			(3,723)		(3,803)
INVESTING ACTIVITIES [Abstract]
Purchase of fixed assets						0						0		0		0		0		0
Purchase of businesses, net of cash acquired						0						0		0		0		0		0
Acquisitions of non-controlling interests						1,136						0		1,136		0		1,136		1,860
Proceeds on sale of fixed assets, net						0						0		0		0		0		0
Net cash used in investing activities						1,136						0		1,136		0		1,136		1,860			6,115		5,263
FINANCING ACTIVITIES [Abstract]
Distributions to non-controlling interests						500						544		2,311		2,002		3,830		2,688			(5,892)		(5,963)
Cash dividends to shareholders - funded						0								0		0		0		0
Proceeds from revolving line of credit						0						0		0		0		0		0
Payments on revolving line of credit						0						0		0		0		0		0
Payments to settle mandatorily redeemable non-controlling interests						(1,136)								(1,136)				(1,136)		(1,860)			(6,115)		(5,233)
Principal payments on notes payable						0						0		0		0		0		0
Tax benefit from equity-based awards						0						0		0		0		0		0
Other						0								0		0		0		0			(17)		(177)
Net cash (used in) provided by financing activities						(636)						544		1,175		2,002		2,694		828			(2,392)		(1,460)
Net increase in cash and cash equivalents						0						0		0		0		0		0
Cash and cash equivalents - beginning of period		0		0		0		0		0		0		0		0		0		0		$ 0	0
Cash and cash equivalents - end of period		$ 0		$ 0		$ 0		$ 0		$ 0		$ 0		$ 0		$ 0		$ 0		$ 0			$ 0		$ 0
[1]	as restated

SCHEDULE II - VALUATION AND Q71

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - Allowance for Doubtful Accounts [Member] - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2016	[1]	Dec. 31, 2015		Dec. 31, 2014
Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance		$ 1,642		$ 1,867		$ 1,628
Additions Charged to Cost and Expenses		3,906		4,170		4,112
Additions Charged to Other Accounts		0		0		0
Deductions	[2]	3,756		4,395		3,873
Ending Balance		$ 1,792		$ 1,642	[1]	$ 1,867
[1]	Related to patient accounts receivable and accounts receivable-other.
[2]	Uncollectible accounts written off, net of recoveries.